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ABSTRACT  
 
The physical and psychosocial consequences of seizures in epilepsy are more prevalent in people 
with uncontrolled seizures, and are lessened with seizure control. Early management strategies 
and patient counselling may be informed by the predictors of control in newly diagnosed 
patients. The main objective of this systematic review was to identify variables that consistently 
and independently predict seizure outcome in people with newly diagnosed epilepsy.  
 
English-language publications identified from electronic databases (MEDLINE and EMBASE) and 
reference lists of included studies, published until March 2010 were reviewed. The publications 
were of nested case control and cohort studies of unselected population of at least 100 people 
with epilepsy with multivariate analysis of the effect on seizure outcome of predictor variables 
collected within the first year of diagnosis in patients followed up for at least 1 year. 
 
The quality of included studies was appraised for their likelihood for bias in five areas: study 
participation, study attrition, prognostic factor measurement, outcome measurement and 
statistical analysis. Data from each study were independently extracted three times; at each 
succeeding stage, the extracted data were compared with the previous extraction and where 
there were discrepancies, clarification made by consulting the publication. Consistent predictors 
were identified in more than 1 study from different cohorts. 
 
There were 52 studies from a total of 33 publications. Five studies predicted immediate 
remission of seizures; 9 studies predicted remission off antiepileptic medication; 20 studies 
predicted remission on or off antiepileptic medication; 12 studies predicted intractability to 
antiepileptic medication and 1 study developed a model to predict not achieving remission after 
1 or more relapses following an initial period of remission. 5 studies externally validated models 
predicting seizure outcome.  
  
Two factors reduce the chance of achieving immediate remission: More than 1 seizure before 
recruitment [RR 0.63 (95%CI 0.36-1.11)] and remote symptomatic aetiology [childhood-onset 
epilepsy: RR 0.59 (95%CI 0.41-0.86), adult-onset epilepsy: RR 0.44 (95% CI 0.26-0.77)].  
 
Having more than 1 seizure in the period between 6 and 12 months on medication [RR 0.24 
(95%CI 0.10-0.60)] and intellectual disability [RR 0.77 (95%CI 0.61-0.94)] reduce the chance of 
achieving remission off medication in childhood-onset epilepsy. None of the studies predicting 
remission off medication were of adult-onset epilepsy. 
 
Five factors reduce the chance of achieving remission on or off medication are: More than 1 
seizure before diagnosis [childhood-onset epilepsy: RR 0.66 (95%CI 0.46-0.95), adult-onset-
epilepsy: 0.81 (95%CI 0.66-0.99)] for the natural logarithm of every additional seizure; seizures 
in the first 6 months after the index seizure [childhood-onset epilepsy: RR 0.50 (95%CI 0.35-
10 
 
0.72), adult-onset-epilepsy: RR 0.59 (95%CI 0.50-0.70) for the natural logarithm of every 
additional seizure; mixed seizure types at onset [RR 0.70 (95%CI 0.37-1.04), adult-onset epilepsy: 
OR 0.23 (95% CI 0.10-0.48)]; intellectual disability [childhood-onset epilepsy: OR 0.40 (95%CI 
0.18-0.90), adult-onset epilepsy: OR 0.10 (95%CI 0.05-0.25)]; and remote symptomatic aetiology 
[childhood-onset epilepsy: RR 0.63 (95% CI 0.47-0.84), adult-onset epilepsy: RR 0.44 (95% CI not 
reported)]. 
 
Onset of seizures in infancy [RR 5.48 (95%CI 2.10-9.64)], intellectual disability [OR 18.2 (95%CI 
5.2-63.6)], and remote symptomatic aetiology [RR 5.48 (95%CI 2.10-9.64)] increase the risk of 
medical intractability, while idiopathic aetiology [RR 0.20 (95%CI 0.0-0.80)] reduces the risk of 
intractability in childhood-onset epilepsy. None of the studies predicting medical intractability 
were of adult-onset epilepsy. 
 
The externally validated models have little predictive gain over information provided by simple 
prevalence rates of seizure outcome, and the models predict wrongly in about 1 out of 3 
children in the development and external validation cohorts. None of the models developed in 
adult-onset epilepsy were externally validated. 
 
The study suggests that onset of seizures in infancy, number of seizures (before diagnosis, in the 
first 6 months after diagnosis, and between 6 and 12 months on medication), intellectual 
disability and the aetiology of seizures are the important predictors of seizure outcome in newly 
diagnosed epilepsy. The study demonstrates the feasibility of systematic review with thorough 
quality appraisal as a means of identifying the consistent predictors of an outcome in 
exploratory prognostic factor studies. The review also shows the need for further studies of the 
prognosis of adult-onset epilepsy. 
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1  CHAPTER ONE: INTRODUCTION AND BACKGROUND 
 
 
This chapter is in 3 parts. The first part introduces and provides an overview of the main thrust 
of the thesis. The second part presents a general background to prognosis studies in epilepsy 
and describes the benefits of early determination of the prognosis of epilepsy in newly 
diagnosed patients. The second part also presents a framework for classifying the different 
potential prognostic categories of a newly diagnosed patient with epilepsy. The third part is an 
overview of the role of systematic review in medicine with particular application to prognosis 
studies in epilepsy.  
 
1.1 INTRODUCTION 
1.1.1 DEFINITION AND EPIDEMIOLOGY OF EPILEPSY 
Epilepsy is a chronic neurological disorder characterised by a recurrent tendency to have 
spontaneous, intermittent, abnormal electrical activity in a part of the brain, which manifest as 
seizures, and diagnosed as the result of a patient having a second unprovoked seizure, with at 
least 24 hours between the first and second seizure. This definition regards an episode of status 
epilepticus (a seizure lasting more than 30 minutes or repeated seizures without intervening 
periods of regained function or consciousness) as a single seizure.(1)  
 
However, the definition of epilepsy as a tendency to have recurrent seizures excludes seizures 
that are provoked (i.e. not spontaneous, therefore “acute symptomatic”) by an obvious and 
immediate preceding cause e.g. an acute systemic or metabolic imbalance, drugs or toxins, or a 
recent cerebral damage from stroke, trauma or infection. Seizures occurring in children between 
6 months and 6 years only within the context of a febrile illness without the evidence of 
intracranial aetiology (febrile seizures) are also excluded, as are seizures occurring only within 
the neonatal period.(1, 2) 
 
The World Health Organisation (WHO) estimates the point prevalence of active epilepsy (i.e. 
people with continuing seizures or the need for treatment) as generally 4 to 10 per 1,000 
people, and in developing countries from 6 to 10 per 1,000. It is also estimated that at least 50 
million people in the world have epilepsy as 43.7 million people were reported to have epilepsy 
from 108 countries covering 85.4% of the world in a WHO survey.(3, 4) The mean number of 
people with epilepsy per 1000 population is 8.93. This varies from 7.99 in high-income countries 
to 9.50 in low-income countries.(3) However, the incidence of epilepsy in developing countries is 
about twice that in developed countries, and the WHO estimates that about 80% of the world’s 
epilepsy patients are in developing countries.(3)  
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In developed countries, new-onset seizure occurs in approximately 80 people per 100,000 in a 
year. The estimates of annual incidence of epilepsy in the general population range from 30 to 
57 per 100,000.(5)  However, the incidence rate of epilepsy has a bimodal pattern in relation to 
age: it is high in the paediatric population (about half of all epilepsy cases are diagnosed in 
childhood or adolescence), decreasing through adulthood until approximately age 60, when the 
incidence again begins to increase.(6, 7) With the onset of epilepsy, a chronic disorder, being 
common in childhood and adolescence, and due to the burden of experiencing unpredictable 
paroxysmal seizure events and its psychosocial implications, epilepsy contributes about 1% of 
the global burden of disease.(4)  
1.1.2 SEIZURES IN EPILEPSY 
A working knowledge of basic clinical epilepsy is assumed in this thesis. However, the following 
account of the clinical and pathophysiological foundations of seizures in epilepsy is based on a 
2009 monograph on clinical epilepsy by Shorvon,(8) updated with the use of terminologies for 
seizure classification from the 2010 report of the ILAE (International League Against Epilepsy) 
Commission on Classification and Terminology.(9) 
 
The term “seizure” refers to the transient clinical manifestation of an episodic, abnormal, 
excessive, hypersynchronous discharge of a population of epileptic cortical neurons. For a 
particular patient, the seizure tends to be stereotyped, although it may take many forms (mixed 
seizure types) in others. The form seizures in epilepsy take could be conceptualised according to 
how it is experienced by the patient (as a motor, somatosensory, autonomic or psychic 
manifestation with or without accompanying impaired level of consciousness) or more 
conveniently, on physiological grounds, as either focal or generalised, in relation to how seizure 
activity originates within the brain.  
 
The terms “focal” and “generalised” have been used to express a dichotomous classification for 
seizures and epilepsy, although they do not represent a clear dichotomy in the pathophysiology 
of seizures.(9) In focal seizures, the paroxysmal neuronal activity giving rise to the seizure is 
limited to a focal area in one half of the cerebrum, with consciousness preserved, impaired or 
completely lost. (Figure 1) 
 
Figure 1 | Pathophysiology of Focal Seizures  
[Image from Dekker 2002(10)] 
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For generalised seizures, the electrophysiological abnormality involves large areas of the 2 
cerebral hemispheres simultaneously and synchronously. These generalised seizures are always 
accompanied by at least impaired level of consciousness. (Figure 2)  
 
 
Figure 2 | Pathophysiology of Primary Generalised Seizures 
[Image from Dekker 2002(10)] 
 
The third category that blurs the distinction between focal and generalised seizures is the 
secondarily generalised seizures in which the initially focal neuronal discharge spreads from 1 
hemisphere to the other to become generalised. (Figure 3) 
 
Figure 3 | Pathophysiology of Secondary Generalisation of Seizures 
[Image from Dekker 2002(10)] 
 
FOCAL SEIZURES 
Focal seizures that remain localised manifest symptoms depending on the area of the cerebral 
cortex affected. In about 15% of patients with epilepsy the only seizure type they experience are 
those that start focally and remain focal with consciousness preserved, impaired or completely 
lost. 
 
Focal seizures with motor manifestations occur when seizure focus is in the precentral gyrus 
(motor cortex) affecting the contralateral face, arm, trunk or leg characterised by rhythmical 
jerking or sustained spasm. The focal seizures with somatosensory or special sensory (simple 
hallucinations) manifestations arise in the sensory cortex, and may cause unpleasant tingling or 
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electric sensations in the contralateral face and/or limb. Focal seizures with sensory 
manifestations may originate from the visual (occipital) cortex with hallucination such as balls of 
light or patterns of colour, or from the temporal lobe, where hallucination may involve faces or 
scenes. Focal seizures with autonomic manifestations include changes in skin colour, blood 
pressure, heart rate, pupil size and piloerection. 
 
Focal seizures with psychic manifestations occur especially when the focus is in the temporal 
lobe, with 6 categories of manifestation: 1.) Dysphasia when cortical speech areas of the frontal 
and temporoparietal lobes are affected; 2.) Dysmnesia, in which memory problems such as déjà 
vu, jamais vu, flashbacks or panoramic experiences; 3.) Cognitive, where dreamy states and 
sensations of unreality or depersonalisation is part of the seizure; 4.) Affective, in which fear 
occurs commonly, but depression, anger and irritability may also be a feature of the seizure; 5.) 
Illusions, which may be of size, weight, shape, distance or sound which occurs usually with a 
temporal or parieto-occipital focus; and 6.) Hallucinations, which may be visual, auditory, 
gustatory or olfactory usually due to temporal or parieto-occipital focus. 
 
GENERALISED SEIZURES 
Generalised seizures may be primary or secondarily generalised. In about 25% of patients with 
epilepsy, only primary generalised seizure occurs. There are 6 categories of primary generalised 
seizure, all accompanied with impaired consciousness from the onset of seizure activity as 
seizure originates extensively within cerebral cortex and subcortical structures. 
 
However, 20% of all patients with epilepsy have primarily generalised seizures with only tonic 
clonic manifestation where the patient suddenly becomes rigid (tonus), then unconscious, falls if 
standing, and respiration is arrested with possible central cyanosis. The rigidity then becomes 
periodically relaxed (clonus). The patient subsequently enters a flaccid state of deep coma. 
When consciousness is regained, there is first a phase of confusion and disorientation following 
which the patient regains full memory, feeling terrible, with headache, and sleepiness. There is 
possibility of loss of continence occurring as well as tongue biting during the seizure. 
 
The other types of primary generalised seizures make up the remaining 5% of patients with 
epilepsy having only primary generalised seizures: 1.) Absence Seizures occur typically as an 
abrupt loss of consciousness, but with preservation of muscle tone, and in its atypical form, loss 
of consciousness is not complete, with varying degrees of loss of muscle tone. 2.) Myoclonic 
Seizures present as brief contraction of a muscle or muscle group or several muscle groups, 
which may be single or repetitive and with varying severity from a twitch to severe jerking. 3.) 
Clonic Seizures are often asymmetric with irregular clonic jerking, while 4.) Tonic Seizures, 
present as tonic muscle contraction without a clonic (jerking) phase and 5.) Atonic Seizures, in its 
most severe form, manifests as a sudden complete loss of postural tone and the patient drops 
or, it may be more restricted, resulting in loss of tone in specific groups of muscle.  
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These seizures types are primary generalised. However, they may also be secondary generalised, 
when the seizure starts with an aura (a partial seizure). These secondary generalised seizures 
occur exclusively in about 60% of patients with epilepsy. 
1.1.3 AETIOLOGY OF SEIZURES IN EPILEPSY 
The concept for assessing, categorising and reporting on the underlying cause of epilepsy, was 
described in the 1989 ILAE Commission on Classification and Terminology report as being 
idiopathic, symptomatic, or cryptogenic.(11) In idiopathic aetiology, “there is no underlying 
cause other than a possible hereditary predisposition… and a presumed genetic aetiology.’’ 
Symptomatic aetiology is “considered the consequence of a known or suspected disorder of the 
central nervous system (CNS). The term cryptogenic “refers to a disorder whose cause is hidden 
or occult… presumed to be symptomatic, but the aetiology is not known.”(11) 
 
Many human beings and other animals will have seizures in abnormal metabolic circumstances 
such as hyponatraemia, hypocalcaemia, hypoxia, hypo or hyperglycaemia.(5)  However, the 
tendency to have recurrent seizures is not common to all and there are aetiological factors 
responsible, even though these factors cannot be identified in about 30% of patients 
(cryptogenic). The cause is genetic in about another 30% (idiopathic) and symptomatic (or 
remote symptomatic, to distinguish from acute symptomatic seizures that are excluded from 
the definition of epilepsy) in about 40% due to cerebrovascular disease (10-20%), malformations 
including hippocampal sclerosis, other neurological disorders and neurodegenerative disease 
(10-20%) intracranial tumour (5-10%), brain trauma (5%), cerebral infection (5%), or metabolic 
disorder and toxins including alcohol (5%). 
 
The more recent 2010 report of the 2005-2009 ILAE Commission on Classification and 
Terminology (9) recommends more clearly defined and less confusing and conflating terms and 
concepts in place of the traditional terminologies. The authors of the report propose that 
“Genetic” replaces Idiopathic, “Structural/Metabolic” replaces symptomatic, and “Unknown 
Cause” replaces cryptogenic. The only major difference in the proposed use and definition of 
these terms relates specifically to advances in the use of genetics to better classify the aetiology 
of epilepsy. This thesis keeps to terminologies in current use. 
 
1.1.4 CHALLENGES OF STUDYING THE PROGNOSIS OF EPILEPSY 
 
DIAGNOSIS AND CASE ASCERTAINMENT  
Epilepsy syndromes (epileptic seizures characterised by a consistent cluster of patient 
characteristics, with signs and symptoms occurring together) are organised with a complex 
relationship to seizure pathophysiology and aetiology.(8)  The ILAE classification of epilepsy 
syndromes follows the pattern of aetiological classification as syndromes of epilepsy arising 
from focal seizures are grouped under the headings of idiopathic, symptomatic and cryptogenic 
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aetiology as are those arising from generalised seizures and those that are not classified either 
as focal or generalised. The fourth category under which epilepsy syndromes are grouped is that 
of “situation-related seizures” but without aetiological subdivisions. Exploration of these 
syndromes is however beyond the scope of this thesis. 
 
Epilepsy, like many clinical constructs is not a singular disease entity, but a manifestation of 
underlying disease processes. The attempt to bring the different entities with a common 
tendency to have repeated seizures, albeit with a myriad of possible seizure types and aetiology 
and syndromes beneath one umbrella is therefore fraught with the contentious issue of 
classification and terminology.(12-17) This has led to repeated attempts by the International 
League Against Epilepsy to standardise definitions, terminologies and classification to provide a 
reproducible conceptual framework for organising and differentiating epileptic seizures and 
types of epilepsy and the standard indices for epidemiological measures of prevalence and 
incidence.(1, 2, 9, 11, 18) 
 
Epilepsy is essentially a clinical diagnosis, based on eyewitness account or video recording of the 
seizure, as clinical examination and investigations may be normal between seizures. Patients 
may also not be aware of the nature of the seizure, and seizures may go unnoticed. These lead 
to seizures going unreported. There may also be denial of occurrence of seizures in order to 
avoid the stigma attached to a diagnosis of epilepsy. It is also possible that patients with 
infrequent seizures or mild epilepsy may not seek medical attention.(19, 20)  
 
These factors result in difficulty with adequate case identification and case ascertainment, in 
determining the specific seizure type, the aetiology, and therefore the specific syndromic 
diagnosis of each patient’s epilepsy; this extends also to the impact on epidemiological studies 
on populations of patients with epilepsy.(1, 2, 14, 20) However, when such syndromic diagnosis 
is made, the small number of patients within each group precludes much statistical analysis 
based on each of these groups as several epilepsy syndromes are rare.(21) Hence, much of the 
epidemiological studies in epilepsy do not classify patients beyond the major seizure type and 
aetiological classifications.  
 
STUDY DESIGN 
The retrospective study design as well as hospital based studies tend to lead to bias in selecting 
for patients with more severe disease manifestation and course.(20, 22) Therefore prospective 
case ascertainment and follow up is preferred as it reduces the risk for selection bias and also 
allows for optimal assessment of predictors and outcome.(23)However, the difficulty and cost of 
ensuring prospective case ascertainment in a population based study makes the study of 
epidemiology and especially prognosis of epilepsy more difficult and tasking in terms of cost and 
logistics. Ideally, to determine the prognosis of epilepsy in a group of patients, they have to be 
assembled at a comparable stage in their disease progression. This is at the point where they 
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could be described as newly diagnosed, and better still, for each patient, at the exact point of 
having a second seizure, which diagnoses epilepsy.(23, 24)  
 
MULTIVARIATE MODELS 
To identify independent predictors of the outcome of newly diagnosed epilepsy, by avoiding the 
effect of confounders, it is imperative that multivariate analysis is conducted within a population 
of people with epilepsy.(23) However, the prognosis of epilepsy is dynamic:(25) some patients 
have a remitting course, some have a remitting-relapsing course and others a worsening course. 
Therefore, a multivariate analysis conducted on such a dynamic population of patients is as 
described by Iezzoni(26) only “a snapshot in place and time, not fundamental truth.”  
 
This thesis investigates the early predictors of the prognosis of epilepsy in newly diagnosed 
patients. It is a systematic review of studies that have used multivariate regression models to 
identify independent predictors of outcome in people with newly diagnosed epilepsy. The 
patients within these studies may be at different stages of the course of their epilepsy. Thus, the 
result of a multivariate analysis that identifies independent predictors may only be a conceptual 
representation, and not necessarily a true reflection of the prognosis of epilepsy.  
 
For a model to be useful in another population, it has to be confirmed as generalisable in an 
external validation study of patients within another cohort. However, this external validation 
only answers the Iezzoni’s question of place.(26, 27) The question of time in the course of the 
epilepsy for individual patients within a particular cohort studied can only be satisfied if all the 
patients in the cohort were recruited and followed at the same point in the course of the 
epilepsy.(27, 28) Although difficult to achieve, the point of a patient’s second seizure may mark 
a gold standard for recruitment and commencement of follow up in prospective studies of the 
prognosis of epilepsy.(24)  
1.1.5 OUTCOMES IN EPILEPSY  
The focus of this thesis is restricted to the prognosis of epilepsy as it relates specifically to the 
outcome of seizure, in terms of the continued occurrence or otherwise of seizure events 
following the diagnosis of epilepsy and does not include circumstances or events that may result 
from seizures: physical effects like fracture, burns and drowning from falls or loss of 
consciousness, psychosocial outcome such as cognitive deficit, psychopathology (depression and 
anxiety), dysfunctional relationships (overprotection and overdependence in relationships), 
restriction in education, employment and leisure activity, and problems relating to low 
confidence and self-esteem leading to underachievement and social withdrawal.(8, 29-31)  
 
These outcomes may be a result of the unpredictability of seizures or as a result of perceived or 
real stigma. They are however by no means less important. Indeed, these secondary 
psychological and social limitations that epilepsy imposes are more an issue for some patients 
than the occurrence of seizures.(31) The fear of death and death itself is another consequence 
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of epilepsy. The annual mortality in people with epilepsy is slightly higher than in the general 
population and there is also relatively lower life expectancy. Death may result from physical 
accidents resulting from seizures, status epilepticus, suicide,(32-34) or sudden unexpected 
death in epilepsy (SUDEP) which occurs following generalised tonic clonic seizures, commonly 
during sleep and possibly as a result of respiratory failure or cardiac arrhythmias.(35-37) 
 
However, these potential consequences of seizures are reduced with control of seizures.(30, 31, 
35-37) For example, the overall risk of SUDEP of 1 per 1000 per year, falls to zero with seizure 
remission and rises to 1 per 100 per year in patients with frequent and severe tonic clonic 
seizures.(8) This fact underscores the importance of this thesis in addressing the question of 
identifying the early predictors of seizure outcome in patients with newly diagnosed epilepsy. 
The results will inform management decisions that not only would help reduce the burden of 
seizures but may also reduce the incidence of the consequences of continued seizures. 
 
1.1.6 ORGANISATION OF THE THESIS 
The thesis is organised into 6 chapters and an appendix thus: 
 
CHAPTER ONE  
Chapter 1 introduces and provides an overview of the main thrust of the thesis. The chapter also 
presents a general background to prognosis studies in epilepsy and describes the benefits of 
early determination of the prognosis of epilepsy in newly diagnosed patients. There is also a 
discussion of the framework for classifying the different potential prognostic categories of a 
newly diagnosed patient with epilepsy. The chapter ends with an overview of the role of 
systematic review in medicine with particular application to prognosis studies in epilepsy.  
 
CHAPTER TWO  
Chapter 2 presents the research questions that the thesis aims to answer. The chapter also 
discusses the central contribution to the thesis to the systematic review and meta-analysis of 
prognosis studies in general and particularly to studies of prognosis in epilepsy.  
 
CHAPTER THREE 
Chapter 3 is a description of the systematic review process: eligibility criteria, the search 
strategy, how each category of papers was excluded, and how studies from the same cohort 
were handled. It also includes a discussion of the iterative process of developing the quality 
appraisal and data extraction forms and how the results of each study was assessed for quality 
i.e. tendency for bias. It also discusses the criteria for assessing the quality of externally 
validated predictive models. The chapter also discusses how consistent predictors of outcome 
were identified and the risk estimates compared across studies. 
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CHAPTER FOUR 
Chapter 4 presents the result of the systematic review. The chapter starts by reporting the 
results of the process of identifying eligible publications, followed by a description of included 
studies, how they relate to the cohorts from which they are derived and the publications that 
report them, and an account of the reporting characteristics of the eligible publications. There is 
a detailed report of the quality appraisal of studies included from each publication. The studies 
were subsequently disaggregated according to the seizure outcome predicted, and each 
category of study is further evaluated and appraised with a view to: 1) Explaining the similarities 
and differences in results in relation to study characteristics and potential for bias, 2) Identifying 
consistent predictors and non-predictors within each outcome category, and 3) Assessing the 
quality and performance of externally validated models within each outcome category.   
 
CHAPTER FIVE  
Chapter 5 is a general discussion of the results of the review. The chapter is presented according 
to recommendations that advocate structured discussion of the results of scientific 
research.(38) The principal findings of 1) the literature search; 2) the quality appraisal of studies 
and reporting characteristics of publications; 3) the study classification; and 4) the studies within 
each category, were stated and interpreted. Thereafter, possible explanations for the results are 
presented and their implications for clinical practice are stated where applicable. There are also 
suggestions for future studies and the direction of future research for each set of results. The 
strengths of the study are highlighted, and the weaknesses are also discussed with a view to 
making recommendations for future studies.  
 
CHAPTER SIX 
Chapter 6 provides a summary of the key findings of the review and considers the results in the 
context a previous review of predictors of outcome in patients with 1 seizure. 
  
APPENDICES 
Five appendices were attached to this thesis. Appendix I is the protocol of the systematic 
review; Appendix II is the complete list of 154 unique citations (from MEDLINE, EMBASE and 
screening the references of eligible publications) with their origin indicated alongside the 
corresponding reasons for inclusion and exclusion; Appendix III contains three versions of the 
data extraction and quality appraisal form, from the first two pilot versions to the final version; 
Appendix IV presents the items to be considered for assessment of bias in prognosis studies as 
identified by Hayden et al(39); Appendix V presents the items to be considered in reporting 
observational studies according to the STROBE (Strengthening the reporting of Observational 
Studies) checklist.(40) 
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1.2 BACKGROUND TO PROGNOSIS STUDIES IN EPILEPSY 
This second part of the chapter discusses the prognosis of epilepsy and the importance of the 
study of the prognosis in epilepsy. 
 
There are different kinds of information that may arise from the study of prognosis. Fletcher et 
al(41) identified 4 characteristics of disorders: response (evidence of improvement), remission 
(disorder becomes undetectable), recurrence (return of the disorder after remission) and 
duration (how long the disorder lasts) all of which are amenable to prognosis studies. These 
studies also investigate the relationship between occurrences of outcomes and predictors in 
defined populations of people with disease.(23, 42)  
 
In addition, Windeler(43)made the observation of similarity between diagnosis and prognosis, 
pointing out that the same factors may be responsible for diagnosis and prognosis. This 
particularly applies to seizure outcome in epilepsy as diagnosis of epilepsy is confirmed on the 
second unprovoked seizure. Therefore, while the study of seizure recurrence after the first 
unprovoked seizure(44) is in effect a study of diagnosis, a prognosis study considers recurrence 
or otherwise after a second unprovoked seizure.  
 
The importance of prognostic research in epilepsy as in other chronic diseases is overwhelming. 
Altman and Lyman (45) identified the uses of prognosis studies among which are to: “1.) 
improve understanding of the disease process; 2.) define risk groups based on prognosis; 3.) 
predict disease outcome more accurately or parsimoniously; and 4.) guide clinical decision 
making, including treatment selection and patient counselling.” 
1.2.1 THE NATURAL HISTORY OF EPILEPSY 
The natural history of epilepsy has important relevance for the better understanding of 
underlying neurobiology of the disorders that result in epilepsy, in planning and evaluating 
treatment strategies and health resource allocation. This segment discusses the natural history 
of epilepsy first with historical considerations of knowledge and attitude towards the prognosis 
of epilepsy, then the prognosis of epilepsy in patients who are not treated with anti-epileptic 
medications and evidence from patient populations who are predominantly treated with 
antiepileptic drugs with an emphasis on the dynamic nature of the course of epilepsy. 
 
HISTORICAL CONSIDERATIONS 
There was an early documented hint at the natural history and prognosis of epilepsy by Plato 
(c.429–347 BC) who wrote in Laws that whoever procures a slave with epilepsy had 1 year to 
return the slave. For him, the prognosis of epilepsy might be ascertained within 1 year, as 
against tuberculosis, renal stones and other chronic and mental illnesses not obvious on physical 
inspection of the slaves and for which the window period is much shorter at 6 months.(46, 47)  
Thus Plato allowed a longer period for the evolution of epilepsy compared to other diseases. 
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However, Hippocrates (c.460–377 BC) whose medicine had a particular focus on prognosis had 
earlier separated epilepsy into the prognostic categories of childhood-onset and adult-onset 
epilepsy: childhood onset epilepsy is initially fatal, but spontaneous remission occurs in children 
as they mature, and adult onset epilepsy has better prognosis as it does not lead to death. 
Hippocrates also thought that status epilepticus portends poor outcome and that early 
treatment of epilepsy could lead to better prognosis.(47, 48)  
 
In spite of the emergence of effective anti-epileptic drugs in the late 19th century and early 20th 
century, accounts from Gowers(49) and Rodin(50) indicate there was much less optimism until 
modern times regarding seizure outcome. Kwan and Sandler(51) have suggested this may be 
due to much research into the prognosis of epilepsy being predominantly small-scale and 
hospital-based retrospective studies which tend to result in bias as the success of follow up 
often depends on a patient having poor seizure outcome. 
 
SEIZURE OUTCOME IN UNTREATED POPULATIONS 
More recent studies of the prognosis of epilepsy have revealed an increasingly positive message, 
buttressed by evidence of spontaneous remission of untreated epilepsy in some low and middle 
income countries with large proportion of untreated patients.(51) The treatment gap for active 
epilepsy exceeds 75% in low-income countries and 50% in middle-income countries whereas 
high-income countries have treatment gaps of less than 10%.(52)  
 
In a study that ascertained the duration of active epilepsy at diagnosis in Malawi,(53) there was 
a steep progressive decline in the duration of active epilepsy at presentation. Much fewer 
people had epilepsy for longer than 15 years compared to those with epilepsy for a shorter 
duration at diagnosis. A survey in northern Ecuador showed that 31% of the total population 
were spontaneously seizure free for at least 12 months in the period immediately before 
assessment.(54) In rural China, about 40% of those in remission had never received anti-
epileptic drug therapy, (55) and in rural Bolivia, after a 10 year follow up, 40% of those who have 
achieved 5 year remission had not taken anti-epileptic drugs for more than 1 year.(56) 
 
While these studies are retrospective and rely on only clinical history to diagnose epilepsy with 
case identification and classification that may not conform to international standards, the 
explanation for the favourable prognosis of epilepsy from these studies cannot be entirely due 
to poor case ascertainment. Life expectancy is lower in low and middle income countries, and 
this fact may bias the result of the Malawi study. However, average life expectancy in China has 
been comparable to that obtainable in the other high income countries in the past 10 years.(57)  
 
The results are also in keeping with a study from Finland in which 42% of people with untreated 
epilepsy achieved 2 years of remission by 10 years after onset.(58) An earlier study in Poland 
also found about 30% of people who had not received any anti-epileptic drug therapy had 
achieved remission.(59) These results may however be partly due to a selection bias as a study 
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in Vietnam found that the most common reason given by patients for never taking AEDs, or for 
deciding to discontinue, was because their seizures were too infrequent to warrant the trouble 
and costs of treatment, (60) a finding consistent with that from the Finnish study that patients 
with milder forms of epilepsy were more inclined to reject anti-epileptic drug therapy compared 
with those with more frequent seizures.(58) 
 
Much has changed since the 1881 comment by Gowers(49) that “the spontaneous cessation of 
the disease is an event too rare to be reasonably anticipated in any given case” although he 
conceded to the more favourable prognosis in patients with newly diagnosed epilepsy treated 
with bromide. Following the introduction of bromides in 1857, was among others, phenobarbital 
(1912), phenytoin (1938), ethosuximide (1955), carbamazepine (1963), sodium valproate 
(1967),(61, 62) and subsequently the newer generation of antiepileptic drugs.(62) Most people 
with epilepsy in the high income countries receive antiepileptic drugs early in the course of their 
illness, a fact that limits what is possible in the study of prognosis of untreated epilepsy.  
 
SEIZURE OUTCOME IN TREATED POPULATIONS 
The natural history of epilepsy within populations of people that are treated with antiepileptic 
drugs has been extensively studied. There are reports of 65 – 80% of patients entering long-term 
remission on or off antiepileptic medication (21, 32, 63-70), of 45 – 55% maintaining remission 
off antiepileptic medication (32, 71, 72) and 10 – 20% satisfying the definition of intractable 
epilepsy (73-77). This thesis will explore the study characteristics that might explain the wide 
discrepancies in the proportion of patients with the seizure outcomes in these studies. There is 
also a group of patients who neither attain remission nor satisfy the definition of medical 
intractability identifiable in some of these studies(72, 76, 78, 79), a group which Camfield et 
al(80) named “something between.”  
 
Most of the studies of prognosis in epilepsy in treated populations do not provide their results in 
terms of seizure outcome by strategy of anti-epileptic drug treatment employed. Hence the 
relationship between outcome and course of antiepileptic medication is not as widely known. 
However, a hospital-based retrospective study by Kwan and Brodie(81) in Scotland shows that in 
a patient group aged between 9 to 93 years, 47% of all patients treated were seizure-free for at 
least 1 year at the time of last follow-up on the first AED, 13% on the second and only 4% for any 
further AED regime: a total of 64% of the cohort was seizure free. Moreover, similar to the 
report by Kwan and Brodie(81) were findings from a prospective hospital-based Dutch childhood 
cohort (66) in which 46% achieved remission (seizure-free for at least 1 year at 5 years of follow-
up) on the first AED, 19% on the second and 9% on any further AED regime: a total of 74% of the 
cohort was in remission. In the childhood Dutch cohort, 58% of the patients achieved remission 
after the first antiepileptic drug failed compared to the Scottish cohort that comprised people 
aged between 9 to 93 years, where 32% achieved remission after first AED failure.(66, 81) The 
difference between the results of these studies may support what Hippocrates had suspected 
and Gowers suggested; that prognosis may be better in childhood onset epilepsy. However, this 
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inference is limited by the study with fewer patients in remission being a retrospective study, 
while in the study with better outcome, patients were prospectively identified. 
 
In a meta-analysis (81-83) that included the Scottish study(81) involving 621 patients overall 
with newly diagnosed epilepsy, Wiebe(84) showed that 48% of patients became seizure free 
with the first AED and of those who failed the first, 27% responded to a second drug, and of 
those who failed a second drug 12% responded to more than 2 combined AEDs. These results 
relating to drug failure and number of antiepileptic drugs required to achieve remission 
notwithstanding, the choice of specific drug used has not been shown to significantly influence 
seizure outcome.(85-87)  
 
No controlled trial has ever shown that any of the first line AEDs is better than the others in 
terms of achieving remission, often leaving the physician to choose which drug, mostly single, to 
use initially based on a case by case consideration of cost (of the drug and necessary follow-up 
investigations), and potential for adverse effects.(88) The AED dose is then usually increased 
gradually to a near toxic level before considering a second drug on account of not achieving 
remission, allergic or other adverse reaction. The second drug is titrated to therapeutic levels as 
the first drug is tapered and discontinued. Subsequent substitutions are done in similar fashion 
before polytherapy is considered; an approach that effectively limits the additive adverse effects 
of multiple antiepileptic drugs.(89) 
 
The course of epilepsy in treated populations therefore has been shown to be good, although 
not as fixed as these studies might suggest. There has been evidence of a remitting-relapsing 
course for certain individuals who enter remission only to experience subsequent recurrence. 
Patients with remitting only course achieve uninterrupted terminal remission, early when within 
12 months of intake or commencement of therapy or late when after 12 months as defined by 
Sillanpaa and Schmidt(25). There is a subset of patients running a remitting course who do not 
have another seizure since intake into a cohort on or off medication, a subset described as 
“smooth-sailing epilepsy” by Camfield et al (90)  
 
In the Nova Scotia, Canada cohort, Camfield et al (71, 90) reported that 21% of 472 children 
(excluding those with absence, myoclonic, or atonic seizures) had smooth-sailing epilepsy, and 
an overall 48% had a remitting course. In the Dutch cohort,(66) 14% of 453 children had smooth 
sailing epilepsy, while altogether 41% had a remitting course. The results are similar in the 
Finnish cohort with 16% of the patients having smooth-sailing epilepsy and 48% overall with 
remitting course.(25) Those with a remitting-relapsing course have their remission interrupted 
by a relapse; some of them however go on to achieve terminal remission.  Of the children who 
experienced relapse in the Finnish cohort, 58% achieved terminal remission, 52% after 1 relapse 
and only 6% after 2 episodes of relapse.(25)  
 
At the other end of the spectrum are those whose seizures will become medically intractable, 
another fluid category. Berg et al(73) defined intractability as “failure, for lack of seizure control, 
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of more than 2 first-line anti-epileptic drugs with an average of more than 1 seizure per month 
for 18 months and more than 3 consecutive months seizure-free during that interval.” In their 
cohort based in Connecticut, USA, 12% of children who had earlier satisfied the criteria for 
intractability went on to attain remission.(73)  
 
In the Dutch cohort, 6 out of 25 (24%) children who had satisfied a similar definition of 
intractability at 2 years follow up, attained 1 year terminal remission at 5 years, and 18% of 
those who had been seizure free for 1 year during follow up did not achieve 1 year terminal 
remission at 5 years, and 2% had even become intractable.(66) In another childhood cohort, 4% 
of patients who had experienced recurrent seizures for 2 years achieved remission with each 
year of follow up.(91) 
 
Therefore patients who have been seizure-free for a particular period of time at the point of 
assessment during follow up may not be categorised as being in such a category at a different 
point, as is the case for those satisfying the definition of medical intractability. The choice of end 
point for analysis varies from study to study. Hence the pictures we have from different studies 
are like snapshots, taken every 2 or so seconds, of for example the screen during a scene in a 
motion picture. Most things might remain in their position, but certain things, no matter how 
few are bound to change or be different – a shift, a change in the position of the mouth, a smile 
becoming stilled in a frown.  
 
This is the state of affairs in prognosis research in epilepsy. While research does not tell exactly 
what the prognosis of epilepsy is – it will take a report on each patient in a cohort to achieve 
that – we at least have snapshots from which we hope we might understand the specific 
predictors of each state covered in the snapshots. Several prognostic factors identifiable at the 
time of diagnosis have been shown to distinguish between those most and least likely to 
experience a particular seizure outcome. They include symptomatic aetiology, history of status 
epilepticus, multiple types of seizures, younger age of onset, having many seizures before 
initiating medication, and failure to respond early to medication.(21, 32, 63-79, 81, 92-107) 
1.2.2 WHEN TO COMMENCE OR DISCONTINUE MEDICATION 
This segment presents information from previous studies regarding making the decision about if 
and when to commence anti-epileptic medication in patients with epileptic seizures. 
 
Antiepileptic medication is readily availability in high income countries where much of the 
studies of the prognosis of epilepsy studies have been conducted. Hence, there has been little 
opportunity to study the course of untreated epilepsy. Ethical considerations have also limited 
prognostic research that may help determine the proportion and characteristics of people with 
epilepsy who enter spontaneous remission. However, it has been shown in clinical trials that 
antiepileptic drug prophylaxis in patients with severe head injury(108, 109) and craniotomy(110) 
only suppress immediate seizures, but not the ultimate development of epilepsy in those at risk.  
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The Italian FIRST (First Seizure Trial) study randomised 419 people with a first tonic-clonic 
seizure into immediate and delayed (until after a recurrence i.e. diagnosis of epilepsy) AED 
treatment groups without significant long term difference in probability of achieving 
remission.(111) In the MESS Trial, 1443 people with single or infrequent seizures for whom 
indication to commence treatment was not clear were randomly assigned to immediate or 
delayed (until physician and patient agree AED is necessary) treatment. Immediate AED therapy 
reduced the occurrence of seizures in the first 2 years, but did not affect long-term prognosis in 
this group of patients.(98)  
 
However, in the short term, next to the prognostic category of people with epilepsy who will 
enter spontaneous remission is the group of those who will enter remission only with AEDs and 
continue in remission even after the drugs are withdrawn. This category can only be determined 
in studies designed to phase out the use of AEDs in patients in remission. Much of prognosis 
research in epilepsy had been on determining the predictors of successful AED withdrawal. The 
decision to discontinue AEDs may be more difficult than the decision to start the drugs.(112) 
The benefit of seizure prevention in the short term does outweigh the risk of potential adverse 
effects, the cost, stigma and inconvenience associated with AEDs.(113)  
 
However, the question as to whether the benefits of AEDs still outweigh the drawbacks of AEDs 
arises for patients in long-term remission. The possibility of the development of serious adverse 
events is a strong argument for discontinuing AEDs, especially in children in remission who in 
their formative years are on drugs that affect their cognition, and women in their child-bearing 
years who are in remission and intend to have children as teratogenicity is a potential problem 
with most of first line AEDs.(112) The discontinuation of AEDs is considered in the light of 
implications of recurrence for patient safety, driving privileges, employment and liability.(113) It 
is important to understand the predictors of recurrence clearly before embarking on AED 
withdrawal. 
 
With rate of relapse following AED discontinuation ranging from 12 to 63%(113) in a wide array 
of studies with different designs, Berg and Shinnar(114) conducted a meta-analysis of 25 studies 
that met strict inclusion criteria, and found that the risk of relapse was 25% (95%CI 21% to 30%) 
after 1 year of initiating AED withdrawal, and 29% (95%CI 24% to 34%) after 2 years. The meta-
analysis also found that the rate of relapse was higher in adult-onset epilepsy compared to 
childhood-onset epilepsy. The patients with remote symptomatic epilepsy and those with 
abnormal EEG also had a higher rate of relapse. However, the meta-analysis by Berg and 
Shinnar(114) addresses relapse after initiating withdrawal, and not after completion. Therefore, 
it does not quite tell us the percentage of patients who remain in remission after completing the 
AED withdrawal process. In the Nova Scotia Canada cohort 48% of the entire cohort was able to 
discontinue AED therapy and remain in remission(71). This was in keeping with the British MRC 
Antiepileptic Drug Withdrawal Study which showed that within the group of patients with at 
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least 2 years terminal remission randomised to slow discontinuation of AEDs, about 50% were 
successfully  discontinued(115).  
 
Further analysis and follow up of the MRC study cohort showed that the rate of seizure 
recurrence after AED withdrawal was same for all the drugs used in the cohort (phenobarbitone, 
phenytoin, and sodium valproate) except cabamazepine for which the rate of recurrence is 
lower(116) It was also found that AED discontinuation does not modify the long-term prognosis 
of a person's epilepsy, although it increases the risk of seizure 2 years following discontinuation, 
(117) a finding that further confirms the time dependent beneficial effects of antiepileptic drugs. 
1.2.3 WHEN TO CONSIDER OTHER INTERVENTIONS 
This segment clarifies the definitions of uncontrolled seizures adopted for the purpose of this 
thesis and presents the literature describing the justification for early consideration of non-
pharmacological interventions such as epilepsy surgery and ketogenic diet in people with 
medically intractable seizures. 
 
DEFINITIONS OF UNCONTROLLED SEIZURES 
Most studies refer to uncontrolled seizures using the term intractable or refractory, and some 
other studies use both terms interchangeably.(72-79) The definition of intractability is usually a 
variation on a “failure, for lack of seizure control, of more than 2 first-line anti-epileptic drugs 
with an average of more than 1 seizure per month for 18 months (some 2 years) and no more 
than 3 consecutive months seizure-free during that interval”(78) The variations on this definition 
of intractability is adopted in this thesis as well as the use of the term “intractability”.  
 
However, the fact that the term intractable is often used interchangeably with refractory is a 
source of confusion.  In this thesis, the term refractory is used to denote the category of 
patients who had not achieved at least 1 year seizure-free period immediately before the last 
assessment. This is in keeping with the definition from Semah et al(103), Kwan and Brodie(81), 
Stephen et al(118) and Hui et al(97). The broader category defined as refractory therefore also 
effectively includes within it patients who will fulfil the criteria for intractability.  
 
SEIZURES BEGET SEIZURES 
The 1881 aphorism by Gowers that “seizures beget seizures”(49) may be wrong in much of 
human epilepsy. However, there are certain patients for whom it does seem apposite. First in 
this category is evidence from a study by Hauser and Lee(119) that in a first unprovoked seizure 
cohort, individuals with low risk for seizure recurrence in the cohort (idiopathic/cryptogenic 
aetiology) demonstrated a significant increase in risk for seizure recurrence with increasing 
numbers of seizures. However, since the majority of these patients will ultimately achieve 
remission and discontinue AED successfully, the authors argued with merit that there must be 
competing forces that increase or decrease risk for seizure recurrence, of which the number of 
previous seizures is only 1 of several contributors.  
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In a further analysis of the Nova Scotia, Canada cohort by Camfield et al(120) children with more 
than 10 seizures (who were also more likely to have focal seizures associated with impaired 
consciousness) were less likely to enter remission. Shorvon and Reynolds(121) had earlier shown 
that the number of focal seizures associated with impaired consciousness occurring prior to 
treatment was dramatically different: 20 (range 2-180) in those who achieved remission and 73 
(range 20-960) in those whose seizures did not remit.(122) These 2 studies suggest that Gowers’ 
“seizures beget seizures” may also be true for patients having focal seizures associated with 
impaired consciousness. Hence, considered alongside the argument for competing forces by 
Hauser and Lee(119), Gowers may have been at least partly right in these specific groups of 
patients. 
 
The continued occurrence of seizures also changes the structure of the brain. Multani et al(123) 
have shown that changes in neuronal ultrastructure are associated with relatively large numbers 
of seizures over long periods of time. They used computerized 3-dimensional image analysis to 
evaluate the features of neurons removed as part of surgery for mesial temporal lobe epilepsy 
(TLE). More synaptic neuronal elements were lost and the 3-dimensional complexity of the 
neurons was simplified in direct relation to the total lifetime number of seizures and the 
distance of the brain tissue away from the seizure focus. Three groups that prospectively 
assessed every 3 to 4 years the degree of cerebral atrophy with magnetic resonance imaging 
(MRI) in patients with chronic(124) and temporal lobe epilepsy(125, 126) demonstrated 
progressive cerebral atrophy in these patients but not in those with newly diagnosed epilepsy or 
those whose seizure are controlled. 
 
PSYCHOSOCIAL ASPECTS OF UNCONTROLLED SEIZURES 
The continued occurrence of seizures is undesirable for reasons beyond the possibility of the 
seizures begetting further seizures. Numbered among other reasons why uncontrolled seizures 
are undesirable is the psychosocial impact on the lives of people with epilepsy.  
 
In a cross-sectional study (N=696) by Jacoby et al(30) of  British adults, 44% of 168 people with 
frequent seizures (1 or more seizures per month in the past 3 months) had Hospital Anxiety and 
Depression Scale (HADS)(127) case defining score for anxiety, compared to 13% of 350 without 
current seizures. The depression case defining score on the HADS was met by 21% of patients 
with frequent seizures compared to 4% without current seizures. In the same study, 62% of 
people with frequent seizures felt stigmatised compared to 25% of those without current 
seizures. Also, fewer people with frequent seizures were married, employed or had a sense of 
social support. The fact that this study is cross-sectional study and does not use any of the more 
usual definitions of uncontrolled seizures limits inferences that could be made from these 
results. 
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However, Thompson et al(128) in a case-control study using the Patient Health Questionnaire-
9,(129) to determine clinically significant depression in another study in adults, also showed that 
clinically depressed people with epilepsy were significantly less likely than non-depressed ones 
to be married or employed and more likely to report comorbid medical problems and active 
seizures in the past 6 months. This study is also limited by being a cross-sectional analysis. 
 
In a prospective cohort study by Camfield et al(130) conducted on the intellectually normal 
children within the Nova Scotia cohort, the proportion with 8 different adverse psychosocial 
outcomes were reported thus – 34% had experienced school failure, 34% used special education 
facilities, there was mental health consultation in 22%, unemployment in 20%, social isolation in 
27%, undesired pregnancy in 12%, 5% were on psychotropic medication and 2% had been 
convicted.  When the children were divided into those with bad social outcome (1 or more of 
the 8 adverse factors) and good social outcome (none of the adverse factors), stepwise logistic 
regression analysis showed that more than 21 seizures before treatment was an independent 
predictor of bad social outcome. Sillanpaa et al (32, 69) also showed in prospective Finnish 
cohort that childhood-onset epilepsy is significantly associated with increased risk for 
considerable psychosocial, vocational, and cognitive dysfunction, persisting into adulthood. 
 
Jokeit and Ebner(131) found that the duration of epilepsy predicted global cognitive impairment 
in a cross-section of adults with intractable temporal lobe epilepsy, where after correcting for 
educational level the duration of epilepsy remained a more important independent predictor of 
cognitive dysfunction than age, age of onset, site of epilepsy, aetiology, use of AEDs, and 
occurrence of generalized seizures. Nolan et al(132) has confirmed this finding in a prospective 
study of childhood epilepsy in Sydney, Australia with earlier age of onset as covariate of longer 
duration of epilepsy. The exact same covariates were found by Pavone et al(133) among 
children with the more benign absence epilepsy. In the Sydney childhood epilepsy series, higher 
frequency of seizures, generalized symptomatic epilepsies, and larger number of AEDs were also 
independently associated with lower overall intelligence. 
 
These outcomes may be due to the seizures themselves or to toxic effects of anti-epileptic 
drugs. It has been conclusively proved in 2 placebo-controlled, randomized trials involving 
healthy adults(134) and people with epilepsy(135) that antiepileptic drugs contribute to 
cognitive dysfunction, the major effects being impaired attention, vigilance, and psychomotor 
speed.(136) These effects increase with higher dosages and number of antiepileptic drugs(137) 
and subjective health status is affected more negatively by adverse effects of antiepileptic 
medication than seizure frequency.(138) 
 
The cause of these psychosocial outcomes is likely to be a complex interplay of underlying 
neurologic abnormalities, effects of recurrent seizures, AED toxicity, and psychosocial factors 
which are more prevalent in people with intractable seizures.(134-138) Therefore if ongoing 
seizures, or the psychosocial factors and long running high doses of AEDs which are in 
themselves consequences of persistent seizures, are responsible for cognitive dysfunction and 
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dysfunctional adaptation to life, then earlier non-pharmacological interventions could reduce 
these immediate and long-term outcomes.(139) 
 
ECONOMIC IMPLICATIONS OF CONTINUED SEIZURES 
There is also an economic argument to be made for early non-pharmacological intervention. 
Heaney and Begley(140) in a systematic review of economic evaluation of epilepsy management 
identified 3 published studies of the cost effectiveness of epilepsy surgery.(141-143) The 
incremental cost of surgery was estimated at US$16,000 to US$27,000 per QALY (Quality 
Adjusted Life Years), and the cost per seizure-free patient to be about 15% of AED use over a 
lifetime in patients with intractable seizures. Begley et al estimate that in the United States, 80% 
of the cost of epilepsy is attributable to patients with medically intractable seizures, which form 
less than 20% of the total epilepsy population.(73-77) This disproportionate cost of people with 
medically intractable seizures is likely due to the cost of continued AED use at high doses to 
control seizures.  
 
EARLY EPILEPSY SURGERY  
Epilepsy surgery is any surgical procedure carried out to control seizures in epilepsy. It may be 
neurosurgical in which the seizure focus is resected, isolated or simulated. It may also be surgery 
carried out to implant stimulator device and electrodes for Vagus Nerve Stimulation (VNS) 
subcutaneously in the chest and neck.  
 
Neurosurgical Epilepsy Surgery and Surgically Remediable Epilepsies 
The benefit of resective surgery especially has been demonstrated repeatedly.(139) Early 
epilepsy surgery may be life-saving as the risk of mortality in people with intractable epilepsy is 
up to 5 times higher than in the general population reversing to normal in those who become 
seizure-free after epilepsy surgery.(37, 144, 145) The risk of SUDEP (sudden unexpected death in 
epilepsy) is zero with seizure remission but up to 1 per 100 per year in patients with frequent 
and severe tonic clonic seizures.(8) Patients who become seizure-free after surgery also had 
better cognitive function, social and behavioural outcome (131, 146, 147) but the effect of an 
older age at surgery(146, 148, 149) or longer duration of epilepsy persisted even after successful 
surgery.(131) 
 
Epilepsy surgery is not without its own risks. However, careful candidate patient selection is 
crucial in preventing these risks. Helmsteader et al(147) posits that the dichotomy of surgical 
outcome is that patients either achieve remission with cognitive stability “double winners” or 
achieve neither  “double losers,” a sad outcome observed mostly in only poorly selected 
candidates - older patients, and patients without hippocampal sclerosis who undergo dominant 
temporal lobe surgery.(150) Otherwise, neurological deficits such as hemiparesis, visual field 
defects, dysphasia are often temporary.(151)  
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Prognosis studies that focus on treatment decision making for epilepsy surgery are conducted in 
cohorts limited to specific seizure types, syndromes or by virtue of having intractable seizures or 
epilepsy surgery. (152-162) Téllez-Zenteno et al(163) have just completed a meta-analysis to 
investigate the surgical outcome in 697 patients with non-lesional epilepsy and 2860 patients 
with lesional epilepsy. They found the odds of being seizure-free to be 2.5 (95%CI 2.1, 3.0) times 
higher in patients with lesions identified on MRI or by histopathology. The outcome was similar 
when they disaggregated studies by surgery type (temporal lobe and extra-temporal lobe 
surgery) and by age (children and adults). A meta-analysis by Tonini et al(164) had earlier 
suggested that having identifiable lesions – mesial TLE, tumors, and abnormal MRI – were the 
strongest positive prognostic indicators of postoperative seizure remission. 
 
Those patients with mesial temporal lobe epilepsy (TLE), localization-related epilepsies with 
well-circumscribed lesions, and unilateral hemispheric disorders in infants and children have 
been dubbed by Engel and Shewmon(165) as having “surgically remediable epilepsies.” Engel 
(166)had initially put up mesial TLE as the prototypical surgically remediable epilepsy syndrome, 
as it is the type mostly found among patients with medically intractable seizures who can expect 
to become free of disabling seizures postoperatively.(151, 156, 167)   
 
The concept of “surgically remediable epilepsies” mooted by Engel and Shewmon(165) was a 
reaction to 2 emerging trends – the fact that new antiepileptic drugs might effectively render 
the definition for medically intractable epilepsy irrelevant as the introduction of new drugs 
makes it impractical to prove that any given patient’s seizures are intractable in spite of trying all 
available medications in every possible combination.(168)Secondly, the time it takes from 
diagnosis to surgery might have increased due to multiple drug trials in patients with little 
chance of remission. (139, 168) The idea of “surgically remediable epilepsies” therefore 
proposes to replace that of “medical intractability.” However while it is true that certain 
epilepsies are recognisable as surgically remediable from an early stage, it is also true that there 
are others who may not be so identifiable and for whom early surgery might be beneficial. In a 
Hong Kong, China unselected childhood epilepsy cohort, Kwong et al(76)reported that only 57%, 
of the children with medically intractable epilepsy had detectable abnormality on CT and/or 
MRI. Ko et al(79) reported 55% in a Massachusetts childhood cohort and Berg et al(73) had 20% 
from a cohort in Connecticut, USA.  
 
Instead of replacing one with the other, there may be more benefit from having a standardised 
definition of medical intractability which allows for context specific application especially for 
“surgically remediable epilepsies” and which also accommodates the concept of remitting-
relapsing epilepsy course. For example, on the Scottish study by Kwan and Brodie(81) only in 4% 
of the patients achieved remission on a third antiepileptic drug singly or in combination. This 
suggests that the present commonly varied definition that limits intractability to more than 2 
antiepileptic drugs singly or in combination may suffice for the pragmatic purpose of timely 
determination of candidates for early epilepsy surgery. 
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Vagus Nerve Stimulation 
In patients whose intractable seizures might not be neurosurgically remediable – especially 
when the seizures have multiple cortical foci, when seizure focus is in the dominant or eloquent 
hemisphere, or cannot be defined – or for other reasons not candidates for epilepsy surgery, 
there is the possibility of Vagal Nerve Stimulation (VNS). VNS is conducted through a surgical 
procedure that implants a stimulator in the chest, connected to bipolar electrodes wrapped 
around the left vagus nerve in the neck. Saneto et al(169) reported a prospective study of 43 
children with medically intractable seizures on VNS who were followed up for more than 12 
months. They achieved an overall median seizure reduction rate of 55%. 37% had at least 90% 
reduction. However, no patients are rendered completely seizure-free on the procedure.(8) 
 
In a pioneering report of the analysis of follow up data of 440 participants from a series of open 
label adult VNS trials (with the participants also on AEDs allowing for dosage adjustment as 
required) between 1988 and 1995, Morris et al(170) demonstrated the efficacy and tolerability 
of VNS in medically intractable seizures. Following implantation of a stimulator, there was more 
than a 50% reduction in seizure frequency occurring in 36.8% of patients at 1 year, in 43.2% at 2 
years, and in 42.7% at 3 years. The adverse effect profile –hoarseness and paraesthesias – was 
tolerable with about 75% of participants still on therapy at 3 years follow up. Other adverse 
effects may include dyspnoea, cough, left vocal cord paralysis and lower facial muscle paresis.(8) 
 
KETOGENIC DIET 
Besides epilepsy surgery, the high fat low carbohydrate “ketogenic” diet (sometimes using 
medium chain triglyceride to boost ketosis), in use since 1921, is another non-pharmacological 
intervention to control intractable seizures. Its use is based on the theory that ketosis has 
antiepileptic properties in the presence of low circulating glucose level.(171) Keene(172) 
showed in a meta-analysis, that 15.6% of children with medically intractable seizures on 
ketogenic diet were seizure-free and 33% had more than 50% reduction in seizures at 6 months 
of follow up. However, patients often discontinue the diet and in a meta-analysis by Henderson 
et al(173) the reasons for discontinuing the ketogenic diet were: less than 50% seizure reduction 
(47%), diet restrictiveness (16%), and presence of incurrent illness or diet side effects (13%). 
 
The only RCT comparing the ketogenic diet against no change in treatment reported on 3 month 
seizure outcome in children with medically intractable seizures.(174) After 3 months, the mean 
percentage of baseline seizures was significantly (75%) lower in the diet group than in the 
controls.  Also, 38% of children in the diet group had greater than 50% seizure reduction 
compared with 6% control; 7% in the diet group had greater than 90% reduction in seizure 
frequency compared with none among the controls.  
 
Therefore, although with relatively poorer results, but wider applicability and less invasiveness, 
VNS and the ketogenic diet remain viable and appropriate options in patients with non-
surgically remediable medically intractable seizures. 
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1.2.4 THE SEIZURE OUTCOME OF EPILEPSY 
The ultimate goal of the prognosis studies is to define specific risk groups based on prognosis 
and to predict different categories of seizure outcome more “accurately or parsimoniously” in 
order to provide tools for making informed treatment decision and patient counselling.(45) 
 
Kwan and Sander(51) came up with an epidemiological synthesis of prognosis studies of the 
natural history of treated and untreated epilepsy that suggests there are 3 prognostic groups 
(see Figure 4). Group 1 (20–30%) are the patients with excellent prognosis. There is long term 
remission after a period of seizures, with or without AEDs. The primary aim of AED therapy in 
this group therefore is to suppress seizures until remission occurs, and patients are successfully 
weaned off AEDs. For group 2 (20–30%) seizure remission occurs and is maintained only with 
AEDs. In group 3 (30–40%) there is continuing seizures despite AEDs with some patients having 
frequent enough to qualifying them as being medically intractable.  
 
 
Figure 4 | Natural History of Newly Diagnosed Epilepsy 
Group 1 will enter “Spontaneous” remission (20-30%), 2 remains in remission only on AED treatment (20-30%) and 3 
continues to have seizures (30-40%) [Adapted from Kwan and Sandler(51)] 
 
However, a further interpretation of available evidence and patterns of seizure outcome suggest 
that this view could be further broken down to achieve a finer granularity in the prognostic 
groups that people with newly diagnosed epilepsy could be predicted to belong at the point of, 
or within 1 year of diagnosis. Group 1 is the group of patients who would enter remission with 
or without AED therapy, those who would automatically achieve remission even if they did not 
have access to AEDs.  
 
Sub-Group 1A therefore will represent those with immediate spontaneous remission (ISR). 
(Figure 5) They will not have a third seizure, i.e. upon starting AED or being recruited into the 
cohort under consideration they enter terminal remission immediately, and will not relapse 
after complete AED withdrawal. In a New York childhood first seizure cohort, Shinnar et al(24) 
reported that out of 182 children who had a second seizure, 28% did not have a third seizure 
(second recurrence) at 5 years follow up, meaning they could be effectively considered as 
having entered into immediate remission.  
 
PEOPLE WITH EPILEPSY
REMISSION
1.REMISSION OFF AED 2. REMISSION ONLY ON AED
NO REMISSION
3. NO REMISSION ON AED
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Figure 5 | Natural History of Newly Diagnosed Epilepsy (with additional granularity) 
Sub-Group 1A will not have a second recurrence (third seizure) and will remain in remission after complete AED 
withdrawal. 1B enters remission, although not immediately and remain in remission after complete AED withdrawal). 
2A achieves and stays in remission only on continued AED. 2B has 1 or more periods of relapse, but achieves remission 
ultimately and stays in remission only on continued AED. 3A has 2 different categories within it: i – those who have 1 
or more periods of relapse, but do not achieve remission ultimately, ii – those who have never achieved remission, but 
who do not fulfil the criteria for medically intractable seizures. Sub-Group 3B medically intractable seizure which could 
also have within it the 2 categories of: i –those whose seizures will remit on non-pharmacological intervention, and ii – 
those who will never achieve remission no matter what is done. 
 
Hauser et al(175) reported that 27% did not have a second recurrence after 4 years of follow up 
in an all age cohort in Minnesota.  Treatment did not influence the rate of second recurrence in 
both studies, although for Hauser et al(175) the risk of additional seizures in those with 2 
previous seizures is greater than the risk of adverse effects of antiepileptic drugs. Neither study 
investigated the subset of these patients who are successfully taken off antiepileptic drugs. 
Hence the proportion of patients within this Sub-Group may be less than they have reported. 
 
Sub-Group 1b thus represents those who although they do not enter remission immediately, 
ultimately do so, and who alongside those who enter immediate remission, will remain in 
remission on antiepileptic drug withdrawal. There is however no study from which an estimate 
of the proportion of patients who will be in this group could be derived. It does however fill an 
important conceptual space within the range of temporal outcomes of seizures in newly 
diagnosed epilepsy. 
 
Notwithstanding their original eligibility into any of the Sub-Groups of Group 1, those who 
cannot be successfully weaned off antiepileptic drugs belong in Group 2. It could also be 
imagined that those within Sub-Group 2A are those whose epilepsy alongside the whole of 
group 1 did run a remitting course only that they could not be taken off AED. Those in Sub-
Group 2B arrived in remission after a remitting-relapsing course. People in Sub-Group 2B made 
up 20% of the Finnish cohort.(25) 
 
Group 3 comprises those patients who will not enter terminal remission either because after a 
remitting-relapsing course they do not achieve terminal remission (14% of Sillanpaa et al’s 
Finnish childhood cohort) or because they continue to have seizures from diagnosis in spite of 
AEDs i.e. they never experience remission. Within this group will be those (Sub-Group 3A) who 
will continue to have seizures, not frequent or debilitating enough to be described as intractable 
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON  AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
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and those (Sub-Group 3b) who will fulfil the definition of medically intractable seizures (10-20%) 
(73-77).  
 
Further subdivision of 3B would give us the 2 categories of those whose seizures will remit on 
non-pharmacological intervention, and those who will never achieve remission no matter the 
intervention. Sub-Group 3A will also have a sub-population of those who ran a remitting-
relapsing course within it. Therefore the whole of Sub-Group 2B and part of Sub-Group 3A is 
made of patients running a remitting-relapsing course, which also indicates that the boundary 
between the 2 Groups will be a potential area of cross-over activity, and certainly an area where 
multivariate regression snapshots will capture different pictures in time. 
 
One group that may exist but is not covered is of newly diagnosed patients who initially enter 
immediate spontaneous remission and then go on to have a remitting-relapsing course, but are 
eventually successfully weaned off AEDs. However, evidence from Sillanpaa et al(25) suggest 
that it is unlikely that such individuals exist. They show that the number of years before entering 
5-year remission is an independent predictor of relapse. Therefore there is a low probability that 
a patient with immediate spontaneous remission will go on to have a remitting-relapsing course, 
and if they do, it may be ill advised to wean them off AEDs. 
 
The ideal prognosis study in unselected populations of people with epilepsy will be a prospective 
cohort which is followed up long enough and in good detail to achieve this level of granularity in 
making out different prognosis groups that will help inform treatment decisions and patient 
counselling regarding issues of if and when to start antiepileptic drugs, if and when to 
discontinue antiepileptic drugs and if and when to consider non-pharmacological intervention. 
The ideal study will also use multivariable approach to analyse for prognostic factors that will 
help guide these decisions, and also provide externally validated tools (models) to estimate 
outcome probabilities based on combinations of these predictors.(23) 
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1.3 SYSTEMATIC REVIEWS OF PROGNOSIS STUDIES 
The third part of this introductory chapter presents an overview of the role of systematic review 
in medical research with its application to observational studies in general and prognosis studies 
in particular. 
1.3.1 THE ROLE OF SYSTEMATIC REVIEWS 
In an exposition on the role of systematic review in health research, Chalmers(176) opened his 
foreword to Systematic Reviews in Health Care: Meta-analysis in Context1 by quoting the 
physicist Lord Rayleigh:  “If, as is sometimes supposed, science consisted in nothing but the 
laborious accumulation of facts, it would soon come to a standstill, crushed, as it were, under its 
own weight… The work which deserves but I am afraid does not always receive the most credit 
is that [of] introducing order and coherence in which not only facts are presented, but their 
relation to old ones is pointed out.” 
 
The introduction of order and coherence into a body of research is the central role of systematic 
reviews. Cook et al(178) defined systematic review as “the application of scientific strategies 
that limit bias by the systematic assembly, critical appraisal and synthesis of all relevant studies 
on a specific topic” and meta-analysis as “a systematic review that employs statistical methods 
to combine and summarize the results of several studies.” The need for this method of research 
arose out of the fact that science itself is a cumulative process. The fast pace, and almost 
exponential increase in the accumulation of scientific papers resulted in a tendency to lose 
information in an abundant mass of facts, necessitating that the results of research be 
synthesised.(179) 
 
However, the traditional /narrative review, synonymous with expert opinion has been shown to 
have a tendency to reflect a singular, often biased opinion that also may lag behind and even 
contradict research evidence.(180-184). Murlow in 1987 was the first to highlight that the 
review of clinical research was largely poor and unscientific.(182) Murlow  reviewed a sample of 
traditional/narrative clinical reviews published in 4 leading American medical journals, and 
demonstrated that most fell short of the standards for systematic reviews. McAlister et al(181) 
did a follow up 10 years later, and found that the situation had only improved marginally. 
 
There is a metaphorical view of systematic review as an epidemiological study, one in which the 
subjects are published and unpublished studies rather than humans. The data collection involves 
taking a representative sample of a well-defined population (of studies) or identifying every 
member of the population if an unbiased sample is impossible.(185) Systematic reviews start 
like all epidemiological studies with a good question, followed by developing a protocol to 
answer that question, collecting, synthesising and analysing the data to arrive at objective 
conclusions.  
                                                          
1
 The book "Systematic Reviews in Health Care: Meta-analysis in Context" has had a defining role in the emergence of 
systematic review and meta-analysis as a central and important tool in health research. (177) 
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1.3.2 HISTORY OF RESEARCH SYNTHESIS IN MEDICINE 
The application of systematic reviews and meta-analysis lagged in medicine, behind the social 
science research fields of education and psychology. In 1933, Peters(186)published a systematic 
review of a series of experiments on the impact of moral instruction on modifying character “in 
order to bring them together into a single form so that we may draw inferences from the whole 
set.” It was a psychologist, Glass(187) who coined the term meta-analysis “to refer to the 
statistical analysis of a large collection of analysis results from individual studies for the purpose 
of integrating the findings.” In these roles systematic review and meta-analysis helped separate 
the wheat from the chaff of available research, performing interpretative functions as well as 
serving as a means of systematising existing accumulated knowledge. 
 
Nevertheless, medicine had much earlier, albeit isolated attempts at systematic review. In 1753, 
James Lind, a Scottish naval surgeon, who had to deal with a series of reports about scurvy came 
up with a treatise containing “an inquiry into the nature, causes, and cure, of that disease 
together with a critical and chronological view of what has been published on the subject." For 
him, "it became requisite to exhibit a full and impartial view of what had hitherto been 
published on the scurvy” and “to remove a great deal of rubbish."(179) Two 18th century 
European journals [Medical and Philosophical Commentaries (Edinburgh) and Comentarii de 
Rebus in Scientia Naturali et Medicina Gestis (Leipzig)] published critical appraisals of available 
research evidence.(188) 
 
However, the 20th century pioneer of research synthesis in medicine was Pearson.(179) In their 
1904 review of a typhoid vaccine, Simpson and Pearson(189) extracted data and conducted a 
meta-analysis of correlation coefficients in 2 groups from 11 selected studies of immunity and 
mortality among British soldiers serving in various parts of the world. In another typhoid review 
3 years later in 1907, Goldberger(190) analysed available data on bacteriuria in typhoid fever in 
Washington DC, in strict adherence to yet-to-be-formulated criteria for systematic reviews and 
meta-analysis.  
 
The terms systematic review and meta-analysis have not always meant what they presently 
mean. The idea of research synthesis has gone through periods of evolution over which these 
terms and others including “research synthesis” have connoted different things. The term 
research synthesis was and is sometimes still used extensively by the social scientists who led 
the development of the science and practice of review in the second half of the 20th 
century.(179) Although the term “systematic review” was used during the first half of the 20th 
century, even before "research synthesis,"(191) it is uncertain whether it was in the same sense 
of what it grew to mean during the second half of the century.(179)  
 
However, the term systematic review slowly gained wider usage and the method became more 
popular and recognised, reaching a tipping point in the late 1990s owing to the earlier use of the 
term by Cochrane(192) in his foreword to a popular 1989 compilation of research syntheses in 
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maternal health,(193) the creation of the Cochrane Collaboration in the early 1990s, and the 
promotion of “systematic review” in contradistinction to meta-analysis, in the first and second 
editions of Systematic Reviews in Health Care: Meta-analysis in Context. (194, 195) 
1.3.3 CRITICISMS OF RESEARCH SYNTHESIS IN MEDICINE 
Nonetheless, there have been epistemological challenges to the claims of the systematic review 
process to objectivity.(196)This view concedes to systematic review its assertion of methodical 
discipline in adhering to an explicit and auditable protocol. The contention is that this 
“procedural objectivity” does not remove the subjectivity of the process(197) as search 
results,(198) quality assessment,(199) data extraction(197) and review conclusions(200) all vary 
with reviewers. The objectivity of the process is then, it was argued, only in its “disciplined 
subjectivity.”(196)  
 
However, on the other end of the spectrum, there is the challenge that over-adherence to 
protocols has sometimes lead to “empty reviews”(201) in cases where no studies meet inclusion 
criteria, with authors missing the opportunity to offer insight into the quality of studies so 
excluded. The contention here is that “bad” research can yield “good” evidence.”(202)  
 
The same subjectivity charge has also been levelled against meta-analysis,(203) especially in the 
interpretation of funnel plots(204) and the use of quality scores.(203)The idea of quantitative 
statistical synthesis (meta-analysis) has drawn strident negative responses.(176) Expressions like 
"shmeta-analysis"(205) “an exercise in mega-silliness”(206) and “statistical alchemy for the 21st 
century”(207) were a rare display of invective in the medical literature. However, the effort at 
distinguishing systematic review from meta-analysis by the editors of Systematic Reviews in 
Health Care: Meta-analysis in Context (194, 195) and others was “to prevent the former being 
discredited by poor versions of the latter”(208). They set meta-analysis in proper context as an 
optional addendum to the systematic review process only to be used with proper discretion.  
1.3.4 SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES 
These criticisms especially of meta-analysis were more directed at reviews of observational 
epidemiology, than of interventional studies. From only 4 identifiable in the 1985 publication 
year(209) to over 400 published in 1996,(210) the use of meta-analysis in observational studies 
is now about as common as in randomised controlled trials. In a random sample of meta-
analyses published available on MEDLINE search in 1999, Egger et al(211) found that 40% of the 
meta-analyses were based on observational studies (mainly cohort and case-control) studies, a 
result that is in keeping with an earlier analysis by the same group, of studies published and 
available on MEDLINE search in 1995.(212) 
 
While the randomised controlled trial (RCT) remains the gold standard in the evaluation of 
intervention, aetiological and prognostic hypotheses can hardly be tested in randomised 
experiments; it is often only by observational studies or laboratory experiments that these could 
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be investigated.(212) However, in meta-analysis, the assumption of random variation in the 
results between studies, while it may be plausible in RCTs (as they are conducted in usually 
homogenous groups of patients and within largely regulated settings) is not quite as plausible in 
observational studies where estimates of association may deviate from true underlying 
relationships beyond variation due to chance, as it is a design that is more susceptible to the 
effects of confounding, and the influence of biases.(185, 212) 
 
The most important threat to the validity of results from a well conducted cohort study is 
confounding, while a plethora of biases may plague the case-control studies. Even in instances 
where confounding factors have been allowed for in statistical analysis, residual confounding, 
where the confounder is unknown, unsuspected or could be reliably or precisely assessed may 
remain.(211-214) Therefore, the systematic review of observational studies is for these reasons 
encouraged over meta-analysis which however remains particularly attractive as it results in 
precise and definite risk estimates when the magnitude of the underlying risks are small or 
when the results from individual studies disagree.(212) 
 
However, the more specific application of systematic review and meta-analysis to prognostic 
factor studies, while it shares the issues that plague that of observational studies in general, also 
presents its own unique problems:(45, 211, 215) greater difficulty in identifying all relevant 
studies compared to RCTs, the problem of publication bias (it is less likely that non-significant 
results will be reported), and many of the studies are retrospective thereby increasing the 
probability of bias.  
 
There is the issue of inadequate and incomplete reporting of methods and outcome measures, 
and the lack of recognised criteria for quality assessment. There is also wide variation and 
inconsistency in study design, inclusion criteria into cohorts, methods of assessing prognostic 
variables, approach to handling continuous variables, the choice of variables to adjust for, 
methods of statistical analysis and adjustment for confounders, length of follow up, and the 
presentation of results by different time points during follow up.(215)  
1.3.5 SYSTEMATIC REVIEWS OF PROGNOSIS STUDIES IN EPILEPSY 
The conduct of prognosis studies in general has been frequently criticised within the medical 
literature.(23, 39, 45, 216, 217) The contention has often been that in spite of its methodological 
demands, prognostic studies are usually not protocol driven, small sized, widely heterogeneous 
in characteristics of patients, choice and number of predictor variables, outcome and follow up 
measures, and often prognostic analyses are conducted post-hoc in studies designed for quite 
another purpose. However, the same issues are not restricted to prognosis research alone, but 
have broader implications for observational studies generally.(218, 219) 
 
The results of prognostic studies are therefore largely fraught with limitations, and with the 
attendant uncertainty about the reliability of conclusions of their synthesis.(42, 217) This led to 
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the creation a new Cochrane Prognosis Methods Group in 2008 aimed at providing support and 
a forum for discussion to facilitate and improve the quality of systematic reviews of prognosis 
research.(220) Systematic review of prognosis studies with special focus on methodology is 
therefore a burgeoning field of interest, and there have been efforts at ensuring the quality of 
such reviews. Hayden et al(39) have developed a set of criteria, for quality assessment through a 
meta-review of systematic reviews of prognosis studies. These criteria were adapted for use in 
the quality appraisal of studies included in this review. 
 
Hitherto, the systematic reviews in the literature of observational studies in epilepsy have only 
focused on the incidence and prevalence of epilepsy generally(221) and with regional focus – 
Asia(222), Latin America(223), Middle East and North Africa(224), Europe(225) and sub-Saharan 
Africa(226). However, these studies, when they do, only make passing reference to the methods 
and/or results of prognosis studies. Ross et al also systematically reviewed the literature, but on 
management issues in epilepsy from 1980 to 1999.(227)The studies on prognosis were therefore 
only partly considered and only in passing, without methodological rigour or consideration of 
prognostic factors.  
 
The studies on AED withdrawal have also been extensively reviewed(113) with meta-analysis of 
prognostic factors conducted(114), as are of studies considering seizure outcome following 
epilepsy surgery (163, 164)and the use of ketogenic diet.(173) However, in spite of the amount 
of work that has gone into analysing prognosis in newly diagnosed epilepsy, there has been no 
systematic review of these studies and neither has there been a meta-analysis of the prognostic 
factors in patients with newly diagnosed epilepsy. However, beyond seizure outcome, no 
systematic review has also considered other prognostic outcomes, especially of psychosocial 
outcomes following newly diagnosed epilepsy, important as they are. 
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2  CHAPTER TWO: THE AIMS AND SIGNIFICANCE OF 
THIS THESIS 
 
This chapter presents the research question that the thesis aims to answer. The chapter also 
discusses the central contribution of the thesis to the systematic review and meta-analysis of 
prognosis studies in general and particularly to studies of prognosis in epilepsy.  
 
The seizure outcome of epilepsy is varied. Epilepsy itself is a multi-aetiological and diverse 
disorder. The first seizure brings with it the opening of a fresh chapter in the life of the patient, 
with tough decisions to be made for the patient and for clinicians especially of when or whether 
to start AEDs as they carry risks of acute idiosyncratic reactions, dose-related and chronic toxic 
effects, and teratogenicity. For some of the patients newly diagnosed with epilepsy, the benefits 
of treatment will far outweigh the risks associated with treatment, but there are those for 
whom this risk to benefit ratio is more finely balanced.(98) There is also the group of patients 
that may be candidates for non-pharmacological intervention as they will develop drug-resistant 
intractable seizures. 
 
There is thus the need for studies that identify independent predictors of seizure outcome. 
These studies have appeared and accumulated in the medical literature. The studies are of 
different quality and they employ varying methods, study population, outcome definition, and 
duration of follow up. It is therefore useful to systematically identify all these studies, review 
their methods and synthesise the results of those studies that have identified the independent 
factors which consistently predict clinically relevant seizure outcomes in patients that have been 
newly diagnosed with epilepsy early in the course of the disease. 
 
There is a greater tendency for publication bias in observational research compared to 
randomised trials(228) and particularly in prognosis studies, as it is more probable that studies 
showing a strong, statistically significant prognostic ability will be published. This can lead to 
invalid results and incorrect inferences.(229)There are also the biases associated with 
observational studies. This systematic review will therefore thoroughly assess for quality of each 
study in a reproducible manner, based on indices that reflect how prone the studies are to 
different types of bias. 
 
The systematic review method has been applied extensively to confirmatory prognostic factor 
studies investigating contribution of one variable to an outcome. The methods for reviewing 
exploratory studies that set out to identify the independent contribution of a range of variables 
to an outcome have received less attention in the literature. However, studies of prognostic 
factors in epilepsy are of the type that investigates more than 1 variable as there are no already 
extensively established set of prognostic variables for seizure outcome in epilepsy. This type of 
study presents its own unique issues and difficulties for the reviewer. Therefore this review also 
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offers an opportunity to explore these issues and to contribute to the understanding of how a 
reviewer might confront these difficulties. 
 
This thesis aims to answer the following questions: 
 
1. What is the quality of prognosis studies that have attempted to identify independent 
predictors of seizure outcome among unselected population patients with newly 
diagnosed epilepsy?  
2. What is the effect of study quality, especially potential risk for bias, on the results of the 
prognosis studies? 
3. Which factors have been consistently identified as independent predictors of seizure 
outcome and which factors have been consistently identified as non-predictors? 
4. Do satisfactory seizure outcome prediction models already exist? 
 
The thesis also proposes to develop a classification scheme for prognostic factor studies in 
newly diagnosed patients with epilepsy so that future studies can be fitted into the scheme and 
their results interpreted more easily and readily within the context of previous studies of the 
same category. 
 
This thesis contributes to the present understanding of the methods of systematic review of 
prognostic factor studies by developing and using a transparent and reproducible method of 
quality appraisal and by showing how multiple prognostic variables might be handled in a 
systematic review of studies that do not specifically investigate one particular prognostic 
variable. 
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3  CHAPTER THREE: METHODS 
 
This chapter has within it a description of the systematic review process: eligibility criteria, the 
search strategy, how each category of papers was excluded, and how studies from the same 
cohort were handled. It also includes a discussion of the iterative process of developing the 
quality appraisal and data extraction forms and how the results of each study were assessed for 
quality i.e. tendency for bias. It also discusses the criteria for assessing the quality of externally 
validated predictive models. This chapter also includes how predictor variables that are 
consistent, independent predictors of particular outcomes were identified and categorised and 
results compared in a meta-analysis where possible.  
 
The guidelines for the design, performance and reporting for meta-analyses of observational 
studies published by the MOOSE group(210) are followed in this systematic review and meta-
analysis. One of the defining characteristics of the systematic review – which itself is a 
retrospective study subject to its own selection bias – is its fidelity to an a priori protocol. This 
protocol is presented in Appendix I.  
 
3.1 ELIGIBILITY CRITERIA 
For a systematic review of observational studies such as this, an overly strict set of inclusion and 
exclusion criteria especially relating to study design may be unduly limiting. Having a strong 
opinion about the best study design to answer the review questions may lead to selection bias 
as it does not necessarily mean that these types of studies exist or that studies of better design 
and higher quality are not available.(230) Therefore, published prospective and retrospective 
studies – randomised controlled trials, cohort studies, nested case control studies and case-
control studies – of unselected (unrestricted) populations of people with newly diagnosed 
epilepsy that assess the independent effect of predictors of seizure outcome using multivariate 
regression analysis were sought for inclusion in the review, excluding as ineligible, case series 
and cross-sectional studies.  
 
Newly diagnosed epilepsy was defined as epilepsy within the first year for the purpose of this 
review. Therefore only studies with predictor variables collected within the first year of onset, 
diagnosis, presentation or treatment, depending on how intake is defined in each study. 
Majority of patients in the studies will also have been followed up prospectively or 
retrospectively for at least 1 year.  
 
There is no consensus on sample size estimations for multivariable models. However the 
standard rule of thumb is 10 or more events per variable (EPV) in the model to allow a robust 
estimation of regression coefficients(231), a value supported by a simulation study,(232) 
although a more recent study showed that it could be a bit lower(233). Since about 30% (21, 32, 
51, 63-70) of patients with newly diagnosed epilepsy will not achieve seizure remission despite 
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continued antiepileptic drug therapy, a study of association of 2 to 3 predictor variables with 
30% outcome rate requires at least 100 patients to achieve an EPV of 10 or more. Therefore to 
be eligible, the studies also included must have at least 100 patients,(234) a figure also in 
keeping with an inclusion criterion in a systematic review of prognosis studies by Hemingway 
and Marmot.(235)  
 
Only studies published in English language were included in the review. The decision to include 
only English-language studies was made, considering the time, logistic and cost constraints of 
translation, and also with the awareness that the influence of bias due to language of 
publication is disputed, and its effect, when and where shown, has been little, and has been 
considered only in reviews and meta-analyses of intervention studies.(236-239) 
3.2 SEARCH STRATEGY 
There is no widely acknowledged optimal database and strategy for searching the literature for 
prognostic studies.(45, 215) However, in a study to ascertain how many databases would be 
necessary to ensure comprehensive coverage of observational studies in diabetes, Royle et 
al,(240) found that no additional articles from English language journals were retrieved from any 
database beyond MEDLINE and EMBASE.They found that MEDLINE alone retrieved about 94% of 
all the articles retrieved from both databases and the overlap in journal coverage between 
MEDLINE and EMBASE was 59%. In a much earlier study considering journal coverage, Smith et 
al(241) in 1992 found the overlap between MEDLINE and EMBASE to be 34%. Therefore these 2 
databases were searched to ensure comprehensive retrieval of prognosis studies in epilepsy for 
potential inclusion in the review. With the wide overlap between MEDLINE and EMBASE, and 
the fact that the indexing of search terms in EMBASE is more extensive with more synonyms, 
compared to MEDLINE,(242) a more focused strategy was developed for searching EMBASE 
using terms specific to study design and analysis.(243) 
3.2.1 MEDLINE 
To develop search strategies that optimise the yield for prognostic studies in MEDLINE(244) and 
EMBASE(245), Wilczynski et al (244, 245) used Ovid's search engine syntax for combination of 
terms. The terms for best sensitivity (keeping specificity ≥50%) in MEDLINE (sensitivity 90.1%, 
specificity 79.7%)2 was:   
 
incidence (MeSH)  
OR explode mortality  
OR follow-up studies (MeSH)  
OR prognos* (text word)  
OR predict* (text word)  
OR course (text word) 
                                                          
2
 Sensitivity is the proportion of high quality articles that were retrieved while Specificity is the proportion of low 
quality articles not retrieved 
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This result served as a guide in deciding the search strategy for the study. The process that 
generated this result was not limited by specific clinical/disease terms. Therefore the 
performance of the search may be improved by combining the search terms with content 
specific terms using the Boolean ‘AND’. In a search from inception to March 2010, the terms 
identified by Wilczynski et al(244)  were combined with:  
 
explode epilepsy (MeSH) 
OR explode seizure (MeSH) 
OR seizure disorder (text word) 
3.2.2 EMBASE 
The reason why it is difficult to formulate search strategy for observational studies is that there 
are many study designs and the terminology is not standardized.(246) Furlan et al(243)therefore 
set out to identify terms in MEDLINE and EMBASE related to study design and analysis that 
could help reverse identify relevant nonrandomized studies in 4 systematic reviews across 4 
different clinical areas. They found that text word “multivariate” was 1 of 2 terms which limit 
topic only searches in all 4 clinical areas. The text word “regression” (Cox regression and logistic 
regression) was among others common to 2 of the 4 clinical areas.  
 
These terms identified by Furlan et al(243) focusing on terms related to study design and 
statistical analysis were used for the EMBASE search. The terms “multivariate” and “regression” 
are common to the inclusion criteria for studies to be included in the review. The terms were 
thus selected, in addition to “multivariable” to limit an “epilepsy” topic search. The search was 
from inception to March 2010, and was not limited to EMBASE records alone; it also included 
papers from MEDLINE present in EMBASE. 
 
multivariate (text word) 
OR multivariable 
OR regression (text word) 
 
AND 
 
explode epilepsy (Emtree) 
OR epilepsy (text word) 
 
3.2.3 SCREENING THE RESULTS FOR ELIGIBLE PUBLICATIONS 
To reduce the likelihood of missing out any publication, the full list of titles and corresponding 
abstracts from MEDLINE was independently screened for eligible papers by 2 reviewers (the 
MPhil candidate and KB3, who has masters level training in epidemiology). Following the first 
                                                          
3
 Ms Kathleen Bongiovanni, who had just completed her Master in Public Health (International), volunteered to join in 
the first round of screening citations retrieved through MEDLINE on EndNote. 
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round of selection based on inclusion and exclusion criteria, the MPhil candidate returned to 
EndNote library and conducted a second screening of titles and abstracts to ensure 
completeness. However, for EMBASE, the first and second rounds of screening, selection, and 
elimination was conducted by the candidate. The list of references of each of the potentially 
eligible papers identified from MEDLINE and EMBASE was also manually searched by the MPhil 
candidate.  
 
3.3 DATA EXTRACTION 
In this review, individual studies (not publications) were the unit of analysis as there were 
papers and cohorts that contributed more than 1 study to the review. For example, a cohort 
might provide more than 1 study considering different categories of seizure outcome, or using 
different methods of multivariate regression analysis to identify independent predictors of 
seizure outcome. 
 
The novel nature of the review precluded the use of any previously designed data extraction 
form. Therefore a data extraction form was designed and initially piloted on 3 papers. The form 
was redesigned and piloted on another 2 papers. Then finally, it was redesigned for a third time, 
and piloted on 2 papers other than the previous 5.  
 
The main issues that had to be addressed in the versions of the quality appraisal forms 
concerned the areas of potential bias in prognosis studies as identified by Hayden et al(39) 
which were successively edited to reflect the important quality issues in the studies included. 
There was also a section on reporting characteristics of included studies in the third (final) 
version of the form. The 3 versions are in Appendix II.  
 
Data from each study were extracted by the candidate 3 times; twice into a data extraction form 
(Appendix II), and during the third time, data were extracted and entered directly onto an Excel 
spreadsheet database. The data extracted were compared with the previous extraction at each 
succeeding stage and where there were discrepancies, clarification made by consulting the 
paper(s).  
 
The extracted data included authors and title of study, year of publication, journal, study design, 
age range (including mean and standard deviation), study recruitment period, length of 
reported follow up, epilepsy subtypes included or excluded, method of multivariate regression 
analysis, investigated seizure outcome measures, and details of AED treatment and withdrawal, 
and how decisions about AED and the choice of drug was made. The risk estimates of the 
prognostic factors in the multivariable model, and corresponding confidence intervals were also 
extracted for each study. All data were extracted from the published studies, including obtaining 
related publications from the same cohort that authors have made reference to for further 
49 
 
details, especially of study population and methods. The authors however were not contacted 
for further information. 
3.4 QUALITY APPRAISAL 
There has been a wide range of scales, scores and checklists available to aid quality assessment 
especially for systematic reviews of intervention studies.(247, 248) However, the use of quality 
scoring in systematic review and meta-analyses is controversial as aggregate scores may 
inappropriately conceal and conflate the elements that define quality and may thus not directly 
be associated with quality.(203, 247-249) It has thus been suggested that key components of 
design, rather than aggregate scores themselves, may be more important.(39, 249) 
 
In keeping with the guidelines of quality appraisal in systematic reviews and meta-analysis, (39, 
178, 195, 250) each eligible study was assessed for bias. Hayden et al(39) developed extensive 
guidelines for assessing quality in prognosis studies on the basis of a framework of potential 
biases. In a meta-review that identified quality measures used in systematic reviews of 
prognosis studies, they pooled quality items into 6 areas of potential bias: study participation, 
study attrition, prognostic factor measurement, confounding measurement and account, 
outcome measurement and analysis. (Appendix IV) 
 
These areas of potential bias are relevant to the purpose and question of the present systematic 
review and were therefore adapted in the analysis of the methods of studies being reviewed. 
However, the 2 areas of “prognostic factor measurement” and “confounding measurement and 
account” were merged into 1 as this thesis is not a review of studies investigating the prognostic 
value of one particular variable. These 5 areas of potential bias as identified by Hayden et al(39) 
are discussed. 
3.4.1 STUDY PARTICIPATION 
The area of study participation is concerned with adequacy of reporting and assessing how well 
the population recruited into each cohort is representative of people with epilepsy within the 
source population. This judgement is made from the authors’ description of study setting, 
location and catchment area in the paper or a previous, referenced, publication. Therefore for 
each cohort, answer (Yes, Partly, or No) was provided to the question “Is the source population 
described?” The explicit description of inclusion/exclusion criteria and baseline characteristics of 
the cohort was also assessed. This included the assessment of the definition of epilepsy in each 
paper which according to International League against Epilepsy (ILAE) standard.(1, 2)  
 
The combined information – from how well the cohort is representative of its source 
population, inclusion and exclusion criteria, and description of the baseline characteristics of the 
cohorts – is used to make a judgement as to whether recruitment of eligible individuals into the 
cohort is adequate. Those studies that attempted to prospectively ascertain all the cases of 
newly diagnosed epilepsy within a particular geographically defined population, with clearly 
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stated and appropriate inclusion and exclusion criteria are the ideal studies meeting the highest 
quality standard within this area of assessment. 
 
In retrospective case ascertainment, investigators go back over a period of time and identify 
patients with recently diagnosed epilepsy for inclusion in the cohort. Prospective studies on the 
other hand use on-going surveillance to identify newly diagnosed patients when they present 
for medical attention, recruit them and subsequently follow them going forward. However, 
studies with retrospective ascertainment of cases may have a prospective follow up component 
to them, and some studies combined prospective and retrospective case ascertainment, 
followed by prospective follow up.(44) 
 
Retrospective case ascertainment is a potential source of bias in that identifying cases for 
inclusion in study may depend on unfavourable outcome, as those who experience recurrence 
will be easier to identify than those who remain seizure-free after a second or third seizure.(44) 
It is also more likely that patients with prospective recruitment are more comprehensively 
assessed for clinical variables and history of previous seizures at the point of diagnosis, thereby 
avoiding under- or over-estimation of the number of seizures before clinical presentation, and 
ensuring the general quality of the assessment potential predictors.(44) 
 
The inclusion of single seizure patients, patients with a single episode of status epilepticus, 
defining epilepsy by a third seizure, excluding patients with poor prognosis or those with 
excellent prognosis within epilepsy cohorts reported and analysed in the studies are also 
potential sources of bias. These deviations from standard inclusion and exclusion criteria were 
highlighted where applicable. 
3.4.2 STUDY ATTRITION 
This area of potential bias considers what happens after patients are recruited into the cohort 
i.e. the proportion of the cohort completing the study at the end of follow up or the proportion 
included in the analysis. The question to answer here is: are those lost during follow up similar 
to those who completed the study? To make this judgement however, it is important to know if 
there is an adequate proportion of cohort in the study analysis (76 – 100% Yes, 65 – 75% Partly, 
<65 No, and when it is not stated in the report – Unsure).  
 
This is considered, together with the reasons for loss to follow up and the characteristics of the 
patients lost to make the judgment as to whether there are important differences between key 
characteristics and outcome in participants who completed the study and those who did not 
that may potentially bias the result of the study. For cohorts with >90% completeness of follow 
up, without evidence of systematic pattern to loss in follow up, it was assumed that patients lost 
to follow up are similar to those who completed the study. 
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However, not all the studies were designed to have the whole cohort included in analysis.  In 
some studies, a case-control analysis of the cohort was conducted instead. The comparison 
groups in the classical cohort study of prognosis are people with a risk factor and all the other 
members of the cohort without the risk factor. The relative proportion of individuals with an 
outcome of interest in each risk factor group is then considered. The outcome groups – cases 
and controls – are made up of the entire cohort.(28)  
 
A variation on this is the nested case-control study in which the whole cohort is not included in 
the analysis: the proportion of people with the risk factor under investigation is compared 
between cases and matched controls or a random sample (sub-cohort) of those without the 
outcome albeit from the same cohort.(251)This design shares all the advantages of the cohort 
over case-control study design, especially when it is a prospective cohort: collecting risk factor 
data before outcome, the time sequence of cause and effect, providing an unbiased estimate of 
relative risk,(252-255) and the fact that cases and controls are from the same cohort, 
notwithstanding the argument by Wacholder et al(256) that at least in theory, every case-
control study takes place within a “cohort” or population, albeit difficult to define. 
 
However, the variant of the nested case control study design available to be included in this 
systematic review was one in which the cases and control groups were defined by outcome, for 
example patients whose seizure is in remission were controls, while for example those with 
medically intractable seizures were treated as cases, thereby leaving out of the analysis patients 
who do not satisfy both definitions.(75, 76, 78, 79, 94) This group of studies will subsequently be 
referred to as “nested case-control” studies although technically, they are not altogether similar 
in design to studies that bear that name in the literature.(251, 257, 258) In the conventional 
nested case-control study, cases are identified in a defined cohort. For each case, a specified 
number of matched controls are selected from among those in the cohort without the case 
defining outcome.  
 
However, especially in prognostic studies of newly diagnosed epilepsy, these studies do have 
the additional advantage of comparing groups that are more homogenous, compared to studies 
that involve the whole cohort. Within a cohort, there is a continuous range of severity of seizure 
outcome. An assumption inherent in logistic and Cox regression is that the outcome being 
considered in the analysis must be discrete. Therefore, by creating a dichotomy of outcomes – 
remission and intractability – and excluding from analysis patients that form a continuum 
between these 2 groups, nested case control studies achieve a better delineation of binary 
outcome categories necessary for logistic and Cox regression analyses. 
 
The judgment on attrition in these studies was also made with full understanding of their 
peculiarity in selecting, based on set criteria in each study, the cases and controls from a defined 
cohort. For these studies, if there was no evidence of systematic pattern to loss in follow up 
beyond the choice of cases and controls, it was also assumed that patients lost to follow up 
were similar to those who completed the study. 
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3.4.3 PROGNOSTIC FACTOR MEASUREMENT 
The definition of each prognostic factor has to be clear and specific to avoid bias. The question 
was therefore asked: are the prognostic variables clearly defined? Answers were reported thus: 
Yes, if all the prognostic factors were clearly defined or described, Partly, if not all, and No if 
none of the prognostic factors were clearly defined or described. 
  
There is also the probability that misclassification bias is introduced by virtue of the method by 
which prognostic factors are assessed. The second question was if the methods of assessing the 
prognostic factors were reliable enough to limit misclassification bias. In this case, it was 
reported as Yes if there was a single site with single assessor, or a fixed protocol, or if there was 
explicit information about training of assessors for multiple sites or if ILAE standards and 
definitions (1, 2, 9, 11, 18) were rigorously followed even if there were multiple assessors and 
there was no information on training assessors for multiple sites. In the absence of these 3 
conditions, the answer was Unsure. 
 
How adequate was the proportion of patients with complete data and how missing data were 
handled in each study formed the third question in this area. Missing data could be in 3 forms: 
missing completely at random (MCAR) when people with missing data are a random subset of 
the complete sample of the cohort, for example the result of some patients’ brain computed 
tomography (CT) scan is lost accidentally. The fact that data are missing is completely 
explainable in terms of a random event as the probability that an observation is missing is not 
related to the patients’ characteristics.(259, 260)  
 
When missing data are MCAR, patients with complete data are also a random sample from the 
cohort. Therefore a technique like simply deleting an entire observation if it is missing on any 
item used in the analyses (listwise deletion) is appropriate as the only loss is statistical power, 
and there is no apparent potential for bias in the estimates.(260) This is also true when data are 
missing at random (MAR) in which case the probability that an observation is missing depends 
on information for that subject that is present, i.e. the reason for missing data is based on other 
observed patient characteristics,(259) for example if the number of seizures before treatment 
cannot be ascertained in a random sample of patients with cognitive impairment, it could be 
said to be missing at random (MAR), and could also be ignorable just like for MCAR. 
 
However, it is not ignorable when data are missing not at random (MNAR). Here, the probability 
that an observation is missing depends on the value of the observation itself,(259) like when the 
reason that the number of seizures before AED cannot be ascertained is because the frequency 
of pre-treatment seizures is high, and the patient or carer cannot recollect. In this case, there 
would be a need to resort to the more complex imputation techniques to handle missing 
data.(259, 260) 
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Therefore the question about if the proportion of patients with complete data was adequate 
and how missing data were handled would have been reported in the following way: Yes when 
data were complete, or when less than 20% of a prognostic factor data were MCAR (missing 
completely at random) or MAR (missing at random) and listwise deletion or imputation was 
used, or when less than 10% were MNAR with listwise deletion or imputation used. Partly when 
MCAR and MAR was 20-30% with appropriate imputation or when MNAR was 10-20% with the 
use of appropriate imputation. No when MCAR, MAR was more than 30% of a prognostic factor 
or when MNAR (missing not at random) was greater than 20%. When these issues were not 
addressed or reported, the answer was Unsure.  
 
However, most authors did not report on these issues at all. Some authors included data 
completeness as an inclusion criterion, making it impossible to assess if the study population is 
representative. 
 
How continuous variables are handled is also important in multivariate analysis. The choice is 
between keeping them continuous or creating categories which may or may not be data 
dependent. Categorizing patients into high- and low-risk groups based on an “optimal cut-point” 
that maximises statistical significance or the non-data dependent division through the median 
into 2 equal groups without a priori justification often leads to bias, loss of potentially important 
quantitative information, loss of power and residual confounding.(261)   
 
Therefore the question about how the continuous variables were handled was answered Yes for 
papers that left all the continuous prognostic factors as continuous variables. However it was 
Partly for those that kept some variables continuous and others categorised in a non-data 
dependent and/or data dependent manner. It was also Partly for those that used only non-data 
dependent method of categorising continuous data and No for those that used only data 
dependent method or in combination with non-data dependent method. 
3.4.4 OUTCOME MEASUREMENT 
It is also important that there is a clear operational definition of the seizure outcome being 
considered in the study, with a long enough time frame to limit misclassification bias as seizure 
outcome in newly diagnosed epilepsy has a temporal pattern, and when patients are followed 
up longer it is more likely that they are classified correctly in their outcome category.(25) The 
question about the clear definition of outcome measure is reported as Yes, Partly or No. It was 
Yes if the outcome was clearly defined in relation to length of follow up and seizure-free period 
or period of continued seizures. It was No if either the outcome was not clearly defined and if 
the time dimension was not explicitly stated. It was Partly if the outcome was clearly defined but 
the related time dimension was not stated explicitly. 
 
The issue of being able to limit misclassification bias was assessed in a manner similar to that of 
prognostic factor measurement. The method of assessment was considered sufficient to limit 
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misclassification bias if follow up for the majority of the cohort was for at least 1 year and it was 
a single site with single assessor. The answer was Partly if there were 2 to 3 assessors in a site or 
if there was 1 assessor in 2 to 3 sites. Multiple sites or multiple assessors without information on 
training or standardization of outcome measure method was answered as a No. 
 
For the third question in this area, the issue was about measuring the outcome and prognostic 
factors blind to each other. It was assumed that in cohorts where cases were prospectively 
identified, whether it was stated or not, the outcome and prognostic factors were assessed 
blind to each other, and for retrospective case ascertainment, the answer is Unsure, unless 
explicitly stated in the affirmative. 
3.4.5 MULTIVARIATE REGRESSION ANALYSIS 
Multivariate regression analysis is the most commonly used method to examine and adjust for 
variables in prognostic factor studies.(45) However, it is also commonly abused, especially as a 
black box that simply produces risk estimates(262) without important details of the process and 
sometimes, details of the results of analysis . The risk estimates tend to vary with the choice of 
the mathematical model, coding of variables, and method of selecting variables.(263) It is 
therefore important that information on the test of assumptions of model building be provided 
such as a test for colinearity and interactions among variables.(263)  It is also important to be 
able to determine how sufficient the reported data are to assess the validity and reliability of 
the results.  
 
Therefore, the first question here was: how detailed were the results presented? If the risk 
estimate or the regression coefficient was presented and the standard error or 95% confidence 
interval of regression coefficients of risk estimate was presented, the report was Yes. However if 
the result from only 1 of these 2 was presented, it was reported as Partly, and if neither, the 
report was No. 
 
The next question concerns whether the method of selecting variables to be included in the final 
model was described. The choice of variables to retain in a regression analysis could be made by 
forward selection (starting with a priori recognised predictor variables) or backward elimination 
(starting with all available predictors, and could be all variables used in univariate analysis, or 
only variables significant at (P < 0.05) in univariate analysis) or using the computer automatic 
selection stepwise procedure (forward or backward), with different criteria for inclusion or 
exclusion of a variable in the model. Important variables from clinical experience or previous 
studies may be forced into the model as well as significance level fixed for prognostic factors to 
retain or eliminate, in a forward or backward stepwise manner, manually or in automated 
algorithms. Did the authors specify how predictor variables were selected? Was there a 
preliminary screen based on the univariate association? Was some form of stepwise analysis 
used, and if not, was colinearity between variables assessed? For this item, the answer is Yes if it 
was stated that there was a stepwise selection of variables, and No if it was not so stated. 
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The risk estimates may however be unreliable if outcome events are too few relative to the 
number of independent variables, leading to a situation where regression coefficients for 
individual prognostic factors may represent spurious associations, or the effects estimated with 
low precision.(231, 263) Therefore the rule of thumb, of having at least 10 events per variable 
(EPV) is a liberal way of assessing if or not there is over-fitting of the data. This is done by 
computing the ratio of the number of predictors in the model and number of patients with less 
common outcome.(231)However it has been shown by Vittinghoff et al(233) that the rule of 10 
could be relaxed a little. 
 
Other issues related to statistical analysis that were also assessed include if the authors 
attempted to justify study sample size, the number of patients lost to follow up and how loss to 
follow up was treated in analysis.(263)  
3.4.6 SUMMARY OF POTENTIAL FOR BIAS IN STUDIES 
To assess the quality of each study, 1 summary measure of judgement about each of the 5 
potential areas of bias (study participation, study attrition, prognostic factor measurement, 
outcome measurement and multivariate analysis) was constructed for each of the individual 
studies included. 
 
The summary assessment for quality of study participation was the report of how adequately 
the eligible individuals were recruitment of into each cohort, which is the answer to the third 
question in the area of study participation. However, for study attrition, cohorts with >90% 
completeness of follow up and nested case control studies, without evidence of systematic 
pattern to loss in follow up, were assessed as adequate. Otherwise, studies were assessed based 
on their report of how similar those lost to follow up are to those who are included in the 
analysis. For studies with minimum follow up > 20 years, the rules were relaxed to allow for 
more than 10% attrition rate. 
 
To be assessed as adequate, methods that were assessed as sufficient to limit misclassification 
bias must be used for prognostic factor measurement.  The factors would at least be “partly” 
defined and continuous variables at least “partly” kept continuous or have adequate proportion 
of patients with complete data. The outcome must first be clearly defined, and the method of 
measure must also be sufficient to limit misclassification bias, or measured blind to prognostic 
factors and vice versa. Multivariate analysis was considered to be adequate only if the EPV was 
at least 9. 
3.5 SYNTHESIS OF RESULTS 
The consistently identified independent predictor variables were considered for synthesis. This 
does not involve the statistical pooling of risk estimates; only the statistical conversion of risk 
estimates into formats that would facilitate comparison in order to ascertain the consistency of 
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exposure-outcome relationship across different studies, and to make a decision on the least 
biased risk estimate(s) for each outcome.(264) Variables that were found to be an independent 
predictor in more than 1 study from different cohorts were considered to be consistent 
predictors. On the other hand, the variables that were examined, but not retained in the model 
in more than 1 study from different cohorts were considered as consistent non-predictors. 
 
Hazard (or rate) ratio (HR) was assumed to be a reasonable approximation of the relative risk 
(RR), as they are both simple quotients of “exposed” and “unexposed” quantities; HR a ratio of 
rates and RR a ratio of probabilities.(265) However, the similarity or disparity of these measures 
depends on the influence of the length of follow-up, which may impact on the average rate of 
the occurrence of the seizure outcome of interest, and the risk of the “exposed” group relative 
to the referent group.(265) 
 
When association is weak and events are uncommon, relative risk, hazard rate ratio, and odds 
ratio (OR) are good numerical approximations of one another; their disparity increases as events 
increase and as risk departs from unity. However, the odds ratio is more subject to the influence 
of these factors (265-267) as the hazard ratio reasonably approximates relative risk under a 
much wider range of circumstances. Therefore, in studies where odds ratio was the risk 
estimate, the Zhang-Yu equation(266) was used to shrink the odds ratio towards unity (in the 
direction of relative risk), when event rate exceeds 10%, and/or odds ratio is greater than 2.5 or 
less than 0.5.(265-267) 
 
The Zhang-Yu equation(266) is such that in a cohort study, if P0 is the incidence of the outcome 
of interest in the non-exposed group and P1  is the incidence in the exposed group: 
 
Odds Ratio (OR) = (P1/1−P1)/ (P0/1−P0) 
 
Therefore (P1/P0) = OR/ *(1 − P0) + (P0×OR)] 
 
However, since relative risk (RR) = P1/P0 
 
The corrected RR = OR/ [(1 − P0) + (P0 × OR)] (Zhang-Yu Equation) 
 
Zhang and Yu(266) proposed the formula to estimate the risk ratio from the odds ratio in cohort 
and cross-sectional studies with univariate and multivariable analyses. They validated the 
formula with a simulation incorporating 2 confounding variables and it was shown that the 
relative risk estimates were close approximations to the true relative risk. The equation was 
recommended for use, and has been used in several meta-analyses.(265, 268-271)  
 
The equation shows that as P0 approaches zero, the denominator approaches 1 and RR 
approaches OR. This situation in which OR approximates RR obtains when the outcome is rare. 
However, as P0 approaches 1, RR approaches 1 regardless of the value of OR, which shows the 
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large differences that occur between RR and OR when the outcome is common. When OR 
equals 1, then RR also equals 1, regardless of the value of P0. For all P0 greater than zero and less 
than 1, RR is less than OR when OR exceeds 1, and RR is greater than OR when OR is less than 1. 
Therefore, as expected, the estimated relative risk is always closer to unity than the odds ratio. 
(272) 
3.6 EXTERNALLY VALIDATED PROGNOSTIC MODELS 
For studies with prognostic models that were externally validated, further quality appraisal will 
be conducted with particular reference to the models. Laupacis et al(273) suggested additional 
criteria specific to prognostic models in their 1997 paper which was an addition to previous 
criteria suggested by Wasson et al (274) in 1985, many of which were again identified in the 
more recent work Hayden et al(39). The factors peculiar to prognostic models from Laupacis et 
al(273) that were not already discussed as one of the potential areas of bias from the study by 
Hayden et al(39) are the sensibility of the model and its performance on internal and external 
validation and in clinical practice. The models were assessed for their performance in internal 
and external validation using the 2 parameters of calibration and discrimination.(23, 27, 275)  
3.6.1 CALIBRATION AND DISCRIMINATION 
The performance of binary outcome models is usually assessed in terms of calibration and 
discrimination. The calibration of a model is its ability to have predicted probabilities that agree 
with the observed proportions of events over the whole range of probabilities. Calibration could 
be investigated by plotting the observed proportions of events against the predicted risks for 
groups defined by ranges of individual predicted risks, usually in 10 groups. Ideally, the plot 
shows a 45 degree line in internal validation i.e. the slope is 1.(23) There is however a loss in the 
calibration when the model is externally validated in another population.  The statistical tests 
sometimes used to assess calibration include Hosmer-Lemeshow test(276) and the calibration 
component of the Brier score.(277) 
 
The 2 probabilities that are often used to express the performance of binary tests were used to 
assess the accuracy of the models as reported in internal and external validation studies: 1.) 
Sensitivity or true positive rate (TPR) which is the proportion of actual positives [patients with 
outcome, i.e. true positives (TP) and false negatives (FN)] that the model correctly identifies as 
true positive (TP) (i.e. the percentage of newly diagnosed epilepsy patients that will enter 
remission who are correctly identified by the model); 2.) Specificity or true negative rate (TNR) 
which is the proportion of actual negatives [patients without outcome, i.e. true negatives (TN) 
and false positives (FP)] which are correctly identified as true negative (TN) (i.e. the percentage 
of newly diagnosed epilepsy patients that will not enter remission who are identified by the 
model).(278)  
 
However, 2 more clinically important probabilities were also used in assessing the accuracy of 
the models.  Positive Predictive Value (PPV) refers to the percentage of the true positive (TP) 
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among all those that the model correctly (TP) or incorrectly (FP) identified as positive (i.e. PPV = 
TP/TP+FP); Negative Predictive Value (NPV) is the percentage of true negatives (TN) among all 
those that the model correctly (TN) or incorrectly (FN) identifies as negative (i.e. NPV = 
TN/TN+FN). The summary of the accuracy of the model is the proportion of patients within the 
cohort with correct prediction, either positive (P) or negative (N) (i.e. TP+TN/P+N) The positive 
and negative predictive values, unlike sensitivity and specificity change with pre-test probability 
i.e. with the proportion of patients with the outcome within the cohort.(279) Therefore the PPV 
and NPV measure in external validation reflect the accuracy of the model in a different cohort, 
and a possible difference in pre-test probability.(279) PPV and NPV were computed from 
available data when they were not explicitly provided. 
 
However, before these probabilities are determined for a particular model, the ROC (receiver 
operating characteristic) curve of the model in the development sample is plotted. The ROC 
curve is a plot of the true positive rate (or sensitivity) versus the false negative rate (or 
1−specificity) as the cut-off point that assigns a higher probability of outcome in the model is 
progressively varied. In effect, it is a comparison of 2 operating characteristics (true positive rate 
and false positive rate) as the discrimination criterion changes.(278)  
 
The area under ROC (receiver operating characteristic) curve (AUC) is used to assess the ability 
of a model to discriminate between individuals with and without the outcome being predicted. 
The AUC represents the chance that given 2 patients, one who will develop an outcome and the 
other who will not, the model will assign a higher probability of having the outcome to the 
patient who will develop, for example, the seizure outcome of interest.(23, 275) The AUC for a 
prognostic model is typically between about 0.60 and 0.85 (the values are higher in diagnostic 
settings) (275) and it is usually deemed good if >0.70 and poor when <0.70 for prognostic 
models. (107, 280) 
 
The other purpose of the ROC curve is that it allows for the detection of an optimal cut-off 
point, at which the combination of true and false positive rates is best for the purpose of the 
model. Therefore values above this point will indicate a higher probability of the indicated 
outcome, and lower values indicate lower probability of outcome. Ideally, this point is chosen to 
assess the accuracy of the model in predicting outcome in the development cohort and in the 
external validation, and the probabilities that assess accuracy at the cut-off point (sensitivity, 
specificity, positive predictive values, negative predictive value and the proportion of patients in 
each cohort with correct prediction) are computed.(107) 
3.6.2 INTERNAL VALIDATION 
Although not explicitly stated and only implied by Laupacis et al,(273) internal validation is 
important in assessing the performance of the model. However, internal validation does not 
provide information about the model’s performance in another population. A model is internally 
validated by splitting the dataset randomly into 2 parts. The model is developed using the first 
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part and its predictive accuracy is assessed on the second portion.  If the available data are 
limited, the model can be developed on the whole dataset and techniques of data re-use, such 
as cross validation and bootstrapping, applied to assess performance.(27) In this review, the 
results of the internal validation of the models that were subsequently subjected to external 
validation were assessed for calibration and discrimination. 
3.6.3 EXTERNAL VALIDATION 
It is important to validate a model intended for clinical use in a group of patients different from 
the group in which it was derived, and preferably with different clinicians. This examines the 
generalisability of the model.(27, 231, 273)This could be external in place and/or external in 
time. When validation is external only in time, it is otherwise called temporal validation. In this 
case, the performance of a model is prospectively evaluated on subsequent patients from the 
same centre.(27, 281) However, a higher hierarchy of validation is when it is external both in 
time and place,(281)as it is the only form of validation that could confirm the wider 
generalisability of the model. The results of the external validation were assessed for calibration 
and discrimination. 
3.6.4 SENSIBILITY 
The evaluation of sensibility was based on judgment rather than statistical methods:  
 
Is the model clinically sensible? Clinicians should think that the items in the model are clinically 
sensible and that no important items are missing. It is difficult to determine which factors are 
important in the prognosis of seizure outcomes in epilepsy, but this was determined 
retrospectively following this systematic review. It was then subsequently documented whether 
these variables were included in the model(234) 
 
Is the model easy to use? This includes consideration of factors like time needed to apply the 
model, and how simple it is to use. Models that require extensive calculations may be less likely 
to be used than models with simpler scoring schemes.(216) Laupacis et al(273) are of the 
opinion that prognostic models that recommend a course of action are more likely to be used 
compared with those that simply describe the probability of an outcome. Therefore, it was also 
assessed if the model was only reported as outcome probability or the authors also recommend 
accompanying course of action. These 3 indices of sensibility were assessed and reported.  
3.6.5 EFFECTS OF USE ON CLINICAL PRACTICE 
This refers to the prospective evaluation of the effect on clinical practice of using the prognostic 
model in a patient population other than the one in which it was developed and validated to 
show if physicians and patients are willing to use the model and how its use affects patient 
behaviour and clinical outcomes. This is best done in randomised trials.(282) These criteria apply 
to models that could be used to predict seizure outcomes in epilepsy, and were therefore used 
in the analysis of methods of the studies with externally validated prognostic models. 
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4  CHAPTER FOUR: RESULTS 
 
This chapter presents the result of the systematic review. The chapter starts by reporting the 
results of the process of identifying eligible publications, followed by a description of included 
studies, how they relate to the cohorts from which they are derived and the publications that 
report them, and an account of the reporting characteristics of each of the eligible publications. 
There is a detailed report of the quality appraisal of studies included from each publication. The 
studies were subsequently disaggregated according to the seizure outcome predicted, and each 
category of study is further evaluated and appraised with a view to: 1) Understanding and 
explaining similarities and differences in results in relation to each study’s peculiar 
characteristics and potential for bias, 2) Identifying consistent independent predictors and non-
predictors within each outcome category, and 3) Assessing the quality and performance of 
externally validated prognostic models within each outcome category.   
 
4.1 IDENTIFYING ELIGIBLE PUBLICATIONS 
When the search terms were run through MEDLINE, (from inception to March 2010) 14,967 
citations were identified and exported to EndNote citation management software.  
 
Following the first round of screening, 144 potentially eligible papers were identified after 
eliminating duplications, review articles, editorials and commentaries, and papers with non-
seizure outcome. Papers with the study population restricted to a particular epilepsy subtype 
(e.g. partial epilepsy or mesial temporal lobe epilepsy) or patient population (e.g. pre-operative 
or post-operative epilepsy surgery candidates) were also eliminated. There were also papers in 
which epilepsy or seizure was studied as an outcome of or in relation to another pathological 
process (e.g. head trauma or autism) which were also eliminated. Reports of first seizure studies 
without follow up to the second seizure and beyond, and studies of AED withdrawal were also 
eliminated as were non-English language articles. (Figure 6) 
 
The second round of screening yielded an additional 5 potentially eligible papers. Then the full 
text of all 149 papers was assessed and 44 studies without relevant outcome, mostly non-
seizure outcome were eliminated, as were 66 prospective or retrospective cohort and 4 case 
control studies without multivariate regression analysis to control for confounding. There were 
also 3 papers with multivariate regression analysis modelled on less than 100 participants,(50, 
92, 102) and 2 papers reporting studies with multivariate regression analysis modelled on more 
than 100 patients but with a selected epilepsy population such as excluding patients with 
remote symptomatic aetiology(67) and including only patients with focal seizures(103); these 
papers were also eliminated. 
 
 A total of 119 papers were eliminated, leaving 30 eligible papers. A manual search through the 
list of references of each of the eligible papers yielded only 1 potentially eligible title, which 
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turned out to be a case control study without multivariable control for confounding, and so was 
eliminated. The full citation details of the papers are in Appendix II. 
 
 
Figure 6 | Flow diagram of the systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† The number selected after 3 rounds of screening 
*The 2 papers eliminated from EMBASE were the same as 2 of the 3 eliminated from MEDLINE 
 
 
 
Articles identified from electronic MEDLINE search (n=14,967) 
Articles identified from electronic EMBASE search (n=3,695) 
 
Excluded after reading title and abstract MEDLINE (n=14,818) 
Excluded after reading title and abstract EMBASE (n=3,675) 
–Duplication within each database 
– Review/Editorial/Comments  
–Non-seizure outcome 
–Study population restricted to a particular epilepsy subtype  
–Study population restricted to a particular patient population (e.g. surgical) 
–Epilepsy or seizure in relation to another pathological process 
–Epilepsy or seizure as an outcome of another pathological process  
–First Seizure Studies  
–AED withdrawal studies  
–Non English language papers  
 
 
 Potentially eligible from title and abstract MEDLINE (n=149)† 
Potentially eligible from title and abstract EMBASE (n=20) 
 
Excluded from MEDLINE (n=119), Excluded from EMBASE (n=3) 
–Cohort Studies without Multivariate Analysis 67 (66 MEDLINE, 1 EMBASE) 
–Case Control Studies without Multivariate Analysis 4 (MEDLINE) 
–Studies without Relevant Outcome 44 (MEDLINE)  
–Multivariate analysis but less than 100 in study 3 (3 MEDLINE, 2 EMBASE)* 
–Multivariate analysis but selected epilepsy 1 (MEDLINE) 
 
Articles included in Review (n=33)  
Validation Only Studies – 2 (None from or unique to EMBASE) 
Cohort Studies with Multivariate Analysis – 25 (2 unique to EMBASE) 
Nested Case Control Studies with Multivariate Analysis – 6 (1 unique to EMBASE) 
Duplication between MEDLINE and EMBASE (n=14) 
 
Eligible from MEDLINE on reading full text (n=30) 
Eligible from EMBASE on reading full text (n=17) 
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The EMBASE search (from inception to March 2010) returned 3,695 papers, expectedly much 
fewer than the broader MEDLINE search. After screening the title and abstracts, 20 papers 
remained following the elimination of duplications, review articles, editorials and commentaries, 
and papers with non-seizure outcome. Papers reporting studies restricted to a particular 
epilepsy subtype or patient population and in which epilepsy or seizure was studied only as an 
outcome of or in relation to another pathological process were also eliminated. Reports of first 
seizure studies without follow up to the second seizure and beyond and studies of AED 
withdrawal were also eliminated as were non-English language papers as in the MEDLINE 
search. No additional potentially eligible papers were identified during the second screening of 
the search results. 
 
The full text of these 20 papers revealed that there was 1 paper reporting a cohort study but 
without multivariate control for confounding. There were also 2 papers with multivariate 
regression analysis to control for predictors of seizure outcome, but in fewer than 100 
patients.(92, 102) These same 2 papers were also eliminated for the same reason from the 
MEDLINE search result. Of the 17 eligible papers from the EMBASE search, 14 had already been 
identified from the MEDLINE search, making 47% of the 30 identified from MEDLINE. The 
additional EMBASE effort contributed 3 papers of the total 33 (9%), 2 of which were published in 
2010. There were no additional papers identified from the list of references of the 3 papers. 
(Appendix II) 
 
4.2 DESCRIPTIVE CHARACTERISTICS OF ELIGIBLE PUBLICATIONS 
Of the 33 publications included, 2 publications exclusively reported on external validation of 
prognostic models developed independently in a Dutch cohort and a cohort from Nova Scotia. 
The first was a validation of the first Nova Scotia model in patients within the Turku, Finland 
cohort.(105) The second was a temporal validation of the first set of models developed from the 
Dutch cohort at 2 years follow up.(107) 
 
However, of the other 31 publications, 23 were reports of multivariate regression analysis 
conducted on entire cohorts,(21, 24, 32, 63-66, 68-74, 77, 93, 95, 97-101, 104) 7 were case 
control analyses of populations nested within cohorts defined by seizure outcome(25, 75, 76, 
78, 79, 94, 96) and 1 was an analysis of a combination of 2 existing cohorts,(106) which also 
contains an external validation study of prognostic models derived from both cohorts. The study 
combined individual patient data from the Dutch and Nova Scotia cohorts, with different 
inclusion criteria from the original publications reporting studies on these cohorts to develop a 
model from each newly constituted cohort and a third model from the combined population. 
The model from each cohort was internally validated on the cohort within which it was 
developed, and then cross-validated externally on the other cohort. 
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The general characteristics of the eligible publications are reported in Table 1, showing that 
more than 80% were published in the last fifteen years, and almost a third were published in a 
single journal, Epilepsia. Only 2 (6%) papers were published in non-neurology journals – New 
England Journal of Medicine (NEJM) and Acta Paediatrica (formerly named Acta Paediatrica 
Scandinavica). Thirty of the papers were from  countries with high income economies, while the 
rest are from the 3 contiguous low-and middle- income countries (LMICs) of Bangladesh, India 
and Nepal as defined in the World Bank’s 2010 World Development Indicators.(283) 
 
Table 1 | Eligible Publications by Year, Journal and Country 
 
 
Category 
 
 
Characteristic 
 
 
Number  
Year of Publication  
 2006 – 2010 8 
2001 – 2005  9 
1996 – 2000  10 
1991 – 1995  4 
1986 – 1990  2 
Publishing Journal   
 Epilepsia 10 
Seizure 3 
Brain 3 
Pediatric Neurology 2 
Annals of Neurology 2 
Acta Neurologica Scandinavica 2 
Others with 1 publication 11 
Journal Category  
 General Medical 1 
General Neurological 12 
General Paediatric 2 
Paediatric Neurology 4 
Epilepsy  13 
Other (Neurophysiology) 1 
Country of Cohort*  
 Finland 6 
Italy 4 
Netherlands 4 
United Kingdom 2† 
USA  6 
Canada 3 
China (Hong Kong) 2 
Others with 1 publication‡ 7 
 
*The sum of this category is 34 instead of 33 as 1 publication is based on 2 cohorts from different countries 
†The second UK publication is from a multinational cohort with 50% of patients from the UK 
‡Four of the 7 countries with 1 publication each are non-European –Bangladesh, India, Nepal and Saudi Arabia; the 
others are Norway, Spain and Sweden 
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There were 47 eligible multivariable regression analyses in all, considering different categories 
of seizure outcome (Table 2 and Table 3). Each of the 3 publications from low-and middle- 
income countries arose from 1 cohort in each of Bangladesh, India and Nepal, with each 
publication reporting the only study from each cohort. The same is true for the studies and 
cohorts from Hong Kong as well as Saudi Arabia. However, there were 24 eligible studies from 
the 10 European cohorts, and 18 studies from 7 North American cohorts. One cohort,(98) 
originally from the MESS trial(284) (a randomised controlled trial of the effect of early AED use 
on seizure outcome) was multi-national from 9 European countries (United Kingdom, Hungary, 
Italy, Netherlands, Poland, Portugal, Slovakia, Turkey and Yugoslavia), 2 South American 
countries (Brazil and Chile), India, and Israel. However, as 50% of the cohort was from the 
United Kingdom (UK) alone,(284) this study was categorised as European. In all, there was no 
cohort from Australasia; neither was there a cohort containing an African population. 
 
Eight (35%) out of a total of 23 unique cohorts were population based cohorts; 5 of the 
population based cohorts were European (out of 10) while the remaining 3 were based in North 
America (out of 7) (Table 2 and Table 3). 
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Table 2 | Descriptive Characteristics of Cohorts, Publications and Studies (European Cohorts) 
Cohort 
Recruitment Period 
Setting 
Age of Population Decision on AED 
Regimen 
Study Design 
 
Seizure Outcome Method of Analysis 
(Risk Estimate) 
Publication 
 
Turku, Finland 
1961-1964, Population 
Children (<15 years) Physician’s Discretion Mixed Cohort Remission on or off AED Logistic (OR) Sillanpaa, 1990  
Mixed Cohort Remission on or off AED Logistic (OR) Sillanpaa, 1993  
Mixed Cohort Remission on or off AED Cox (HR) Sillanpaa, 1998 
Mixed Cohort Remission off AED Cox (HR) Sillanpaa, 1998  
Prospective Cohort Remission off AED Cox (HR) Sillanpaa, 1998 
Prospective Cohort No Remission after Relapse Logistic (OR) Sillanpaa, 2006  
Prospective Cohort Remission on or off AED Cox (HR) Sillanpaa, 2009 
 
DSEC, The Netherlands 
1988-1992, Hospital 
Children (<16 years) Physician’s Discretion Prospective Cohort Remission on or off AED Logistic (OR) Arts, 1999 
Prospective Cohort Remission on or off AED Logistic (OR) Arts, 1999 
Prospective Cohort Remission on or off AED Logistic (OR) Arts, 2005 
Prospective Cohort Remission on or off AED Logistic (OR) Arts, 2005 
Prospective Cohort Remission off AED Logistic (OR) Geelhoed, 2005 
 
NGPSE, UK 
1984-1987, Population 
Children and Adults 
(>5 years) 
Not Stated / Unclear Prospective Cohort Remission on or off AED Cox (HR) MacDonald, 2000 
Prospective Cohort Remission on or off AED Cox (HR) MacDonald, 2000 
 
MESS, UK (50%) 
1993-2000, Hospital 
Children and Adults Randomised Mixed Cohort Early Remission Cox (HR) Kim, 2006  
 
CGSE, Italy 
1982-1985, Hospital 
Children and Adults Physician’s Discretion Mixed Cohort Early Remission Cox (HR) CGSE, 1988 
Mixed Cohort Remission on or off AED Cox (HR) CGSE, 1992 
Mixed Cohort Remission on or off AED Cox (HR) CGSE, 1992 
 
Copparo, Italy 
1964-1984, Population 
Children (<19 years) Not Stated / Unclear Prospective Cohort Intractability Logistic (OR) Casetta, 1999 
 
Bari & Monza, Italy 
1989-1999, Hospital 
Children and Adults Physician’s Discretion Mixed Cohort Early Remission Logistic (OR) Del Felice, 2010 
 
Västerbotten, Sweden 
1985-1987, Population 
Adults Physician’s Discretion Mixed Cohort Early Remission Cox (HR) Lindsten, 2001 
 
Akershus, Norway 
1987-1994, Population 
Adults Not Stated / Unclear Retrospective Cohort Remission on or off AED Logistic (OR) Lossius, 1999 
 
Almeria, Spain 
1994-2004, Hospital 
Children (<14 years) Physician’s Discretion Mixed Cohort Intractability Logistic (OR) Ramos-Lizana,2009 
 
Mixed Cohort – Combined prospective and retrospective case ascertainment; OR – Odds Ratio; HR – Hazard Ratio 
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Table 3 | Descriptive Characteristics of Cohorts, Publications and Studies (Other Cohorts) 
Cohort 
Recruitment Period, 
Setting 
Age of Population Decision on AED 
Regimen 
Study Design 
 
Seizure Outcome Method of Analysis 
(Risk Estimate) 
Publication 
 
Nova Scotia, Canada 
1977-1985, Population 
Children (<16 years) Physician’s Discretion Mixed Cohort Remission off AED Logistic (OR) Camfield, 1993  
Mixed Cohort Remission off AED Logistic (OR) Camfield, 1993 
Mixed Cohort Remission off AED Logistic (OR) Geelhoed, 2005 
 
DSEC and Nova Scotia Children (<16 years) Physician’s Discretion Mixed Cohort Remission off AED Logistic (OR) Geelhoed, 2005 
 
Montreal, Canada 
1991-2000, Hospital 
Children (2 -17 years) Not Stated / Unclear Retrospective Cohort Remission off AED Cox (HR) Oskoui, 2005 
Retrospective Cohort Remission off AED Cox (HR) Oskoui, 2005 
Retrospective Cohort Intractability Logistic (OR) Oskoui, 2005 
Retrospective Cohort Intractability Logistic (OR) Oskoui, 2005 
Retrospective Cohort Intractability Logistic (OR) Oskoui, 2005 
Retrospective Cohort Intractability Logistic (OR) Oskoui, 2005 
 
New York, USA 
1983-1993, Hospital 
Children (<19 years) Not Stated / Unclear Prospective Cohort Early Remission Cox (HR) Shinnar, 2000 
Prospective Cohort Remission on or off AED Cox (HR) Shinnar, 2000 
 
Connecticut, USA 
1993-1997, Population 
Children (<15 years) Protocol Prospective Cohort Intractability Cox (HR) Berg, 2001a 
Prospective Cohort Remission on or off AED Cox (HR) Berg, 2001b 
 
Boston, USA 
Not Stated, Hospital 
Children (<18 years) Not Stated / Unclear Retrospective Cohort Intractability Logistic (OR) Ko, 1999 
Retrospective Cohort Intractability Logistic (OR) Ko, 1999 
 
Rochester, USA 
1935-1978, Population 
Children and Adults Not Stated / Unclear Retrospective Cohort Remission on or off AED Cox (HR) Shafer, 1988 
 
New Haven, USA 
Not Stated, Hospital 
Children (Not Stated) Not Stated / Unclear Retrospective Cohort Intractability Logistic (OR) Berg, 1996  
 
Hong Kong, China I 
1997-NS, Hospital 
Adults Protocol Mixed Cohort Remission on or off AED Logistic (OR) Hui, 2007 
 
Hong Kong, China II 
1982-1997, Hospital 
Children and Adults Not Stated / Unclear Mixed Cohort Intractability Logistic (OR) Kwong, 2003 
 
Riyadh, Saudi Arabia 
1994-1996, Hospital 
Adults Protocol Mixed Cohort Remission on or off AED Logistic (OR) Abduljabbar, 1998 
 
Dhaka, Bangladesh 
1996-NS, Hospital 
Children (<15 years) Protocol Retrospective Cohort Remission on or off AED Logistic (OR) Banu 2003  
 
New Delhi, India 
Not Stated, Hospital 
Children (Not Stated) Not Stated / Unclear Mixed Cohort Intractability Logistic (OR) Chawla, 2002 
 
Kathmandu, Nepal 
1995-NS, Hospital 
Children and Adults Physician’s Discretion Retrospective Cohort Remission on or off AED Logistic (OR) Lohani, 2010 
 
Mixed Cohort – Combined prospective and retrospective case ascertainment; OR – Odds Ratio; HR – Hazard Ratio 
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4.3 REPORTING CHARACTERISTICS OF ELIGIBLE PUBLICATIONS 
Table 4 presents the results of 10 reporting characteristics of the 31 eligible publications 
reporting multivariate analysis. The publications are assessed based on information documented 
within them or within referenced publication(s). 
 
None of the publications reported a power calculation or attempted to justify their sample size 
or discuss limitations that may arise as a result of sample size, whereas all the studies reported 
on loss to follow up albeit to differing degrees, including studies in which it was reported that no 
patient was lost. Only a quarter of the studies mentioned the issue of missing data in the cohort 
analysed. However, data completeness was generally poorly described. In several studies, 
absence of missing data was a criterion for inclusion in the study analysis. Of the 8 papers that 
reported on missing data,(66, 68, 71, 98-100, 104, 106) 3 explicitly stated the number of 
participants excluded from analysis for that reason, (68, 104, 106) and 2 reported the use of 
imputation to replace missing data.(98, 106) 
 
In their analysis for predictors of seizure outcome, all the studies dichotomised seizure outcome. 
However, 3 papers (10%) failed to report the exact proportion or number of participants with 
the seizure outcome.(72, 98, 104) The risk estimate or regression coefficient with accompanying 
confidence interval or standard error was not reported for all the studies contained in 5 
publications.(63, 71, 95, 104, 106) More than half (58%) of the publications reported the 
statistical package or software used to conduct the multivariate analysis. The report on the test 
of assumptions of multiple regression analysis is as follows: 2 out of 13 (15%) papers using Cox 
regression explicitly reported on the test of the assumption proportional hazards.(71, 72) 
However, only in 1 paper(65) was there a report of a test for colinearity as a consideration for 
including variables in analysis, while 8 papers(24, 65, 66, 73, 96, 98, 101, 104) reported a test of 
interaction terms. 
 
Sixteen of the 31 (52%) publications stated the significance level, at which prognostic variables 
were retained or excluded from the model, while 2 reported the deliberate inclusion of 
prognostic factors considered to be important.(21, 65)Sixteen papers (52%) reported the use of 
stepwise selection of variables, backwards, forwards or a combination of both. (Table 4) 
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Table 4 | Reporting characteristics of publications with multivariate analysis 
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✘ 
 
✘ 
 
✘ 
 
✘ 
 
✘ 
 
✘ 
 
✘ 
 
0/31 
Report on Loss to  
Follow Up 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 31/31 
Report on N 
 with Outcome 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✘ ✔ ✔ ✘ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 29/31 
Report of Statistical  
Package Used 
✔ ✔ ✘ ✔ ✘ ✘ ✘ ✔ ✘ ✔ ✔ ✘ ✔ ✔ ✔ ✘ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✔ ✔ ✘ ✔ ✔ ✔ ✘ ✘ 18/31 
Report on/Discussion  
of Missing Data 
✘ ✘ ✔ ✘ ✘ ✘ ✔ ✘ ✘ ✔ ✘ ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ 8/31 
Report on Test for 
Collinearity 
✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ 1/31 
Report on Test for 
Interaction Terms 
✘ ✔ ✔ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘ ✔ ✘ ✘ ✔ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘ 8/31 
Discussion of 
Model Assumptions 
✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ 2/31 
Report on Criteria for  
Variables in Model 
✔ ✔ ✘ ✔ ✘ ✔ ✔ ✘ ✘ ✔ ✔ ✔ ✘ ✔ ✔ ✔ ✘ ✔ ✘ ✔ ✘ ✘ ✘ ✔ ✔ ✘ ✘ ✔ ✘ ✘ ✘ 16/31 
Report on Results  
of Analysis  
✘ ✔ ✔ ✔ ✔ ✔ ✘ ✘ ✔ ✔* ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✘ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 27/31 
✔ - Yes (Reported); ✘ - No (Not Reported) 
* For Geelhoed et al 2005, reporting >1 study where reporting characteristics vary between analyses, the better reporting characteristic is chosen as summary for the paper. 
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4.4 QUALITY APPRAISAL OF ELIGIBLE PUBLICATIONS 
This segment of the chapter presents the results of quality items on the 31 eligible publications. The 
publications are assessed based on information documented within them or within referenced 
publication(s). 
4.4.1 STUDY PARTICIPATION 
Every eligible publication had documented within it or within a referenced publication, information on 
inclusion criteria and baseline characteristics of the patients included. However, for 7 papers little or no 
information on the setting from which the cohort was derived could be retrieved. Four of them provided 
insufficient information (78, 93, 96, 100) while the remaining 3 contained no further information beyond 
stating the geographical location of the cohort. Two of the 3 were reports from the same cohort (CGSE 
in Italy) (64, 95). The third publication was a hospital based nested case control study, (Chawla et al) (94) 
and it was the only publication/cohort without the necessary information to make a judgment on 
adequate study participation; the judgement was made in the affirmative for all 28 of the other 30 
papers. 
 
The studies reported by Ko et al(79)have a clear inversion in the proportion of cases and controls. The 
number of patients satisfying the definition of medical intractability in the cohort was more than 3 times 
(3.7) as many as those in remission on or off AED. There was also an over-representation of patients 
satisfying the criteria for intractability in the study reported by Berg et al 1996.(78) This however may be 
explained by the fact that both studies are hospital based retrospective cohorts. It was therefore 
concluded that recruitment of eligible individuals into these 2 studies was not adequate.  
4.4.2 STUDY ATTRITION 
Two out of the 24 publications reporting analysis of an entire cohort (as against nested case-control 
analysis) conducted their analysis on less than two thirds of the patients in the cohort,(100, 104) owing 
mostly to incompleteness of data as they were both retrospective studies. In the case of 1 other 
retrospective study,(93) it was uncertain how the cohort was constituted and if there was loss to follow 
up.  
 
Two publications with less than 90% completeness of follow up (72, 98) gave details of the 
characteristics of patients lost to follow up. In the MESS Trial cohort(98)information from the linked 
paper(284)suggest that there were no important clinical differences between those who did not consent 
to be randomised into the study and those who consented.  However in the second publication,(72) 
there was significant difference only in the proportion of patients within the 3 aetiologic groups 
(cryptogenic, idiopathic and remote symptomatic). For 4 other publications (reporting studies 
conducted on an entire cohort), information upon which to base such judgement was not provided, 
even though the studies had >10% participant attrition rate. (69, 77, 100, 104)  
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However, for Chawla et al,(94)a report of a nested case-control study, there was enough reason to 
conclude that information on how similar patients included in the analysis compared to those not 
included would be important. This was because the study did not provide information about how equal 
number (50 in each group) was selected as cases and controls. 
4.4.3 PROGNOSTIC FACTORS 
Twenty three of the 31 publications contained clear definition or description of the prognostic factors 
considered for analysis, and only partly so in the remaining 8. However, the handling of continuous 
variables was poorly reported, and inferences concerning this were made by a combination of observing 
how continuous data were reported and how the authors stated they were handled. In all, only 4 of the 
31 publications contained studies in which no continuous variable was categorised.(72, 78, 79, 97)The 
poor reporting of missing data reflects on the ability to know if there is adequate proportion of patients 
with complete data. This judgement could be made for only 7 publications, 5 (63, 66, 68, 98, 106) of 
which had complete data, and 2 (100, 104) that did not have complete data. Also, all the publications 
reported on cohorts for which it was unlikely that there would be misclassification bias in assessing the 
prognostic factors.  
4.4.4 OUTCOME MEASUREMENT 
As it was for prognostic factor measurement, all the publications reported on cohorts for which it was 
unlikely that there is misclassification bias in assessing the chosen outcome measure, as the majority of 
patients were followed up for at least 1 year with the outcome clearly defined. The outcome measure 
was also clearly defined in all the studies reported in all the publications. Three out of 7 publications 
reporting studies with exclusively retrospective ascertainment of cases provided information to 
demonstrate that prognostic factors and outcome were assessed blind to each other.(72, 78, 
104)However, for Chawla et al,(94) a mixed cohort with retrospective and prospective ascertainment of 
cases, the report does suggest that the assessment of the prognostic factors may not have been blind to 
outcome assessment at least for some of the patients in the cohort. 
4.4.5 MULTIVARIATE ANALYSIS 
Sixteen papers out of 31 reported the use of some kind of stepwise procedure in the model building 
strategy, while only 2 did not report enough data for the results of analysis. Therefore, the calculation of 
events per variable ratio was not possible for the 2 publications for which the proportion of patients 
with the outcome studied could not be retrieved.(101, 104) It was however less than 10 in studies 
reported in 5 publications: 9.8 for 1 of the 2 studies included in Arts et al 2004(66) , 7.5 for the study in 
Berg 2001a(73) 8.3 and 4 respectively for 2 categories of study reported by Oskoui et al(72), 9.5 for the 
study in Sillanpaa 1993(77)and 7.8 and 6.5 for the 2 studies in Ko et al(79) 
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Table 5 | Details of Quality Appraisal of Publications 
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Study Participation  
The source population was 
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Inclusion criteria and baseline 
cohort described Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Adequate recruitment of eligible 
individuals into cohort  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y U Y N Y Y 
Study Attrition  
There is adequate proportion of 
cohort in study/analysis Y Y Y U Y Y Y Y Y Y Y Y Y N Y Y Y Y N Y P P Y* Y Y Y Y Y Y Y Y 
Reasons for loss and 
characteristics described – Y Y U – – – Y Y Y – Y – P – – N N P – Y Y – – – – U – – – – 
Those lost are similar to those 
who completed the study – – – U – – – – – – – Y – U – – P – U – U U – – – – U – – – – 
Prognostic Factors  
The prognostic variables were 
clearly defined P P P Y Y Y Y Y Y Y P Y Y Y P Y Y Y Y Y P P Y Y Y P Y Y Y Y Y 
Continuous variables  
were kept continuous P P P N P P P P P P Y P N P P P Y P N P P P P P Y P N P Y P P 
Methods sufficiently limit 
misclassification bias  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
There was adequate proportion 
of patients with complete data Y U Y U U U U U U Y U Y U N Y U U U N U U U U U U U U U U U U 
Outcome Measurement  
The outcome measures are 
clearly defined P Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Measure methods sufficiently 
limit misclassification bias Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Outcome & prognostic factor  
measured blind to each other Y Y Y U Y Y Y Y Y Y Y Y Y U U Y Y Y Y Y Y Y Y Y Y Y U Y U Y Y 
Multivariate Analysis  
There is sufficient data to assess 
adequacy of the analysis Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y 
The model building strategy is 
described as being stepwise Y Y N Y N N Y Y N Y N Y N N Y Y N N Y N Y Y N N N N Y Y N Y Y 
There is no over-fitting the data 
(i.e. EPV at least 9) Y Y Y* Y N Y Y Y Y Y* Y Y Y Y Y Y* Y* Y Y Y Y Y Y Y Y Y Y Y N Y Y 
Y-Yes, P-Partly, U-Unsure, N-No | Dash (–) is used when the item is not stated, while it is either not applicable or unimportant as a potential source of bias in the cohort/study being reported. 
 *For papers reporting >1 study where result of quality appraisal vary between studies, (Geelhoed et al, Oskoui et al and Sillanpaa et al 1998) the quality of the better study is reported in this table. 
EPV – Events per Variable
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4.5 STUDY CATEGORIES BY OUTCOME MEASURE 
The next segment of this chapter considers each study within designated categories, classified 
according to the seizure outcome predicted in the study in order to facilitate comparability 
among studies as different seizure outcome measures were considered across studies. The 5 
categories (Type I-V) of studies are introduced. The results are subsequently reported in relation 
to quality considering the following – 1) Proportion of patients with outcome; 2) Predictors of 
the outcome; 3) Non predictors of the outcome; and 4) Prognostic models for predicting the 
outcome 
 
STUDIES PREDICTING EARLY/IMMEDIATE REMISSION (TYPE I) 
Type I Studies are those that identified independent predictors of belonging or not to Sub-Group 
1A, which is the category of patients with immediate or early spontaneous remission (ISR). 
These patients will not have a third seizure, i.e. upon starting AED or being recruited into the 
cohort under consideration they enter terminal remission immediately, and will not relapse 
after complete AED withdrawal. These studies (24, 95, 98, 99) typically include the entire cohort 
i.e. all the patients with early or immediate spontaneous remission (ISR) compared with those 
who did not enter ISR. (Figure 4)There was however 1 atypical study, a nested case-control 
study, by Del Felice et al(96) that was classified within this category. The study compares 
patients with early or immediate spontaneous remission (ISR) i.e. no additional seizure once 
AED therapy started with “late” remission i.e. those who continued to have seizures until 2 years 
after AED therapy was commenced with those patients. (Figure 7) 
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
STUDIES PREDICTING REMISSION OFF AED (TYPE II) 
Type II Studies, illustrated in Figure 8, identified independent predictors of remission off AED, 
i.e. patients in prognosis Group 1. This group consists of patients in Sub-Group 1A (immediate 
spontaneous remission – ISR) and Sub-Group 1B with non-immediate spontaneous remission 
(NISR) i.e. patients who although do not enter remission immediately, ultimately do so, and 
remain in remission upon AED withdrawal. The other comparison group therefore is all the 
other patients on AED whether in remission or not.(32, 71, 72, 106) 
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
Figure 7 | Type I studies (Predicting Immediate Remission) 
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Figure 8 | Type II studies (Predicting Remission off AED) 
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
STUDIES PREDICTING REMISSION ON OR OFF AED (TYPE III) 
Type III Studies consider as an outcome group, those patients in remission, on or off AED. These 
patients belong in the prognosis Group 1 and Group 2. Therefore the other comparison group 
for this category of studies are those patients who do not enter remission either for a specified 
period during the course of follow up or immediately before the last follow up assessment. This 
is illustrated in Figure 9, and shows how the second comparison group contains patients with 
intractable seizures, and those who although are not in remission, do not meet the criteria for 
intractability.(24, 32, 63-66, 68-70, 77, 93, 97, 100, 101, 104)  
 
 
Figure 9 | Type III studies (Predicting Remission on or off AED) 
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
STUDIES PREDICTING INTRACTABILITY (TYPE IV) 
These are studies predicting patients that will have medically intractable seizures. There are 2 
kinds of Type IV Studies identified as eligible. There are those where patients satisfying the 
definition of medical intractability (Sub-Group 3B) are compared with all other patients who do 
not (Group 1, Group 2 and Sub-Group 3A). These studies include all the patients within the 
entire cohort (72-74) as shown in Figure 10. 
 
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
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Figure 10 | Type IV studies (Predicting Intractability including the entire cohort)  
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
The other kind of study are case control studies nested within cohorts that compare only 
patients with remission on or off AED (Group 1 and Group 2) being controls with patients 
satisfying the definition of intractability (Sub-Group 3B) as cases, leaving out those patients in 
Sub-Group 3a who are not in remission but also do not fulfil the criteria for medical 
intractability.(75, 76, 78, 79, 94) This is illustrated in Figure 11, with Sub-Group 3A taken off. 
 
 
Figure 11 | Type IV studies (Predicting Intractability in nested case control studies) 
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
STUDIES PREDICTING NO REMISSION AFTER RELAPSE (TYPE V) 
The last type of study, Type V Studies, has only 1 study within the category. This study reported 
by Sillanpaa and Schmidt 2006(25) considers the predictors of not achieving remission on or off 
AED after a patient’s seizures have run a remitting-relapsing course. Sub-Group 3A represents 
patients without remission that do not satisfy the criteria for intractability. However, although 
there are also within the group those who have never experienced remission, Figure 12 assumes 
that Sub-Group 3A sufficiently represents those who have not achieved remission after a 
remitting-relapsing course.  
 
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
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Figure 12 | Type V studies (Predicting no remission after relapse) 
The colour differences (lemon and grey) in the lowest set of boxes indicate comparison groups. 
 
4.6 REVIEW OF STUDIES BY OUTCOME CATEGORY 
The studies are now reviewed within these categories, especially in relation to: 1) 
Understanding and explaining similarities and differences in results given each study’s peculiar 
characteristics and potential for bias, 2) Identifying consistent independent predictors and non-
predictors within each category, and 3.) Assessing the quality and performance of externally 
validated prognostic models within each outcome category. 
 
PREDICTING EARLY/IMMEDIATE REMISSION (TYPE I) 
Five studies investigated the predictors of early or immediate remission (Table 6).(24, 95, 96, 98, 
99) One of the studies, Del Felice et al,(96) was a nested case control study with patients 
achieving remission after at least 2 years of antiepileptic drug therapy as cases(11% of the entire 
cohort), and having patients with immediate remission as controls, i.e. those without seizure 
recurrence once started on antiepileptic drugs, and who remained in remission for 2 years (33% 
of the entire cohort). 
 
In the remaining 4 studies, the proportion of patients without seizure recurrence at 2 years of 
follow up (i.e. early or immediate remission) ranged from 37% in Shinnar et al,(24) (the only 
study with exclusively prospective case ascertainment) to between 42% and 57.5% in studies 
with mixed case ascertainment, including different proportions of first seizure, prospectively 
identified, and retrospectively ascertained cases.  
 
Two of the studies, CGSE 1988 (95) and Del Felice 2010 (96), both in all age cohorts, had 
remarkably similar proportion of patients in each seizure category with the ratio of 1st seizure 
to 2-5 seizures and >5 seizures being roughly 4:9:7 in both studies. In spite of this similarity, the 
proportion of patients that achieved immediate remission at about 2 years of follow up varied 
widely: 48% in CGSE 1988,(95) and 33% in Del Felice 2010.  
 
Table 6 presents potential predictors that were examined by at least 2 studies. Neither age nor 
gender was found to be significantly related to achieving early/immediate remission.  
 
PEOPLE WITH EPILEPSY
REMISSION
1. REMISSION OFF AED
1A. NO 3RD SEIZURE 1B >2 SEIZURES
2. REMISSION ONLY ON AED
2A NO PRIOR RELAPSE 2B PRIOR RELAPSE(S)
NO REMISSION
3.NO REMISSION ON OR OFF AED
3A RELAPSE OR NO 
RELAPSE
3B INTRACTABLE
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The number of seizures (as a continuous variable), was only significant in 2 studies in the 
univariate analysis. However, the 2 studies found having “2 or more” seizures before the index 
seizure or AED was retained in their multivariable models (Box 1): 
 
 
 
 
 
 
All 5 studies considered the early or intake Electro Encephalogram (EEG). In 3, EEG finding was 
not associated with early remission on univariate analysis. One found that EEG finding was 
associated, and in 1 study, having an abnormal EEG was retained in the multivariable model. 
Neither a family history of epilepsy nor a prior history of febrile seizures was found to be 
predictive of early or immediate remission. 
 
The 5 studies included also considered having aetiological factors as potential predictors, with 
three of the 5 retaining the variable in their multivariable models: 
 
 
 
 
 
 
None of the models were externally validated. 
Kim et al 2006         | RR 0.74 (95%CI 0.58-0.94) 
Shinnar et al 2000  | RR 0.59 (95%CI 0.41-0.86) 
Lindsten et al 2001 | RR 0.44 (95% CI 0.26-0.77) 
 
Lindsten et al 2001 | RR 0.63 (95%CI 0.36-1.11) 
CGSEPI 1988            | (Not Stated) 
    Box 1 | Relative risk (RR) of achieving early remission in patients with two or more seizures before intake 
 
Box 2 | Relative risk (RR) of achieving early remission in patients with remote symptomatic aetiology 
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Table 6 | Studies predicting immediate remission with information on potential for bias 
 
 
 
 
 
 
 
Age*  
(Years) 
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 Remarks 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
Outcome Measure 
% with Outcome• 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0 – 19 Shinnar, 
2000(24) 
Prospective  
Hospital 
N=182 
Y Y Y Y Y Excellent case 
ascertainment –  
NDE‡ (100%) 
 8.4yrs 
(Mean) 
No 3rd Seizure 
(37% at 2 years, 
28% at 5 years) 
Remote Symptomatic Aetiology 
AED within 3mo of 2nd
 
Seizure 
AED after 3mo of 2nd Seizure 
2nd Seizure within  3months 
2nd Seizure between 3-6months 
HR: 1.69 (1.16-2.47) 
HR: 0.37 (0.22-0.63)  
HR: 1.28 (0.75-2.18)  
HR: 4.00 (2.28-7.00) 
HR: 0.86 (0.49-1.50) 
2 – 81 (19) CGSE, 
1988(95) 
Mixed† 
Hospital 
N=283 
Y Y Y Y Y Progressive neurological 
disorders excluded  
1st Seizure (18%),  
2-5 Seizures (46%),  
>5 Seizures 34%) 
0.1-3.3yrs Next seizure after 
Intake  
(48% at ≈2.5 years)     
≥2 seizures before intake  
Mixed seizure types 
NS 
NS 
IQR 
(17.4-43.4) 
Kim, 
2006(98) 
Mixed† 
Hospital 
N=1443 
Y Y Y Y Y RCT, therefore known 
poor prognosis excluded. 
1st seizure (57%), 2nd 
seizure – NDE‡ (24%), 
and 3 or more seizures – 
retrospective case 
ascertainment (19%) 
3.0-6.3yrs Next seizure after 
Intake 
(57.5% at 2 years, 
47% at 5 years, 
43.5% at 8 years) 
 
Log No seizures before intake 
Abnormal EEG 
Neurological Disorder 
HR:1.56 (1.42-1.72) 
HR: 1.54 (1.27-1.86) 
HR: 1.35 (1.07-1.72) 
17-83 Lindsten, 
2001(99) 
Mixed† 
Population 
N=107 
Y Y N Y Y 1st seizure (29%), 2nd 
seizure – NDE‡ (15%), 
and 3 or more seizures – 
retrospective case 
ascertainment (56%) 
8.8-13.5yrs  Next seizure after 
Index  
(42%at 2 years) 
≥2 seizures before intake  
No AED Therapy 
Remote Symptomatic Aetiology 
HR: 1.6 (0.9-2.8) 
HR: 0.29 (0.11-0.74) 
HR: 2.25 (1.3-3.9) 
3-84 (31.5) Del Felice, 
2010(96) 
Mixed† 
Hospital 
N=352 
Cases 38 
Controls 115 
 
Y Y Y Y Y 1st Seizure (16%),  
2-5 Seizures (46%),  
>5 Seizures 38%) 
This is a case control 
study nested within a 
cohort 
6.9yrs 
(Mean) 
Cases  
2 year seizure- 
freedom begins at 
least 2 years after 
AED therapy starts  
Controls 
2 year seizure- 
freedom begins 
with AED  
(33% at 2 years)  
 2–5 Partial Seizures before AED  
>5 Partial Seizures before AED  
OR: 2.7 (1.0-6.8) 
OR: 6.7 (2.3-19.3) 
*Age range in years (Mean ± Standard Deviation); •The proportion reported is of those who did not have a relapse following diagnosis (2nd seizure), recruitment or 
commencement of AED; †Mixed–Cohort combined prospective and retrospective identification of cases; ‡NDE – Newly Diagnosed Epilepsy i.e. cases that were ascertained on 
having the second seizure. Case ascertainment after 2nd seizure is considered retrospective; Y–Yes, N–No, CI-Confidence Interval, CI-Confidence Interval, IQR–Interquartile 
Range, RCT–Randomised Controlled Trial, AED–Antiepileptic Drug, EEG–Electro Encephalogram, No–Number, NS–Not Stated, OR–Odds Ratio, HR–Hazard Ratio 
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Table 7 | Consistent predictors and non-predictors of immediate remission 
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Demographic  
Age at Onset  ✘   ✘ 
Gender  ✘  ✘ ✘ 
Epilepsy Before AED, Intake or Index  
Duration  ✘ Θ ✘ ✘ 
≥2 seizures before Intake  ✔  ✔  
N of Seizures before Intake    ✔ ✔ 
EEG  
Intake/Early - EEG Abnormal ✘ ✘ ✔ ✘ ✔ 
Seizure Type  
Generalised Onset  ✘   ✔ 
Partial  ✘   ✔ 
Aetiology | Syndrome  
Remote Symptomatic Aetiology ✔ ✘ ✔ ✔ ✘ 
Neurological Signs  
Neurological Examination  ✘   ✘ 
Others  
Family History  ✘ Θ  ✘ 
Febrile Seizure ✘ ✘    
✔ - Variable is significant or retained in multivariate model 
✔ - Variable is only significant on univariate analysis 
✘- Variable is not significant on univariate analysis 
Θ – Variable is not reported in univariate analysis, but reported as not significant on multivariate analysis 
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PREDICTING REMISSION OFF ANTIEPILEPTIC DRUGS (TYPE II) 
Nine studies considered the predictors of remission off antiepileptic drugs. They were all conducted 
in childhood cohorts. Three were from the Nova Scotia cohort,(71, 106) 2 from each of the 
Turku,(32) and Montreal cohorts,(72) 1 from the Dutch cohort,(106) and the last one was an 
analysis of reconstituted and combined data from the Nova Scotia and Dutch cohorts.(106) (Tables 
8 and 9) 
 
The proportion of patients that remained in remission while successfully weaned off antiepileptic 
medication ranged from 52% in a retrospective cohort to between 47% and 55% in mixed cohorts 
and from 56% to 65% in prospective cohorts. It was 59% in the combined cohort of the 
reconstituted (after including patients with known poor prognosis and generalised absence 
seizures) Nova Scotia cohort (55%) and the Dutch DSEC cohort (65%). 
 
The potential predictors considered for remission off antiepileptic drugs and found to be consistent 
predictors or non-predictors are presented in Table 10. Age at onset of seizures and gender were 
not found to be significantly related to remaining in remission while taken off antiepileptic 
medication. However, having more than 1 seizure in the period between 6 and 12 months while on 
AED was assessed in the 2 studies that considered onset variables in combination with variables 
assessed after 1 year of AED medication,(71, 72)and was found to consistently predict remission off 
AED. The relative risk was 0.24 (95% CI 0.10-0.60) from Oskoui et al,(72) while the relative risk is 
similar at 0.25 (95% confidence intervals not provided) from Camfield et al(71). 
 
         
 
 
 
 
Cognitive impairment at onset or diagnosis of epilepsy was another consistent predictor of 
remission off AED, considered in all the 9 models. It was retained in 6 of the 9, and excluded in the 
remaining three studies, which however did not report the test of univariate association. The 
relative risk from 2 of the three studies using only intake variables, diverged widely, albeit  with 
overlapping confidence intervals, at 0.77 (95% CI 0.61-0.94) from the combined Nova Scotia and 
Dutch cohort [Geelhoed et al(106)] and 0.23 (95%CI 0.07-0.74) from the Montreal cohort [Oskoui 
et al(72)]. The third study, Camfield et al,(71) did not report 95% confidence interval. The Geelhoed 
et al cohort(106) includes patients from the Camfield et al cohort.(71) 
 
 
 
 
 
 
 
Oskoui et al 2005    |RR 0.24 (95%CI 0.10-0.60) 
Camfield et al 1993 |RR 0.25 (95% CI Not Stated) 
Oskoui et al 2005      | RR 0.23 (95%CI 0.07-0.74) 
Geelhoed et al 2005 | RR 0.77 (95%CI 0.61-0.94)  
Camfield et al 1993   |RR 0.25 (95%CI Not Stated) 
 
 
Box 3 | Relative risk (RR) of remission off AED in children having more than 1 seizure 6 to 12 months on AED 
 
Box 4 | Relative risk (RR) of remission off AED in children with intellectual disability (models with only onset variables) 
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Table 8 | Studies predicting remission off AED (Nova Scotia and DSEC Cohort) 
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Remarks 
 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome) 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-16 
(6.7±4.5) 
Nova Scotia 
Camfield, 
1993(71) 
Mixed 
Population 
N=486 
Y Y Y Y Y Patients with known 
poor prognosis, 
generalised absence and 
progressive neurological 
disorders excluded  
Only intake variables 
 7.1yrs 
(Mean) 
Off AEDs at Last 
Follow up (54%) 
Age ≤ 1yr 
Age 1-12yrs 
Intellectual disability 
History of Neonatal Seizures 
1-2 Seizures before AED 
≥3 Seizures before AED 
HR: 0.23 (NS) 
HR: 0.21 (NS) 
HR: 4.00 (NS) 
HR: 0.17 (NS) 
HR: 0.42 (NS) 
HR: 0.31 (NS) 
0-16 
(6.7±4.5) 
Nova Scotia 
Camfield, 
1993(71) 
Mixed 
Population 
N=486 
Y Y Y Y Y Patients with known 
poor prognosis, 
generalised absence and 
progressive neurological 
disorders excluded  
Intake and 1yr variables 
 
7.1yrs 
(Mean) 
Off AEDs at Last 
Follow up (54%) 
Age ≤ 1yr 
Age 1-12yrs 
Intellectual disability 
History of Neonatal Seizures 
1-2 Seizures before AED 
≥3 Seizures before AED 
≤1 Seizure 6-12months on AED 
>1 Seizure 6-12months on AED 
HR: 0.37 (NS) 
HR: 0.17 (NS) 
HR: 3.45 (NS) 
HR: 0.16 (NS) 
HR: 0.42 (NS) 
HR: 0.31 (NS) 
HR: 2.78 (NS) 
HR: 4.00 (NS) 
0-16 Nova Scotia 
Geelhoed, 
2005(106) 
Mixed 
Population 
N=602 
Y Y Y Y Y Includes all epilepsy 
types from the Nova 
Scotia cohort 
8.8yrs 
(Mean) 
Off AEDs at Last 
Follow up (55%) 
Idiopathic Partial Epilepsy 
Cryptogenic Partial Epilepsy 
Intellectual disability 
NS 
NS 
NS  
0-16 
(5.9±4.2) 
 
DSEC Cohort  
Geelhoed, 
2005(106) 
Prospective 
Hospital 
N=453 
Y Y Y Y Y Exact same cohort as 
reported in Arts et al, 
2004 
5yrs 
(Minimum) 
Off AEDs at Last 
Follow up (65%) 
Age >12yrs 
Symptomatic Gen. Epilepsy 
Cryptogenic Gen. Epilepsy 
Symptomatic Partial Epilepsy 
Cryptogenic Partial Epilepsy 
NS 
NS 
NS 
NS 
NS 
0-16 Nova Scotia & 
DSEC Cohort  
Geelhoed, 
2005(106) 
Combination 
Mixed 
(Hospital and 
Population) 
N=1055 
 
 
Y Y Y Y Y Includes all epilepsy 
types from Nova Scotia 
cohort merged with the 
Dutch DSEC cohort 
5yrs 
(Minimum 
for >95%) 
Off AEDs at Last 
Follow up (59%) 
Age >12 yr 
N seizures before AED 
Neurologic Deficits  
Intellectual disability  
Absence Seizures  
Cryptogenic Gen. Epilepsy 
Symptomatic Partial Epilepsy  
Cryptogenic Partial Epilepsy + 
History of Febrile Seizures  
OR: 2.04 (1.67, 2.63) 
OR: 1.02 (1.01, 1.04) 
OR: 1.61 (1.04, 2.5) 
OR: 1.81 (1.19, 2.28) 
OR: 0.57 (0.36, 0.95) 
OR: 2.17 (1.22, 3.85) 
OR: 2.94 (1.92, 4.34) 
OR: 1.75 (1.33, 2.38) 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, HR-Hazard Ratio, OR-Odds Ratio, AED-Antiepileptic Drug, NS-Not Stated 
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Table 9 | Studies predicting remission off AED (Montreal and Turku Cohort) 
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Remarks 
 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome) 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-15 
(4.3) 
Turku, Fin 
Sillanpaa, 
1998(32) 
Mixed 
Population 
N=176 
Y U Y Y Y Three seizures diagnosed 
epilepsy 
23-39yrs Off AEDs 5yrs 
before Last Follow 
up (47%) 
75-100% reduction in seizures 
within 3months of AED 
Complex Partial Seizures 
Cryptogenic vs. R. Symptomatic 
Idiopathic vs. R. Symptomatic 
HR:  0.09 (0.03, 0.31) 
 
HR: 3.03 (1.40, 6.67) 
HR: 0.33 (0.15, 0.71) 
HR: 0.32 (0.16, 0.65) 
0-15 Turku, Fin 
Sillanpaa, 
1998(32) 
Prospective 
Population 
N=117 
Y Y Y Y Y Three seizures diagnosed 
epilepsy 
Only prospectively 
identified patients in 
Turku cohort 
11-39yrs Off AEDs 5yrs 
before Last Follow 
up (56%) 
75-100% reduction in seizures 
within 3months of AED 
Complex Partial Seizures 
Atonic Seizures 
Cryptogenic vs. R. Symptomatic 
Idiopathic vs. R. Symptomatic 
HR: 0.45 (0.25, 0.81) 
 
HR: 3.57 (1.70, 7.69 ) 
HR: 3.85 (0.83, 16.68) 
HR: 0.30 (0.14, 0.64) 
HR: 0.38  (0.18, 0.83) 
2-17 
(7.6±3.7) 
Montréal, Ca 
Oskoui, 
2005 (72) 
Retrospective 
Hospital 
N=196 
Y P Y Y Y Only onset variables 
Data collection was 
remarkably good  
2-13.6yrs Off AEDs at Last 
Follow up (52%) 
Intellectual disability  
Remote Symptomatic Epilepsy  
Mixed Seizure Types  
HR: 4.35 (1.35, 14.29) 
HR: 2.17 (1.09, 4.35) 
HR: 2.94 (1.28, 6.67) 
2-17 
(7.6±3.7) 
Montréal, Ca 
Oskoui, 
2005(72) 
Retrospective 
Hospital 
N=196 
Y P Y Y Y Onset and 1yr variables 
Data collection was 
remarkably good  
2-13.6yrs Off AEDs at Last 
Follow up (52%) 
Intellectual disability  
>1 Seizure 6-12months on AED 
Mixed Seizure Types  
HR: 5.26 (1.70, 16.68) 
HR: 4.17 (1.67, 10.0) 
HR: 2.5 (1.08, 5.56) 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, Unclear, P-Partly, HR-Hazard Ratio, OR-Odds Ratio, AED-Antiepileptic Drug 
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Table 10 | Consistent predictors and non-predictors of remission off AED 
 
C
am
fi
e
ld
, 1
9
9
3
 
C
am
fi
e
ld
, 1
9
9
3
 
G
e
e
lh
o
e
d
, 2
0
0
5
N
 
G
e
e
lh
o
e
d
, 2
0
0
5
D
 
G
e
e
lh
o
e
d
, 2
0
0
5
N
D
 
Si
lla
n
p
aa
, 1
9
9
8
 
Si
lla
n
p
aa
, 1
9
9
8
†
 
O
sk
o
u
i, 
2
0
0
5
 
O
sk
o
u
i, 
2
0
0
5
*
 
Demographics  
Age at Onset      Θ Θ Θ Θ 
Gender   Θ Θ Θ   Θ Θ 
Epilepsy Before AED, Intake or Index   
N of Seizures before Intake or AED     ✔ Θ Θ Θ Θ 
Early Epilepsy Characteristics  
>1 Seizure from 6 - 12months  ✔       ✔ 
EEG  
Intake/Early - EEG Abnormal ✔  Θ Θ Θ   Θ Θ 
Aetiology | Syndrome  
Remote Symptomatic Aetiology ✔  Θ     ✔ Θ 
Cryptogenic Epilepsy   Θ ✔ ✔   Θ Θ 
ILAE Syndrome      Θ Θ Θ Θ 
Cognition  
Abnormal Cognitive Development ✔ ✔ ✔ Θ ✔ Θ Θ ✔ ✔ 
Neurological Sign  
Neurological Examination ✔  Θ Θ ✔ Θ Θ Θ Θ 
✔ - Variable is significant or retained in multivariate model 
✔ - Variable is only significant on univariate analysis 
✘- Variable is not significant on univariate analysis 
Θ – Variable is not reported in univariate analysis, but reported as not significant on multivariate analysis 
 
 
Intellectual disability was also retained in 2 studies (71, 72) that combined variables assessed at 
intake or onset with those only assessable at 1 year after onset/intake (e.g. number of seizures 
between 6-12 months while on AED): 
 
 
 
 
 
 
None of the studies that considered abnormal EEG at intake or early in the course of epilepsy 
confirmed it as an independent predictor of remission off AED. However, 1 study (106) out of 5 
found the number of seizures before intake to be an independent predictor. The same model 
(106)also retained deficit on neurological examination as an independent predictor out of 8 
studies that considered signs on neurological examination. 
 
Oskoui et al 2005    | RR 0.19 (95%CI 0.06, 0.59) 
Camfield et al 1993 |RR 0.29 (95%CI Not Stated) 
Box 5 | Relative risk (RR) of remission off AED in children with intellectual disability (models combining onset and 1 
year variables) 
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Three of the models were externally validated. The results of the validation studies are 
presented in Table 11. Sillanpaa et al(105) externally validated the Nova Scotia model 
(developed using the intake variables only) on the Turku cohort, although this was to predict 
three years seizure-free status immediately before last follow up on or off medication instead of 
remission off AED. This was because physicians handling patients within the Turku cohort were 
reluctant to discontinue medication and as 75% of those with 3 year remission at last follow up 
had been in remission for at least 10 years, it was considered unlikely that these patients would 
relapse off medication.  
 
Patients in the Turku cohort were selected with the same specific inclusion criteria in the Nova 
Scotia cohort for the validation study. The performance of the Nova Scotia intake model(105) 
had greater specificity (88% vs. 64%) and positive predictive value (84% vs. 71%) compared to 
the results of internal validation, but much poorer sensitivity (43% vs. 73%) and negative 
predictive value (51% vs. 67%), and fewer instances of correct prediction (61% vs. 67%)  
 
The other 2 externally validated models were reported by Geelhoed et al(106), from the model 
derived from the reconstituted Nova Scotia cohort and from the DSEC cohort to predict 
remission off AED, externally validated in the other, with similar results on external and internal 
validation in both models. 
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Table 11 | Externally validated models predicting remission off AED 
 
 
 
 
 
 
 
Predictors in Model 
 
 
 
 
 
 
 
Derivation Cohort 
 
 
 
 
 
Internal Validation: 
Performance of Model in 
Derivation Cohort 
 
 
 
 
 
 
Validation 
Study 
 
 
 
 
 
 
 
Validation Cohort 
 
 
 
 
 
External Validation: 
Performance of Model 
in Validation Cohort Sc
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Age at Onset 
-< 1 yr, -1-12 yrs, ->12 yrs 
Intelligence 
-Normal/-Retardation 
Neonatal Seizure 
No/Yes 
Seizures before AED 
-1 or 2, -3 to 20, ->20 
Camfield 1993(71) 
Nova Scotia 
 
Patients with known poor 
prognosis, generalised 
absence and progressive 
neurological disorders 
excluded 
 
 
Pre-Test Probability (54%) 
AUC 
(NS) 
 
Best probability cut-off 
(NS) 
 
Sensitivity (74% ± 4%) 
Specificity (64% ± 5%) 
PPV (71% ± 4%) 
NPV (67% ± 5%) 
Correct Prediction (68%) 
Sillanpaa  
1995(105) 
Turku Cohort 
141 patients with the same 
inclusion criteria as the 
Nova Scotia Cohort. The 
Turku cohort had 
significantly more patients 
with intellectual disability 
Validated predicting 
remission, and not 
remission off AED 
Pre-Test Probability (60%)  
AUC 
(NS) 
 
Probability cut-off 
(NS) 
 
Sensitivity (43%) 
Specificity (88%) 
PPV (84%) 
NPV (51%) 
Correct Prediction (61%) 
Y Y Y Pr N 
Idiopathic Partial Epilepsy 
Cryptogenic Partial Epilepsy 
Intellectual disability 
Geelhoed 2005(106) 
Reconstituted Nova Scotia 
Cohort to includes all epilepsy 
types 
 
 
 
 
 
 
Pre-Test Probability (55%) 
AUC 
(NS) 
 
Best probability cut-off 
(≈50%) 
 
Sensitivity (69%) 
Specificity (69%) 
PPV (73%) 
NPV (35%) 
Correct Prediction (69%) 
Geelhoed 
2005(106) 
 
Geelhoed 2005 
DSEC Dutch Cohort 
Validation cohort similar to 
derivation cohort 
 
 
 
 
 
 
Pre-Test Probability (65%) 
AUC 
(NS) 
 
Probability cut-off 
(50%) 
 
Sensitivity (71%) 
Specificity (58%) 
PPV (76%) 
NPV (53%) 
Correct Prediction (64%) 
N N Y Pr N 
Age >12yrs 
Symptomatic Gen. Epilepsy 
Cryptogenic Gen. Epilepsy 
Symptomatic Partial Epilepsy 
Cryptogenic Partial Epilepsy 
Geelhoed 2005(106) 
DSEC Dutch Cohort 
 
 
 
 
 
 
 
 
Pre-Test Probability (65%) 
AUC 
(NS) 
 
Best probability cut-off 
(≈50%) 
 
Sensitivity (70%) 
Specificity (66%) 
PPV (79%) 
NPV (55%) 
Correct Prediction (69%) 
Geelhoed 
2005(106) 
 
Geelhoed 2005 
Reconstituted Nova Scotia 
Cohort 
Validation cohort similar to 
derivation cohort 
 
 
 
 
 
Pre-Test Probability (55%) 
AUC 
(NS) 
 
Probability cut-off 
(50%) 
 
Sensitivity (57%) 
Specificity (67%) 
PPV (67%) 
NPV (56%) 
Correct Prediction (61%) 
N N N Pr N 
AUC-Area Under Receiver Operator Characteristics (ROC) Curve, PPV-Positive Predictive Value, NPV-Negative Predictive Value, NS-Not Stated, Pr-Probability, N-No, Y-Yes,  
AED-Antiepileptic Drug 
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PREDICTING REMISSION ON OR OFF AED (TYPE III) 
Twenty studies (Table 12 to 14) investigated the independent predictors of achieving remission 
irrespective of whether patients continue on antiepileptic medication or are taken off AEDs 
successfully. Eleven of the studies were analysed using logistic regression analysis with the odd 
ratio for developing refractory seizures (i.e. not entering remission on or off AED) as risk 
estimate, whereas studies using the Cox regression analysis, estimated the relative risk for 
achieving remission. However, the Nepalese study reported by Lohani et al(100)was not 
conducted among patients with newly diagnosed epilepsy as 50% had seizures for more than 1 
year before intake into the cohort and antiepileptic medication. 
 
The proportion of patients in remission ranged from as low as 50% in a retrospective cohort (93) 
to as high as 76% in 2 prospective studies (66, 70) and even higher at 80% in a mixed cohort (63) 
with the proportion of patients in remission varying widely within the same study design 
according to how remission was defined: studies that defined remission as “seizure-free period 
immediately before last assessment” (terminal remission) tend to have less proportion in 
remission than studies that defined remission simply as “seizure-free period during follow up.” 
For example, in 2 adult-onset epilepsy mixed cohorts with 1 year minimum follow up, the study 
that defined remission as 1 year terminal had 60% in remission,(97) while the study that defined 
remission as 1 year “seizure free period during follow up” had 80%. (63) However, in prospective 
studies more patients were in remission than in mixed or retrospective studies with the same 
outcome definition and minimum follow up period. (Tables 15 and 16) 
 
Having mixed (multiple) seizure types at onset was found to predict remission in studies from 2 
independent cohorts. The Italian CGSE cohort retained mixed seizure types in the model 
predicting remission as 2 years seizure-free status during follow up [relative risk 0.70 (95% CI 
0.37-1.04)]and 3 years seizure-free status [relative risk 0.70 (95%CI 0.37-1.04)] by 5 years of 
follow up.(64) Banu et al (93) found that the odds of achieving remission (3 months terminal 
remission at I year minimum follow up) was about 0.23 (95% CI 0.10-0.48) times in patients with 
multiple seizure types at onset compared to those with single seizure types. However, Banu et 
al(93) did not provide sufficient data to assess the absolute risk of not achieving remission in 
patients without multiple seizure types in order to compute the relative risk from odds ratio. 
 
 
 
 
 
*RR-Relative Risk, •OR-Odds Ratio  
 
 
 
 
 
 
CGSEPI 1992      | RR* 0.70 (95%CI 0.37-1.04) 
Banu et al 2002 | OR• 0.23 (95% CI 0.10-0.48) 
          Box 6 | Risk of achieving remission in patients with mixed seizure types at onset 
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Four studies from different cohorts found remote symptomatic aetiology to be an independent 
predictor of remission with similar risk estimates.(21, 24, 77, 104) 
 
 
 
 
 
 
 
 
Banu et al(93) and Hui et al(97) also identified intellectual disability as an independent predictor 
of remission. However the outcome measure used in the cohort reported by Banu et al(93) [3 
months terminal remission] is not comparable to that used by Hui et al(97) [1 year terminal 
remission]This difference in outcome measure, together with the disparity in the proportion of 
patients in remission – 50% (Banu et al) and 60% (Hui et al) – and possible difference in the 
definition of intellectual disability (Hui et al did not specify how this was defined), and the fact 
that Banu et al(93) was a childhood cohort while Hui et al (97) was in adults may be responsible, 
at least in part, for the wide disparity in the risk estimates: 
 
 
 
 
 
The frequency of seizures, before and after intake or AED, albeit defined differently in studies, 
was also found to be a consistent predictor of remission.  The model fitted by Arts et al 1999(65) 
with only intake variables, retained the natural logarithm transformation of the number of 
seizures before intake as an independent predictor. The model reported by MacDonald et 
al(101)to predict 1 year seizure-free period during follow up also retained the log 
transformation of the number of seizures before intake. The estimate of the relative risk in Arts 
et al 1999 (predicting 6 months terminal remission) is compared with that from MacDonald et al 
(predicting experiencing 1 year free of seizures during follow up): 
 
 
 
 
 
 
Shinnar et al 2000 | RR 0.47 (95% CI 0.27- 0.81) 
Berg et al 2001b    | RR 0.63 (95% CI 0.47-0.84) 
Sillanpaa 1993        | RR 0.44 (95% CI 0.25-0.92) 
Shafer et al 1988   | RR 0.44 (95% CI Not Stated) 
 
Box 7 | Relative risk (RR) of achieving remission in patients who have remote symptomatic aetiology 
 
Arts et al 1999              | RR 0.66 (95%CI 0.46-0.95) 
MacDonald et al 2000 | RR 0.81 (95%CI 0.66-0.99) 
 
Banu et al 2003 | OR 0.40 (95%CI 0.18-0.90) 
Hui et al 2007    | OR 0.10 (95%CI 0.05-0.25) 
 
Box 8 | Odds ratio (OR) of achieving remission in patients with intellectual disability 
 
      Box 9 | Relative risk (RR) of achieving remission in patients as a function of Log N of Seizures before index 
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Table 12 | Studies predicting remission on or off AED (the DSEC Cohort) 
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Remarks 
 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome)• 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI)‡ 
0-16 
(6.7±4.5) 
Arts, 1999 Prospective 
Hospital 
N=466 
Y Y Y Y Y Only intake variables 
Included 1 status 
epilepticus in epilepsy 
definition 
2yrs 
(Minimum) 
6 months seizure-
free immediately 
before 2yrs follow 
up (68.7%) 
Log N of Seizures before intake 
Simple Partial vs. GTCS 
Infantile Spasms, Myoclonic, 
Atonic vs. GTCS 
R. Symptomatic vs. Idiopathic 
Cryptogenic vs. Idiopathic 
OR: 1.51 (1.05, 2.19) 
OR: 3.15 (1.32,7.51)  
 
OR: 3.01 (1.45, 6.23) 
OR: 1.90 (1.06, 3.39) 
OR: 2.20 (1.25, 3.87) 
0-16 
(6.7±4.5) 
Arts, 1999 Prospective 
Hospital 
N=466 
Y Y Y Y Y Intake and 6 month 
variables 
Included 1 status 
epilepticus in epilepsy 
definition 
2yrs 
(Minimum) 
6 months seizure 
free immediately 
before 2yrs follow 
up (68.7%) 
Simple Partial vs. GTCS 
Cryptogenic vs. Idiopathic 
Abnormal EEG at 6 months 
During 1
st
 6 months after intake: 
3 months seizure free  
>25 Seizures  
Log N seizures  
OR: 2.72 (1.07, 6.89) 
OR: 1.95 (1.05, 3.61) 
OR: 2.21 (1.12, 4.36) 
 
OR: 0.32 (0.18, 0.58) 
OR: 2.20 (1.06, 4.56) 
OR: 1.99 (1.39, 2.85) 
0-16 
(6.7±4.5) 
Arts 2004 Prospective 
Hospital 
N=453 
Y 
 
Y Y Y Y Only intake variables 
Included 1 status 
epilepticus in epilepsy 
definition 
5yrs 
(Minimum) 
1 year seizure free 
immediately before 
5yrs follow up 
(76%) 
Age  <6 years at intake  
Not Idiopathic Aetiology + No 
history of febrile seizures  
No history of febrile seizures + 
Idiopathic Aetiology   
OR: 0.62 (0.39, 0.99) 
OR: 3.72 (2.20, 6.30) 
 
OR 4.37 (1.70, 11.26) 
 
0-16 
(6.7±4.5) 
Arts, 2004 Prospective 
Hospital 
N=453 
Y Y Y Y Y Intake and 6 month 
variables 
Included 1 status 
epilepticus in epilepsy 
definition 
5yrs 
(Minimum) 
1 year seizure free 
immediately before 
5yrs follow up 
(76%) 
Female 
Post-ictal Signs 
Not Idiopathic Aetiology + No 
history of febrile seizures  
No history of febrile seizures + 
Idiopathic Aetiology   
≤2 Seizure free months 
immediately before 6 month 
follow up 
OR: 1.64 (1.00, 2.70) 
OR:2.23 (1.08, 4.63) 
OR:3.58 (2.05, 6.27) 
 
OR:5.28 (1.92, 14.51) 
 
OR: 4.47 (2.00, 9.99) 
*Age range in years (Mean ± Standard Deviation); •The proportion reported is of those who achieved remission on or off AED; ‡Risk estimates for not achieving remission are 
presented; CI-Confidence Interval, Y-Yes, OR-Odds Ratio, GTCS-Generalised Tonic Clonic Seizures, EEG-Electroencephalogram, NS-Not Stated 
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Table 13 | Studies predicting remission on or off AED (Others 1) 
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Remarks 
 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome)• 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI)‡ 
0-15 Banu, 
2003(93) 
Retrospective 
Hospital 
N=151 
Y U N Y Y  1yr  
(Minimum) 
3 months seizure 
free immediately 
before last follow 
up (49.7%) 
Multiple Seizure Types 
Intellectual disability  
Abnormal EEG  
OR: 4.42 (2.07, 9.57) 
OR: 2.49 (1.11, 5.70) 
OR:4.09 (1.53, 12.11) 
0-15 Berg, 2001b Prospective  
Population 
N=594 
Y Y Y Y Y  2-8yrs 2 year seizure free 
period during 
follow up (74%) 
Log Initial Seizure Frequency  
Family History of Epilepsy 
Remote Symptomatic Aetiology 
Abnormal EEG 
Idiopathic Generalized Epilepsy 
Age 5–9 yrs at onset 
HR: 0.90 (0.86, 0.95) 
HR: 0.58 (0.42, 0.81)  
HR: 0.63 (0.47, 0.84)  
HR: 0.71 (0.54, 0.93) 
HR: 1.65 (1.28, 2.12)  
HR: 1.23 (1.01, 1.50) 
0-15 
(4.8±1.6) 
Sillanpaa, 
1990 
Mixed 
Population 
N=182 
Y U Y Y Y Three seizures diagnosed 
epilepsy 
 
23-39yrs 3yrs seizure free 
immediately before 
last follow up 
(76.4%) 
High initial Seizure Frequency 
Occurrence of Status Epilepticus 
Abnormal Fine Motor Status 
OR: 8.5 (3.1, 25.8) 
OR: 3.2 (1.5, 6.9) 
OR: 9.6 (3.4, 27.1) 
0-15 
(4.8±1.6) 
Sillanpaa, 
1993 
Mixed 
Population 
N=178 
Y U Y Y Y Three seizures diagnosed 
epilepsy 
 
23-39yrs 12 seizure free 
months during last 
10 years of follow 
up (77.5%) 
Remote Symptomatic Aetiology 
High Initial Seizure Frequency 
Occurrence of Status Epilepticus 
No Seizure Freedom within 3 
months of AED 
OR: 2.9 (1.1, 8.2) 
OR: 4.6 (1.1, 19.3) 
OR: 11.4 (3.2, 41.0) 
OR: 3.6 (1.2-10.4) 
 
0-15 
(4.3) 
Sillanpaa, 
1998 
Mixed 
Population 
N=176 
Y U Y Y Y Three seizures diagnosed 
epilepsy 
 
23-39yrs 5yrs seizure free 
immediately before 
last follow up (64%) 
75-100% reduction in seizures 
within 3months of AED 
Complex Partial Seizures 
Atonic Seizures 
HR: 0.27 (0.15, 0.49) 
 
HR: 3.33 (2.04, 5.56) 
HR: 4.55 (1.37, 14.3) 
0-15 Sillanpaa, 
2009 
Prospective 
Population 
N=102 
Y Y Y Y Y Three seizures diagnosed 
epilepsy 
Only prospectively 
identified patients  
St. Epilepticus excluded 
11-40yrs 1yr seizure free 
immediately before 
last follow up (76%) 
< Weekly seizures:  
Before AED 
During first year of AED 
 
HR: 0.37 (0.2, 0.67) 
HR: 0.59 (0.35, 0.96) 
0 – 19 Shinnar, 
2000 
Prospective  
Hospital 
N=182 
Y Y Y Y Y Excellent identification. 
10 recurrences defined 
refractoriness. 
 8.4yrs 
(Mean) 
Not up to 10th 
seizure (71.4%) 
Remote Symptomatic Aetiology 
2nd Seizure within 1 year 
HR: 2.13 (1.22, 3.71) 
HR: 6.94 (1.56, 30.7) 
*Age range in years (Mean ± Standard Deviation); •The proportion reported is of those who achieved remission on or off AED; ‡Odds Ratio for not achieving remission are 
presented; CI-Confidence Interval, Y-Yes, U-Unsure, OR-Odds Ratio, HR-Hazard Ratio, AED-Antiepileptic Drug, EEG-Electroencephalogram, NS-Not Stated 
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Table 14 | Studies predicting remission on or off AED (Others 2) 
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Remarks 
 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome)• 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI)‡ 
2 – 81 (19) CGSE, 1992 Mixed 
Hospital 
N=280 
Y Y Y Y Y  0.1-7.25yrs 2 year seizure free 
period by 5 years 
follow up (67.5%) 
≥2 Seizures before AED 
Mixed Seizure Types 
HR: 1.49 (0.98-3.13)   
HR: 1.43 (0.96-2.70) 
2 – 81 (19) CGSE, 1992 Mixed 
Hospital 
N=280 
Y Y Y Y Y  0.1-7.25yrs 3yrs seizure free 
period by 5 years 
follow up (51.1%) 
≥2 Seizures before AED 
Mixed Seizure Types 
HR: 1.52 (0.94, 5.0) 
HR: 1.61 (0.98-4.35) 
 
2 – 68 (24) Lohani, 2010 Retrospective 
Hospital 
N=284 
Y U Y Y Y Not a newly diagnosed 
epilepsy cohort. 50% had 
seizures for >1yr before 
AED and only6.5% <1mo 
6mo on AED 
(Minimum) 
6mo seizure free 
immediately before 
last follow up 
(73.2%) 
Neurological Deficit  
Failure of first AED 
 
OR:6.69 (1.37, 32.67) 
OR:71.82  
(16.51, 312.44) 
 
5->50 MacDonald, 
2000 
Prospective 
Population 
N=289 
Y Y Y Y Y Age < 5 excluded from 
analysis to avoid 
interactions 
5.6-7.6yrs 
(IQR) 
1 year seizure free 
period during 
follow up (NS) 
Log N Seizures before index  
Log N Seizures (index - 6months) 
>10 Seizures before index 
HR: 0.81 (0.66, 0.99) 
HR:0.59 (0.50, 0.70) 
HR: 1.89 (1.14, 3.13)           
5->50 MacDonald, 
2000 
Prospective 
Population 
N=289 
Y Y Y Y Y Age < 5 excluded from 
analysis to avoid 
interactions 
5.6-7.6yrs 
(IQR) 
5 years seizure free 
period during 
follow up (NS) 
Log N Seizures (index - 6months) 
>10 Seizures before index 
HR: 0.64 (0.51, 0.81) 
HR: 1.80 (1.10, 2.92) 
All ages 
(NS) 
Shafer, 1988 Retrospective 
Population 
N=298 
Y U N Y Y Patients without EEG or 
information on GTC 
Seizure excluded 
≈13-17yrs 
Mean 
(NS) 
5 years seizure free 
period during 
follow up (NS) 
Unknown Aetiology 
No Gen. Spike Waves on 1st EEG 
No Gen. Tonic Clonic Seizures 
HR: 2.27 (NS) 
HR: 1.58 (NS) 
HR: 1.4 (NS) 
12-85 
(28.7±12.4)  
Abduljabbar, 
1998 
Mixed 
Hospital 
N=826 
Y Y Y Y Y  1yr 
(Minimum) 
1 year seizure free 
period during 
follow up (80%) 
≥2 AEDs 
Compliance 
Therapeutic Drug Level 
Short duration btw onset & AED 
OR: 7.39 (NS) 
OR: 40.44 (NS) 
OR: 3.0004 (NS) 
OR: 1.003 (NS) 
15-79 (34) Hui, 2007 Mixed 
Hospital 
N=260 
Y Y Y Y Y  1-17yrs 
7years 
(Mean) 
1yr seizure free 
immediately before 
last follow up (60%) 
Intellectual disability 
Mesial Temporal Sclerosis 
OR:9.39 (3.98, 22.12) 
OR: 7.6 (3.53, 16.4) 
 
18-67 
(44±12) 
Lossius, 
1999 
Retrospective 
Population 
N=669 
Y Y Y Y Y  NS 1yr seizure free 
immediately before 
last follow up 
(72.5%) 
≥2 AEDs vs. No Treatment 
Age ≥ 50 years 
OR: 5.6 (2.7, 11.9) 
OR: 1.7 (1.1, 2.6) 
*Age range in years (Mean ± Standard Deviation); •The proportion reported is of those who achieved remission on or off AED; ‡Odds Ratio for not achieving remission are 
presented; CI-Confidence Interval, Y-Yes, U-Unsure, N-No, OR-Odds Ratio, HR-Hazard Ratio, AED-Antiepileptic Drug, EEG-Electroencephalogram, NS-Not Stated 
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Table 15 | Consistent predictors and non-predictors of remission on or off AED (1) 
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Demographics  
Age at Onset ✘      ✘  Θ ✘  Θ Θ ✘ ✘ ✘   ✘  
Gender ✘  ✘ ✔*      ✘  Θ Θ ✘ ✘ ✘ ✘  ✘ ✘ 
AED Therapy  
≥2 AEDs              ✔    ✔   
Epilepsy Before AED, Intake or Index    
Duration ✔           ✘ ✘ ✘    ✔   
N of Seizures before Intake      ✘   Θ   ✔ ✔        
Log N of Seizures before Intake  ✔              ✔ ✔     
Seizure Frequency     ✔ ✔ ✔ ✔ Θ ✔    ✔    ✔   
Early Epilepsy Characteristics  
Log N (+1) of Seizures from 0 - 6mo  ✔             ✔ ✔     
Status Epilepticus (SE)      ✔ ✔ ✔ Θ            
EEG  
Intake/Early - EEG Abnormal ✘ ✘   ✔ ✘     ✘ ✘ ✘    ✘    
Intake Epileptiform Abnormality  Θ ✘   ✘               
Gen (Epileptiform) Spike and Wave      ✘           ✔    
Focal                 ✘   ✘ 
✔ - Variable is significant or retained in multivariate model, ✔ - Variable is only significant on univariate analysis, ✘- Variable is not significant on univariate analysis 
Θ – Variable is not reported in univariate analysis, but reported as not significant on multivariate analysis 
*In this study, female was the gender retained in the model 
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Table 16 | Consistent predictors and non-predictors of remission on or off AED (2) 
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Seizure Type  
Mixed Seizure Types     ✔       ✔ ✔        
Seizure Type          ✘       ✘ ✘   
Generalised Onset               ✘ ✘ ✘     
Partial              ✘ ✘ ✘     
Complex Partial       ✘  ✔            
Secondarily Generalised      ✘ ✘        ✘ ✘     
Atonic      ✘   ✔            
Generalised Tonic Clonic      ✘ ✘        ✘ ✘ ✔    
Aetiology | Syndrome  
Remote Symptomatic Aetiology      ✔  ✔  ✔ ✔ ✘ ✘  ✘ ✘ ✔  ✔ ✔ 
Cryptogenic               ✘ ✘   ✔  
West Syndrome       ✔ ✔             
Cognition  
Abnormal Cognitive Development     ✔  ✔ ✔ Θ          ✔  
Neurological Sign  
Neurological Examination ✔  ✘      Θ   ✘ ✘ ✔    ✔  ✔ 
Neuroimaging Findings ✔  ✘           ✘    ✔  ✘ 
Others  
Family History ✘    ✘ ✔ ✘     ✘ ✘    ✘    
Perinatal Asphyxia     ✘          ✘ ✘     
Neonatal Seizures     ✘       ✘ ✘        
Febrile Seizure ✘  ✘   ✘     ✘ ✘ ✘        
Tumour               ✘ ✘   ✘  
Vascular Malformation               ✘ ✘   ✘  
✔ - Variable is significant or retained in multivariate model, ✔ - Variable is only significant on univariate analysis, ✘- Variable is not significant on univariate analysis 
Θ – Variable is not reported in univariate analysis, but reported as not significant on multivariate analysis 
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The natural logarithm transformation of the number of seizures from intake to 6 months was 
also consistently identified as independent predictor of remission in Arts et al 1999(65) (in the 
model including 6 months variables) and MacDonald et al(101) (although it is also retained in 
the model predicting a 5 year seizure-free period, the model predicting I year free of seizures 
during follow up is used in this comparison owing to its greater similarity to the outcome 
measure in Arts et al 1999): 
 
 
 
 
 
 
No demographic variable was found to consistently predict remission; only 1 study,(66) found 
gender to be an independent predictor on multivariate analysis, albeit with borderline statistical 
significance. Other variables not associated with remission include age at onset, abnormal EEG 
at intake and the range of seizure types considered, as were factors like family history of 
epilepsy, history of neonatal seizures and the specific aetiological factors considered.  
 
The 2 models derived in Arts et al 1999(65) were externally validated in a temporal cohort from 
the same centre as the derivation cohort. (Table 17) The model derived from only variables 
assessed at intake showed poor discriminative ability (AUC, <0.70) in both internal and external 
validation. However, the model that was fitted with both intake and 6 month variables showed 
good discrimination (AUC, >0.70), with the AUC reducing from 0.78 in internal validation to 0.71 
when externally validated. The proportion of patients with correct prediction (accuracy) also 
reduced from 73% to 63% in external validation. 
 
The 2 models were calibrated, with a plot of 4 risk groups of unequal size, which suggest that 
the percentage of children correctly predicted not to achieve remission did increase with the 
predicted chance of not achieving remission. The calibration was however not assessed using a 
formal statistical test.  
Arts et al 1999              | RR 0.50 (95%CI 0.35-0.72) 
MacDonald et al 2000 | RR 0.59 (95%CI 0.50-0.70) 
 
Box 10 | Relative risk of achieving remission in patients as a function of Log N of Seizures from index to 6 months 
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Table 17 | Externally validated models predicting remission on or off antiepileptic drugs 
 
 
 
 
 
 
 
Predictors in Model 
 
 
 
 
 
 
 
Derivation Cohort 
 
 
 
 
 
Internal Validation: 
Performance of Model in 
Derivation Cohort 
 
 
 
 
 
 
Validation 
Study 
 
 
 
 
 
 
 
Validation Cohort 
 
 
 
 
 
External Validation: 
Performance of Model in 
Validation Cohort Sc
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Log N of Seizure before intake 
>/<25 Seizures before intake 
Seizure Type 
-Generalised Tonic Clonic 
-Complex Partial 
-Simple Partial 
-Absences 
-Other Types 
Aetiology  
-Remote symptomatic 
-Cryptogenic, -Idiopathic 
Yes/No Neurological signs 
Arts 1999 
 
Only intake variables 
Included 1 status epilepticus 
in epilepsy definition 
 
Remission defined by 
6 months seizure free  
immediately before 2yrs 
follow up 
 
Pre-Test Probability (31%) 
AUC 
0.69 (0.64, 0.74) 
 
Best probability cut-off 
(38%) 
 
Sensitivity (61.6%) 
Specificity (69.1%)  
PPV (47.2%) 
NPV (20.0%) 
Correct Prediction (66.7%) 
 
Geerts 
2006 
Temporal Validation 
N=273 
 
2 years  
(Minimum Follow up) 
 
The 2 cohorts were similar 
except there were more 
children with normal EEG 
findings than in the 
derivation cohort. 
Pre-Test Probability (34%) 
AUC 
0.62 (0.55, 0.69) 
 
Probability cut-off 
(38%) 
 
Sensitivity (60.0%) 
Specificity (61.4%) 
PPV (44.5%) 
NPV (25.1%) 
Correct Prediction (59.9%) 
 
Y N Y Pr N 
Seizure Type 
-Generalised Tonic Clonic 
-Complex Partial 
-Simple Partial 
-Absences 
-Other Types 
Aetiology  
-Remote symptomatic 
-Cryptogenic, -Idiopathic 
During 1
st
 6 mo after intake: 
-Log N Seizures 
->/<25 Seizures 
-Yes/No 3 month remission 
EEG at Intake  
-Normal, -Epileptiform,-Other 
EEG 6 mo after intake 
-Normal,-Epileptiform, -Other 
Arts 1999 
 
Intake and 6 month 
variables 
Included 1 status epilepticus 
in epilepsy definition 
 
Remission defined by 
6 months seizure free  
immediately before 2yrs 
follow up 
 
Pre-Test Probability (31%) 
AUC 
0.78 (0.73, 0.82) 
 
Best probability cut-off 
(34%) 
 
Sensitivity (72.6%) 
Specificity (73.1%) 
PPV (54.8%) 
NPV (14.4%)  
Correct Prediction (73.0%) 
 
Geerts 
2006 
Temporal Validation 
N=273 
 
2 years  
(Minimum Follow up) 
 
The 2 cohorts were similar 
except there were more 
children with normal EEG 
findings than in the 
derivation cohort. 
 
Pre-Test Probability (34%) 
AUC 
0.71 (0.64, 0.78)  
 
Probability cut-off 
(34%) 
 
Sensitivity (67.4%) 
Specificity (60.2%) 
PPV (46.6%) 
NPV (21.8%) 
Correct Prediction (62.7%) 
 
 
Y N Y Pr N 
AUC-Area Under Receiver Operator Characteristics (ROC) Curve, PPV-Positive Predictive Value, NPV-Negative Predictive Value, NS-Not Stated, Pr-Probability, N-No, Y-Yes,  
AED-Antiepileptic Drug
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PREDICTING INTRACTABILITY (TYPE IV) 
Twelve studies, all conducted in childhood epilepsy cohorts, attempted to identify independent 
predictors of medically intractable seizures. Six of the analyses were conducted on the entire 
cohort, (Table 18) while the other 6 fitted their model with a case control analysis nested within 
cohorts. (Table 19 and 20) 
 
The proportion of patients with intractable seizures in the cohorts varied among the studies 
depending on design and how medical intractability was defined and conceptualised in each 
study. Most of the studies defined intractability as having “at least 1” or “more than 1” seizure 
per month for about 1 year (ranged between at least 6 months and at least 2 years) after more 
than 2 antiepileptic drug trials singly or in combination, at the maximum tolerable dose. 
 
The frequency of seizures that define medical intractability in each study influenced the 
proportion of patients that met the criteria. The studies that defined intractability as having “1 
or more” seizures per month(72, 75, 76) had more patients who met the criteria for 
intractability (13% to 14%) compared to the studies(73, 74) that defined intractability as only 
“more than 1” seizure per month (9% to 10%). However, in a retrospective, hospital based study 
reported by Berg et al 1996(78), with the seizure frequency that defined epilepsy being “1 or 
more” seizures per month, one third (32.5%) of the patients met the criteria for medical 
intractability. 
 
Two of the studies reported by Oskoui et al(72)and the report by Ko et al(79) included patients 
who required epilepsy surgery during follow up as medically intractable even when they did not 
meet the usual criteria for intractability. The same 2 studies by Oskoui et al(72) also included 
patients who required the use of the ketogenic diet to control seizures, and only patients who 
have had recurrent seizures in the last 6 months of follow up in a category designated as having 
“poor outcome.” 7% of the cohort was included in this category. 
 
The age of children at the onset of seizures, kept as a continuous variable, was retained in the 
models predicting medical intractability in three different cohorts, with nested case control 
analysis (75, 78, 79): 
 
 
 
 
 
 
 
Casetta et al 1999 | RR 0.98 (95%CI 0.97-1.28) 
Ko et al 1999          | RR 0.86 (95%CI 0.75-0.97) 
Berg et al 1996      | RR 0.78 (95%CI 0.69-0.89) 
 
    Box 11 | Relative risk (RR) of having intractable seizures for each increasing year of age at onset of seizures 
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Table 18 | Studies predicting intractability (full cohort) 
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Study 
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 Remarks 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
Outcome Measure 
(% with Outcome) 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-15 Berg, 2001a Prospective 
Population 
Y Y Y Y N  5yrs 
(Median) 
>1 Seizure per 
month for ≥1.5yrs 
with >2AEDs (10%) 
Cryptogenic and Symptomatic 
Generalized Syndrome 
Idiopathic Syndrome 
Log Initial Seizure Frequency  
Abnormal EEG (Focal Slowing) 
Age 5 to 9 at Onset  
Provoked, Non-Febrile and 
Neonatal Status Epilepticus 
Myoclonic Seizures + Log Initial 
Seizure Frequency 
 
HR: 3.01 (1.32, 6.85)  
HR: 0.23 (0.09, 0.63) 
HR: 1.41 (1.23, 1.62) 
HR: 2.31 (1.13, 4.74) 
HR: 0.42 (0.19, 0.92) 
 
HR: 5.96 (2.00, 17.71) 
 
HR: 0.73 (0.57, 0.95) 
0-14 
(4.8±3.8) 
Ramos-
Lizana, 2009 
Mixed 
Hospital 
Y Y Y Y Y All variables measured at 
6 months of follow up 
2-11.6yrs >1 Seizure per 
month for ≥1.5yrs 
with >2AEDs (8.7%) 
Age <1 year at Onset   
Idiopathic Aetiology 
>1 Seizure (diagnosis -6 months) 
HR: 2.6 (1.0, 6.9) 
HR: 0.2 (0.0, 0.8) 
HR: 4.8 (1.8, 13.0) 
2-17 
(7.6±3.7) 
Oskoui, 2005 Retrospective 
Hospital 
Y P Y Y Y Only onset variables 
Data collection was 
remarkably good  
2-13.6yrs ≥1 Seizure per 
month for >1yr with 
>2AEDs (12.8%) 
Multiple Seizure Types  OR: 17.4 (4.8–63.1)  
 
2-17 
(7.6±3.7) 
Oskoui, 2005 Retrospective 
Hospital 
Y P Y Y N Onset and 1yr variables 
Data collection was 
remarkably good  
2-13.6yrs ≥1 Seizure per 
month for >1yr with 
>2AEDs (12.8%) 
Multiple Seizure Types  
Intellectual disability  
Seizure 6 to 12 months on AED  
OR: 6.5(1.9–35.4) 
OR: 7.2 (1.0–50.8) 
OR: 70.4 (7.5–661.4) 
2-17 
(7.6±3.7) 
Oskoui, 2005 Retrospective 
Hospital 
Y P Y Y N Only onset variables 
Data collection was 
remarkably good  
Outcome included 
having required epilepsy 
surgery or ketogenic diet 
2-13.6yrs Recurrent seizures 
on adequate AED 6 
months immediately 
before last follow up 
(6.9%) 
Multiple Seizure Types  
Intellectual disability  
Idiopathic Epilepsy  
OR: 14.7 (4.7–46.1)  
OR: 3.3 (1.1–10.2)  
OR: 0.13 (0.03–0.52) 
 
2-17 
(7.6±3.7) 
Oskoui, 2005 Retrospective 
Hospital 
Y P Y Y N Onset and 1yr variables 
Data collection was 
remarkably good  
Outcome included 
having required epilepsy 
surgery or ketogenic diet 
2-13.6yrs Recurrent seizures 
on adequate AED 6 
months immediately 
before last follow up 
(6.9%) 
Multiple Seizure Types  
Intellectual disability  
Seizure 6 to 12 months on AED  
OR: 8.9 (2.6–31.2) 
OR: 8.9 (2.4–32.7) 
OR: 21.6 (6.3–74.0) 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, P-partly, N-No, HR-Hazard Ratio, OR-Odds Ratio, AED-Antiepileptic Drug, EEG-
Electroencephalogram 
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Table 19 | Studies predicting intractability (nested case control) 
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Follow Up 
 
 
 
 
 
 
 
Outcome Measure 
 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-19  
Cases 
3.3 
Controls  
6.4 
Casetta, 
1999 
 
Prospective 
Population 
N=222 
Cases  31 
Controls 95 
Y Y Y Y Y Two models – I with age 
as continuous variable 
and II with age 
dichotomous 
 
13.96% of patients in the 
cohort had intractable 
seizures 
Cases 
20.97yrs 
Controls 
20.98yrs 
 
Cases 
≥1 Seizure per 
month for ≥2yrs 
with >2AEDs 
Controls  
5 years seizure free 
period during 
follow up 
Model I   
Age at Onset (in years)  
Remote Symptomatic Aetiology  
Weekly Seizures before AED  
Model II 
Age <1 year at Onset  
Remote Symptomatic Aetiology  
Weekly Seizures before AED  
 
OR: 0.98 (0.97, 1.28) 
OR: 8.6 (2.3, 32.2) 
OR: 4.5 (1.3, 16)  
 
OR: 3.9 (1.1, 14.25) 
OR: 8.6 (2.4, 26.1) 
OR: 4.1 (1.3-13.8) 
0-15 Kwong, 
2003 
 
Mixed 
Population 
N=309 
Cases 44 
Controls 211 
Y Y Y Y Y 14.24% of patients in the 
cohort had intractable 
seizures 
3yrs 
(Minimum) 
Cases 
5.88yrs 
Controls 
4.67yrs 
Cases 
≥1 Seizure per 
month for ≥2yrs 
with ≥3AEDs 
Controls  
2 year seizure free 
period during 
follow up 
Daily Seizures before AED  
≥3 Seizures 6-12 months on AED  
History of Febrile Seizure  
Abnormal Neurodevelopmental 
Status (Intellectual disability 
and/or Cerebral Palsy)  
OR: 1.58 (1.0, 2.51) 
OR:21.86(7.35,65.01) 
OR:4.83 (1.31, 17.83) 
OR:18.16(5.19,63.61) 
Cases 
 1.58±2.38  
Controls 
5.83±2.54 
Chawla, 
2002 
 
Mixed 
Hospital 
N=(NS) 
Cases 50 
Controls 50 
U U N U Y Equal number of cases 
and controls were 
selected from the cohort 
 
The total number of base 
population not presented 
1yr 
(Minimum) 
Cases 
≥1 Seizure per 
month for ≥0.5yr 
with ≥2AEDs 
Controls  
6 months seizure 
free immediately 
before last follow 
up 
Age <1 year at Onset  
Remote Symptomatic Aetiology  
Neurological Impairment 
Initial Seizure Type (Myoclonic 
or Infantile Spasms) 
 
OR: 11.7 (2.95,46.43) 
OR: 2.91 (1.14, 7.44) 
OR12.25 (3.58,41.89) 
OR: 10.36 (2.39, 
44.94) 
Cases 
1.8  
Controls 
 5.8 
 
Berg,  
1996 
Retrospective 
Hospital 
N=234 
Cases 76 
Controls 96 
N Y Y Y Y Case control study nested 
in a cohort 
 
32.5% of patients in the 
cohort had intractable 
seizures 
Cases 
6yrs 
Controls 
 5yrs 
 
Cases 
 ≥1 Seizure per 
month for ≥2yrs 
with >2AEDs 
Controls  
2 year seizure free 
period during 
follow up 
Age at Onset (in years)  
Remote  Symptomatic Epilepsy  
Occurrence of Status Epilepticus  
Infantile Spasms  
 
OR: 0.78 (0.69, 0.89) 
OR: 2.24, (1.05, 4.80) 
OR: 3.30 (1.06,10.28) 
OR: 10.42 (1.27, 
85.39) 
 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, N-No, U-Unclear, OR-Odds Ratio, AED-Antiepileptic Drug, NS-Not Stated 
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Table 20 | Studies predicting intractability (nested case control by Ko et al) 
 
 
 
 
 
 
 
Age  
(Years)* 
 
 
 
 
 
 
 
Study 
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Setting 
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 Remarks 
 
 
 
 
 
 
 
Follow Up 
 
 
 
 
 
 
 
Outcome Measure 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-18  
Cases 
 2.9 
Controls 
 5.2 
Ko, 1999 
 
Retrospective 
Hospital 
N=(NS) 
Cases 144 
Controls 39 
N Y Y U N Patients without EEG at 
intake were excluded 
Only clinical variables 
entered in this model 
 
The total number of base 
population not 
presented 
2yrs 
(Minimum) 
Cases 
5.3yrs 
Controls 
4.9yrs 
Cases 
“Continued 
Seizures” with 
≥3AEDs or having 
required epilepsy 
surgery 
Controls  
1 year seizure free 
period during 
follow up 
Age at Onset (in years)  
Remote Symptomatic Aetiology  
Occurrence of Status Epilepticus  
Simple Partial Seizures  
Absence Seizures  
Tonic Seizures  
OR: 0.86 (0.75, 0.97 ) 
OR: 4.41 (1.68, 13.0) 
OR: 7.7(1.42, 143.48) 
OR: 5.11(1.21, 36.08) 
OR: 0.92 (0.32, 2.70) 
OR:13.5(2.56,249.74) 
 
0-18  
Cases 
 2.9 
Controls 
 5.2 
Ko, 1999  
 
Retrospective 
Hospital 
N=(NS) 
Cases 144 
Controls 39 
N Y Y U N Patients without EEG at 
intake were excluded 
Only EEG variables 
entered in this model 
 
The total number of base 
population not 
presented 
2yrs 
(Minimum) 
Cases 
5.3yrs 
Controls 
4.9yrs 
Cases 
“Continued 
Seizures” with 
≥3AEDs or having 
required epilepsy 
surgery 
Controls  
1 year seizure free 
period during 
follow up 
Photo-convulsive Response  
3 Hz Spike and Wave  
Diffuse Slowing  
Focal Spike and Wave  
Frequent Sharp Wave/ Spike 
(>1/60 s)  
OR: 0.10 (0.02, 0.51) 
OR: 0.21 (0.05, 0.74) 
OR: 2.59 (1.05, 6.84) 
OR: 5.21 (1.25,38.16) 
OR: 1.68 (0.67, 4.43) 
 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, P-partly, N-No, HR-Hazard Ratio, OR-Odds Ratio, AED-Antiepileptic Drug, NS-Not Stated 
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Table 21 | Consistent predictors and non-predictors of intractability 
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Demographics  
Age at Onset (in years)* ✔  Θ Θ Θ Θ ✔ ✔  ✔ ✔  
Age at onset <1 year† ✔ ✔     ✔  ✔    
Gender ✘ ✘ Θ Θ Θ Θ ✘      
Epilepsy Before AED, Intake or Index   
Seizure Frequency - Daily  ✔       ✔ ✔  ✔  
Early Epilepsy Characteristics   
Status Epilepticus (SE) ✔ ✘     ✔ ✔ ✘ ✔ ✘  
EEG  
Intake/Early - EEG Abnormal ✘ ✘ Θ Θ Θ Θ  ✔  ✘   
Focal Slowing ✔           ✘ 
Seizure Type  
Mixed Seizure Types ✔ ✘ ✔ ✔ ✔ ✔       
Generalised Onset  ✘         ✘   
Partial ✘      ✔   ✘   
          Simple ✘          ✔  
          Complex ✘          ✘  
Myoclonic ✔          ✔  
Absence ✔         ✔ ✔  
Generalised Tonic Clonic          ✘ ✘  
Aetiology | Syndrome  
Remote Symptomatic Aetiology ✔ ✔ Θ Θ Θ Θ ✔ ✔ ✔ ✔ ✔  
Idiopathic ✔ ✔ Θ Θ ✔ Θ       
West Syndrome  ✔        ✔ ✔  
ILAE Syndrome ✔  Θ Θ Θ Θ  ✔     
Cognition  
Abnormal Cognitive Development  ✔ Θ ✔ ✔ ✔  ✔   ✔  
Neurological Sign   
Neurological Examination   Θ Θ Θ Θ   ✔    
Normal Neuroimaging Findings ✔ ✔      ✔   ✔  
Others  
Motor disability  ✘         ✔  
Family History  ✘ Θ Θ Θ Θ ✘  ✘  ✘  
Neonatal Seizures ✔ ✘     ✘ ✔ ✔ ✔ ✘  
Febrile Seizure ✘ ✘     ✘ ✔ ✘ ✘ ✘  
Multiple Seizures within 24 Hours ✔ ✔           
Microcephaly         ✔ ✔ ✘  
✔ - Variable is significant or retained in multivariate model, ✔ - only significant on univariate analysis, ✘- not significant on 
univariate analysis Θ – not reported in univariate analysis, but reported as not significant on multivariate analysis 
*Where “age in years” was retained, the risk of intractability reduces with each additional year increase in the age of onset.   
†“Age at onset < 1 year” was retained as a variable which increases the risk of intractability.
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Three studies also retained onset of seizures in infancy (age at onset < 1year) as an independent 
predictor of medically intractable seizures (74, 75, 94): 
 
 
 
 
 
 
 
The presence of remote symptomatic aetiology was also found to be a consistent predictor of a 
patient developing medically intractable seizures in 4 studies, all nested cohort studies, with the 
risk estimate from Casetta et al(75) being remarkably higher than the rest: 
 
 
 
 
 
 
 
Three studies also retained idiopathic aetiology/syndrome as an independent predictor of 
patients developing medically intractable seizures, with similar estimates although the study 
from Oskoui et al (72) was one in which “intractability” defined as “poor outcome” (patients 
who required epilepsy surgery and/or the use of ketogenic diet to control seizures, or who have 
had recurrent seizures in the last 6 months of follow up) was rather atypical: 
 
 
 
 
 
 
Intellectual disability was another consistent predictor of patients developing medically 
intractable seizures, with the variable retained in three of the 4 studies on intractability 
reported by Oskoui et al(72) and in the only study reported by Kwong et al(76). The result of the 
study from Oskoui et al(72) whose definition of medical intractability is most similar to that from 
Kwong et al(76) is presented for comparison. Kwong et al(76) includes patients with cerebral 
palsy, and the compared estimate from Oskoui et al(72) was assessed alongside variables 
collected at 1 year follow up. 
 
However, as Oskoui et al(72) did not provide enough data (absolute risk of intractability in non-
intellectually disabled patients) to compute the relative risk, the estimates are compared as 
odds ratio: 
 
 
  
Ramos-Lizana et al 2009 | RR 0.20 (95%CI 0.0-0.80) 
Oskoui et al 2005             | RR 0.13 (95%CI 0.03-0.52) 
Berg et al 2001a               | RR 0.23 (95%CI 0.09-0.63) 
Oskoui et al 2005 | OR 7.2 (95%CI 1.0-50.8) 
Kwong et al 2003 | OR 18.2 (95%CI 5.2-63.6) 
      Box 14 | Relative risk (RR) of having intractable seizures in patients with idiopathic aetiology 
 
Box 15 | Odds ratio (OR) of having intractable seizures in patients with intellectual disability 
 
Chawla et al 2002 | RR 2.06 (95%CI 1.11-3.10) 
Casetta et al 1999 | RR 5.48 (95%CI 2.10-9.64) 
Ko et al 1999          | RR 1.34 (95%CI 1.15-1.43) 
Berg et al 1996      | RR 1.67 (95%CI 1.04-2.36) 
 
Box 13 | Relative risk (RR) of having intractable seizures in patients with remote symptomatic aetiology 
 
Ramos-Lizana et al 2009 | RR 2.6 (95%CI 1.0-6.9) 
Chawla et al 2002             | RR 3.1 (95%CI 2.0-3.6) 
Casetta et al 1999            | RR 2.6 (95%CI 1.1-4.3) 
 
 
        Box 12 | Relative risk (RR) of having intractable seizures with onset of seizures in infancy (age <1 year) 
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Having mixed seizure types was only found to be a predictor of intractability in studies reported 
by Oskoui et al(72). Other potential predictors related to seizure type were not confirmed to be 
consistently predictive of intractability, as were the occurrence of status epilepticus, family 
history of epilepsy or history of neonatal seizures, seizure frequency, and abnormal EEG. 
 
None of the models were externally validated. 
 
 
PREDICTING NO REMISSION AFTER RELAPSE (TYPE V) 
Only 1 study, Sillanpaa and Schmidt 2006(25) investigated the predictors of not achieving 
remission after 1 or more relapses following initial remission. In the study, 14% of the cohort 
belonged in this category. The only independent predictor was having remote symptomatic 
aetiology with the odds 8 [8.2 (95%CI 2.7-24.8)] times as high compared to those without 
remote symptomatic aetiology. Intellectual disability, localisation related epilepsy and temporal 
lobe epilepsy were not included in the model. The model was not externally validated. 
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Table 22 | Studies predicting no remission after relapse 
 
 
 
 
 
 
 
Age  
(Years)* 
 
 
 
 
 
 
 
Study 
 
 
 
 
 
 
Design 
Setting 
N S
tu
d
y 
P
ar
ti
ci
p
at
io
n
 
St
u
d
y 
A
tt
ri
ti
o
n
 
P
ro
gn
o
st
ic
 F
a
ct
o
r 
O
u
tc
o
m
e
 
A
n
al
ys
is
 
 
 
 
 
 
 
 
 Remarks 
 
 
 
 
 
 
 
Follow 
Up 
 
 
 
 
 
 
 
Outcome Measure 
 
 
 
 
 
 
 
Independent Predictors 
 
 
 
 
 
 
 
Risk Estimate 
(95%CI) 
0-15 Sillanpaa, 
2009 
Prospective 
Population 
N=144 
Cases 20 
Controls 97 
Y Y Y Y Y Three seizures diagnosed 
epilepsy 
Cases and controls 
nested within a selection 
of only prospectively 
identified patients in 
Turku cohort 
11-42yrs Cases 
Patients who after 
relapse, did not 
achieve 5 years 
seizure free status 
immediately before 
last follow up 
Controls 
5 years seizure free 
immediately before 
last follow up 
Remote Symptomatic Aetiology  OR: 8.2 (2.7–24.8) 
 
*Age range in years (Mean ± Standard Deviation); CI-Confidence Interval, Y-Yes, HR-Hazard Ratio, OR-Odds Ratio 
 
Table 23 | Predictors and non-predictors of no remission after relapse 
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Aetiology | Syndrome  
Remote Symptomatic Aetiology ✔ 
  
Cognition  
Abnormal Cognitive Development Θ 
  
Others   
Localisation Related Epilepsy Θ 
Temporal Lobe Epilepsy Θ 
✔ - Variable is significant or retained in multivariate model,  
Θ – not reported in univariate analysis, but reported as not significant on multivariate analysis 
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5  CHAPTER FIVE: DISCUSSSION 
 
This chapter presents a general discussion and reflection on the results of the review. The 
chapter is presented according to recommendations that advocate structured discussion of the 
results of scientific research.(38) The principal findings of 1) the literature search; 2) the quality 
appraisal of studies and reporting characteristics of publications; 3) the study classification; and 
4) the studies within each category, were stated and interpreted. Thereafter, possible 
explanations for the results are presented and their implications for clinical practice are stated 
where applicable. There are also suggestions for future studies and the direction of future 
research for each set of results. The strengths of the study are highlighted, and the weaknesses 
are also discussed also with a view to making recommendations for future studies.  
 
5.1 THE LITERATURE SEARCH 
MEDLINE alone retrieved 91% of all eligible publications, with an overlap of 42% (14 out of 33 
publications) between MEDLINE and EMBASE. This distribution of search results mirrors that of 
the study by Royle et al(240) which sought to ascertain how many databases were necessary for 
a comprehensive coverage of observational studies of diabetes published in English language. 
MEDLINE alone accounted for 94% of all the articles retrieved and the rest were from EMBASE. 
No additional English language publication was retrieved beyond these 2 databases. This 
suggests that the search in this thesis was likely exhaustive; a notion further reinforced by the 
fact that the screening of reference lists of eligible publications did not yield any eligible study. 
These findings further confirm that the 2 databases are generally complimentary.(241, 285-288) 
 
The 3 eligible publications unique to EMBASE(96, 97, 100) were all published in journals indexed 
on MEDLINE.(289) That 2 of the 3 publications were published in 2010 may support the claim 
that EMBASE is much more current than MEDLINE.(242) The fact that all the articles were 
published in the last 15 (1988 to 2010) years may reflect the period when multivariate analysis 
became popular due to proliferation of computer software packages that made the statistical 
technique much easier to conduct, beginning in the late 1980s.(263)  
 
One journal, Epilepsia, accounted for about a third of the 33 eligible publications. Future 
systematic reviews of observational studies in epilepsy may therefore also benefit from hand-
searching Epilepsia. Evidence from the search and systematic reviews of intervention studies 
suggest that hand searching of selected high impact journals may be necessary to ensure 
comprehensive search as the processes associated with indexing and electronic search are not 
infallible. (290, 291) The greatest value of hand searching has been found to be in identifying 
publications in supplement editions and abstract sections of journals.(291) This is particularly 
the case in MEDLINE search(291) and in this review, as 1 (292) of the 4 EMBASE unique 
publications (although not eligible) was published in the abstract section of a supplement 
edition of Epilepsia, a MEDLINE-indexed relatively high impact journal.  
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Notwithstanding that the care of patients with newly diagnosed epilepsy is often initiated and 
followed up in primary care,(293, 294) only 1 out of the 33 publications was in a non-specialist 
journal. This may have implications for the uptake of research findings, as the category of 
physicians who often have first contact with patients may not be specialists and they may be the 
physicians with the responsibility to assess prognosis and plan further care or referral.(295)  
 
5.2 QUALITY AND REPORTING CHARACTERISTICS 
The report of important study items in the eligible publications was generally poor, which 
impacted negatively on the ability to conduct a detailed critical appraisal of the quality of some 
studies, this being so despite seeking out referenced publications for further information on the 
studies.  
 
No study gave a power calculation to justify their sample size. However, the more important 
issue, which affects the stability and reliability of risk estimates from multivariate models is the 
number of patients with the outcome under consideration in relation to the number of 
independent variables in the model.(263, 296) Nine out of the 47 studies with multivariate 
analysis failed to meet the criterion that there must be at least 10 times the number of patients 
with the less frequent outcome per prognostic variable in the model. Two (66, 77) of the 9 
studies had more than 9 events per variable. The overall small sample size may also be a major 
source of unreliability, especially with the use of a stepwise algorithm for selecting the variables 
to retain in the model, if continuous markers are dichotomized, (an act that effectively reduces 
the sample size by 30% or more) and when interactions between variables is investigated.(45, 
296)  
 
Eight of 31 publications reported testing for interaction terms, 16 reported the use of stepwise 
selection of variables and only 4 handled continuous variables appropriately. However, Altman 
and Lyman suggested, rather arbitrarily, that studies that use stepwise algorithm, dichotomise 
continuous variables and investigate interaction terms should be based on at least 250 to 500 
patients with outcome. In this review, only 2 publications (reporting 4 studies) had such rate of 
outcome. The 2 studies were reports of international collaborative studies. The sample size of 
the cohorts included in this review ranged from 102 to 1443 (median 287, mean 390).  
 
The practice in 2 previous systematic reviews of prognosis studies, as in this review, was to have 
100 participants in a study as minimum requirement for inclusion.(234, 235) However, to ensure 
robustness of results of multivariate analyses, future prognosis studies of seizure outcome in 
newly diagnosed patients with epilepsy may benefit from international collaborations and the 
meta-analysis or reanalysis of individual patient data from different cohorts. Having a large 
sample size can only improve the precision and stability of models, but will not necessarily make 
up for inherent weaknesses in study design and execution.(45, 296)Therefore, these 
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international collaboration studies will also ensure that other quality measures such as 
prospective case ascertainment and long follow up to allow patients to be reliably grouped into 
appropriate outcome categories.  
 
Less than 60% of the publications reported the statistical package or software used to conduct 
the multivariate analysis, a practice which Concato et al(263) described as “analogous to a 
laboratory researcher [not] indicating the particular experimental protocol used for physiologic 
measurements.” The reporting of issues directly related to multivariate analysis was also 
deficient. The test for collinearity was reported in only 1 publication; model assumptions were 
tested in 2, missing data was mentioned in 8, and the statistical criteria for including variables in 
models were stated in only 50% of the 31 papers reporting studies with multivariable models.  
However, all but 1 paper(68) reported a measure of follow up, while all but 2 (101, 104) 
reported the proportion with outcome. 
 
The poor reporting of studies is not unique to prognosis studies; it affects observational studies 
in general.(297) Therefore in 2007, the STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) checklist was produced in order to serve as guidelines for reporting 
observational studies.(298) The checklist consists of a flexible 22-item checklist which provides 
reporting recommendations for all sections of manuscripts of the 3 types of observational study 
design (cohort, case control and cross-sectional) while allowing authors to utilize their 
preferences and creativity when selecting the order and format of presenting the details.(298) 
Eighteen of the items are applicable to all the 3 study designs. Four are design-specific: 
information in the methods section regarding participants (item 6) and statistical methods (item 
12); information in the results section regarding descriptive data (item 14) and outcome data 
(item 15).(40) The checklist is presented in Appendix V  
 
However only 2 journals (Lancet Neurology and Neurology, containing 1 publication each) out of 
the total 17 journals where the papers in the review were published have endorsed the STROBE 
statement by way of referring to it in their Instructions for Authors.(299) The 2 articles in the 
STROBE-endorsing journals were published before the STROBE statement was produced, 
therefore it was not possible to compare the reporting characteristics of the publications with 
the others published in journals that are yet to endorse the STROBE guidelines.  
 
5.3 THE CLASSIFICATION OF STUDIES 
The task of developing a method for classification of studies to assist quality assessment and to 
guide the present and also future systematic reviews and meta-analyses is an important role for 
systematic reviews. This is especially important for observational studies, given the range of 
differences in quality, methods and potential for heterogeneity.(300) This thesis developed a 
classification system for studies of prognosis of seizure outcome in epilepsy. The classification is 
based on: 1) the potential seizure outcome category where a newly diagnosed patient could 
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belong e.g. immediate remission, remission off medication, remission on or off medication or 
medical intractability; and 2) how in the analysis to identify independent predictors of each 
outcome, patients belonging to different outcome groups are compared to identify exposure or 
epilepsy characteristics that are significantly different between the groups. The studies included 
in this review were classified into 5 types and systematically reviewed within the categories.  
 
5.4 EARLY/IMMEDIATE REMISSION 
 
PROPORTION WITH EARLY/IMMEDIATE REMISSION 
The rate of recurrence after a second seizure is not influenced by antiepileptic drug therapy,(24, 
175) although randomised trials have suggested that this may only be a long term outcome and 
that medication may suppress seizures in the short term.(98, 108-111) The studies predicting 
immediate remission employed different approaches to antiepileptic drug therapy: 2 studies(95, 
96) had all the patients in the cohort placed initially on antiepileptic monotherapy; 1 study(98) 
randomised treatment; the other 2 studies treatment did not randomise patient allocation to 
medication (80% on medication in 1,(99) and 44% in the other(24)) with choice of therapy at the 
discretion of the physician. These different approaches to treatment in the cohorts were not 
reflected in the proportion of patients that achieved immediate remission. However, 3 factors 
were important in influencing the proportion of patients that entered immediate remission: 
case ascertainment, inclusion criteria, and the age of patients within the cohort. 
 
 
 
 
 
 
 
 
Where there was exclusive prospective case ascertainment i.e. all the patients in the study were 
identified at the exact point of their second seizure, fewer patients (37%) did not experience a 
next seizure after 2 years(24) compared to between 42% and 57.5% in 3 of the 4 studies with 
mixed case ascertainment,(95, 98, 99)especially including different proportions of first seizure, 
prospectively identified and retrospectively ascertained patients. The proportion of the cohort 
without immediate remission was highest (57.5%) where more than half of the patients were 
single seizure patients.(98) In the other 2 cohorts, single seizure cases were less than a third of 
the cohort. This supports previous evidence that for most patients, the rate of seizure 
recurrence reduces with increasing number of seizures.(119, 301, 302) 
 
However, among the cohorts with mixed retrospective and prospective case identification, 2 
hospital based studies with similar proportions of patients in each seizure category (the ratio of 
1st seizure to 2-5 seizures and >5 seizures being roughly 4:9:7 in both studies) had widely 
33% in immediate remission at 2 years | 100% on AED | Del Felice et al 2010 
37% in immediate remission at 2 years | 44% on AED | Shinnar et al 2000 
42% in immediate remission at 2 years | 80% on AED | Lindsten et al 2001 
48% in immediate remission at 2 years | 100% on AED |CGSEPI 1988 
58% in immediate remission at 2 years | 50% on AED | Kim et al 2006  
 
Box 16 | Proportion of patients in immediate remission at 2 years by the proportion of patients on AED 
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different proportion of patients in immediate remission at about 2 years of follow up: it was as 
high as 48% in 1 (95) and only 33% in the other.(96) The hypothesised explanations for this 
difference were: 
 
 1) The age difference between the cohorts. The cohort with 48% in immediate remission at 2 
years after intake had a mean age of 19 years while the cohort with 33% had a mean age of 
about 32 years suggesting that younger/childhood-onset epilepsy may have a better prognosis 
than adult onset epilepsy,(48) which may be due to more symptomatic epilepsy occurring in 
adult-onset epilepsy(303, 304) and benign syndromes occurring more in childhood(305). 
 
2) Inclusion criteria in the cohorts. The study with 48% of the cohort in immediate remission at 2 
years excluded patients with progressive neurological disorders associated with increased risk of 
seizures e.g. brain tumour, while the other cohort included every patient with newly diagnosed 
epilepsy. 
 
The 2 studies (95, 98) that excluded patients with known poor prognosis compared to the other 
3, had a higher proportion of patients in immediate remission at 2 years after intake (57.5% and 
48%) at 2 years follow up. The study from a randomised controlled trial(98) (with 57.5%) 
excluded all the patients for whom indication for antiepileptic drug therapy was certain, while 
the other study(95) only excluded the patients with progressive neurological disorder. This 
finding also suggests that patients with known poor prognosis, or “for whom indication to 
commence treatment was not clear” are more likely to have a recurrence after diagnosis. 
 
PREDICTORS AND NON PREDICTORS 
There were 2 consistent independent predictors of early/immediate remission in people with 
newly diagnosed epilepsy: having 2 or more seizures before intake and a patient having remote 
symptomatic epilepsy. 
 
The patients with adult-onset epilepsy with 2 or more pre-intake seizures are 37% (95%CI -11% 
to 64%) more likely than people with a single seizure before diagnosis to have a recurrence, 
again showing that the risk of having a subsequent seizure may depend on the number of 
previous seizures. However, the 95% confidence interval crosses unity for this estimate and is 
therefore not particularly reliable. The second study that retained “having 2 or more pre-intake 
seizures” was from an all age cohort with mostly young (mean age 19 years) patients. The study 
however did not report the risk estimates. This predictor would anyway not have been available 
in an ideal prognosis study of epilepsy, especially one that is predicting early remission, a 
category in which the number of seizures being only 2 at intake into the cohort is particularly 
important to limit potential for bias.  
 
The children with remote symptomatic aetiology are 41% (95%CI 14% to 59%) more likely than 
children with idiopathic/cryptogenic aetiology to have a recurrence.(24) The estimates from 2 
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other studies,(98, 99) while similar, may be fraught with the bias that the inclusion criteria of 
the studies might introduce. The estimate from Kim et al,(98) an all age cohort which excluded 
patients “for whom indication to commence treatment was not clear” and which also included 
single seizure cases and people with more than 2 seizures prior to intake was: 26% (95%CI 6% to 
42%). Lindsten et al,(99)also a mixed cohort, but of patients with adult-onset epilepsy, found 
that  adults with remote symptomatic aetiology are 66% (95%CI 23% to 74%) more likely than 
people with idiopathic/cryptogenic aetiology to have a recurrence. These estimates suggest that 
while remote symptomatic aetiology is a predictor of seizure recurrence in patients with newly 
diagnosed epilepsy, it may be a more important predictor in adult-onset epilepsy. 
 
The other variables – gender, age at onset of seizures, duration of epilepsy before intake into 
cohort, abnormal EEG, seizure focus, family history and history of febrile seizures – assessed in 
more than 1 study, were not found to be consistent independent predictors of early/immediate 
remission in newly diagnosed epilepsy. That the age at onset of seizures is not associated with 
recurrence suggests that the age difference in the proportion of people that achieve immediate 
remission is accounted for by the fact that a higher proportion of patients with adult-onset 
epilepsy have symptomatic aetiology (303, 304) and that benign epilepsy syndromes are more 
common in childhood-onset epilepsy.(305) 
 
5.5 REMISSION OFF ANTIEPILEPTIC MEDICATION 
 
PROPORTION WITH REMISSION OFF ANTIEPILEPTIC MEDICATION 
Three study factors were important in explaining the variation in the proportion of patients that 
were successfully weaned off antiepileptic medication: the study setting, the method of case 
ascertainment, and the readiness of the treating physician to wean patients off medication. If 
the proportions of patients in remission off medication at last follow up in the respective studies 
are arranged according to the hypothesis that prospective, population based studies are the 
least likely to be biased, and retrospective, hospital based studies are the most likely to be 
biased,(20) the progression of the proportion of patients off AED is largely linear. (Box 17) The 
less biased studies have a higher proportion of patients in remission off AED, except for 2 data 
points from the Turku cohort (32) where the definition of remission off AED was such that the 
patient had to have continued in remission off medication for at least 5 years. The relatively 
lower proportion of patients in remission off AED may have been further accentuated by the 
fact that 3 seizures instead of 2 diagnosed epilepsy in the Turku cohort and that the physicians 
responsible for patients in the cohort were more reluctant to discontinue AED(105). This finding 
however suggests that in childhood-onset epilepsy, more than two thirds of patients may be 
successfully taken off antiepileptic medication.  
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*(Physicians were reluctant to discontinue AED) 
 
The progression was not significantly affected by the fact that patients with generalised absence 
seizures and known poor prognosis, including progressive neurological disorders were excluded 
from the cohort with 54% in remission off medication(71) compared to 55% when the previously 
excluded patients were included.(106) It is possible that the poor prognosis and the good 
prognosis of generalised absence seizures balance each other in such a way that it did not 
reflect in the proportions. 
 
PREDICTORS AND NON PREDICTORS 
Two factors consistently predicted achieving remission off antiepileptic medication: intellectual 
disability and having more than 1 seizure in the period between 6 and 12 months on 
antiepileptic medication. Two types of model retained intellectual disability as independent 
predictor of seizure-free status off medication: models that included only variables assessed at 
intake/onset, and models that combined variables assessed at intake/onset with those only 
assessable after 1 year of follow up such as having more than 1 seizure in the period between 6 
and 12 months on antiepileptic medication. 
 
The risk estimates from models with only intake/onset variables vary widely, but with 
overlapping 95% confidence intervals. The model from the combined Dutch and reconstituted 
Nova Scotia cohorts estimated that children with intellectual disability are 23% (95%CI 6% to 
39%) less likely to achieve remission off medication than intellectually normal children.(106) The 
estimate was much higher in the other 2 studies which were more prone to bias: 75% (95%CI 
not stated) in Camfield et al(71) with generalised absence seizures and known poor prognosis 
excluded, and 77% (95%CI 26% to 93%) in Oskoui et al,(72) a retrospectively ascertained, 
hospital based cohort.  
 
The risk estimates from models with both intake/onset and 1 year variables are also from these 
2 more biased cohorts, showing that children with intellectual disability are 81% (95%CI 41% to 
94%) less likely than intellectually normal children to achieve remission off medication in Oskoui 
et al(72) and 71% (95%CI not stated) in Camfield et al. (71) However, the fact that the 4 
estimates from 2 possibly biased studies are similar may be due to the fact that the true 
52% Retrospective | Hospital | off AED at last follow up | Oskoui et al 2005 
47% Mixed | Population |5 years off AED at last follow up | Sillanpaa et al 1998* 
54% Mixed | Population |off AED at last follow up | Camfield et al 1993 
55% Mixed | Population |off AED at last follow up| Geelhoed et al 2005 
59% Mixed/Prospective | Population/Hospital |off AED at last follow up | Geelhoed et al 2005 
65% Prospective | Hospital |off AED at last follow up | Geelhoed et al 2005 
56% Prospective | Population |5 years off AED at last follow up | Sillanpaa et al 1998* 
 
 
 
Box 17 | Proportion of patients in remission off AED arranged according to potential for bias 
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estimate of the risk of not achieving remission off medication may be closer to the estimate 
from the study(106) that is less likely to be biased.  
 
These same 2 potentially biased studies had models with both intake/onset and 1 year variables 
which show that children with more than 1 seizure in the period between 6 and 12 months 
while on antiepileptic medication are: 75% (95%CI not stated) and 76% (95%CI 40% to 90%) less 
likely to achieve remission off medication compared with children who have 1 or no seizure 6 to 
12 months on medication. 
 
None of the other variables such as gender, age at onset, number of seizures before intake into 
cohort, abnormal EEG, epilepsy syndrome and abnormal sign on neurological examination that 
were assessed in more than 1 study, were consistently retained as an independent predictor of 
remission off AED in children with newly diagnosed epilepsy. 
 
EXTERNALLY VALIDATED MODELS 
Three models were externally validated and of the 3 models, 1 was derived with Cox regression 
and 2 were derived by logistic regression. Neither of the logistic regression-derived models 
reported the area under the receiver operating characteristics (ROC) curve, AUC, an important 
measure of discrimination. However, the 2 logistic regression models reported the best 
probability cut off (≈50%) at which the accuracy of the model was assessed and reported. None 
of the 3 models was assessed for calibration. 
 
The model that was derived using the reconstituted Nova Scotia cohort performed slightly 
worse in the external validation study in the Dutch cohort.(106) Specificity reduced from 69% to 
58% in external validation, while sensitivity increased marginally from 69% to 71%. This shows 
that the model’s ability to detect negative outcome (no remission off AED) was poorer 
compared to its ability to detect patients with remission off AED. The positive and negative 
predictive values show that positive prediction was right 73% of the time, whereas negative 
prediction was right in only 35% of the instances when it was made. However, the PPV and NPV 
were expectedly higher in the validation study (PPV rises from 73% to 76%, NPV from 35% to 
53%) owing to the fact that the pre-test probability (i.e. proportion of cohort with outcome, 
being in remission off AED) was higher in the validation sample at 65% compared to 55% in the 
derivation cohort.(279) This means that in the validation cohort, just knowing that a child has 
epilepsy allows the prediction of remission off AED to be right 65% of the time. However, if the 
prediction were to be based on the model and not prevalence, the positive predictive gain only 
improves by 11%, compared to the negative predictive gain that rises by 18%. However, in spite 
of these predictive gains, the model predicts wrongly in about 1 out of 3 children, although 
worse in the external validation cohort (36% vs. 31%).  
 
The second externally validated model that was derived using logistic regression was developed 
on the Dutch cohort and validated on the reconstituted Nova Scotia cohort.(106)  Specificity was 
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remarkably worse (reduced from 70% to 57%) in external validation with a marginal increase in 
specificity (66% to 67%), showing that the model’s ability to detect negative outcome (no 
remission off AED) was better compared to its ability to detect patients with remission off AED 
in external validation. In spite of lower pre-test probability in the validation cohort (55% vs. 
65%), the NPV slightly increases from 55% in derivation cohort to 56%. The PPV however 
reduces from 79% to 67%. Therefore, in external validation, the positive predictive gain was 12% 
while the negative predictive gain was 11% above pre-test probability. However, in spite of 
these predictive gains, the model predicts wrongly in about 1 out of 3 children, although worse 
in the external validation cohort (39% vs. 31%). 
 
The model derived from the Nova Scotia cohort by Camfield et al(71) using Cox regression had a 
marked loss in sensitivity when externally validated in the Turku cohort (74% to 47%), although 
the specificity increased from 64% to 88%. However, owing largely to the pre-test probability 
being higher in the validation cohort, (60% vs. 54%) the PPV increases from 71% to 84%, 
although the NPV decreases to 51% from 67%. Therefore from a pre-test probability of 60% in 
the validation cohort, the model increases the accuracy of positive prediction by 24% and of 
negative prediction by 11%. The increase in positive prediction over pre-test probability may 
however be due to the fact that instead of predicting remission off AED in external validation, 
the model was used to predict remission on or off AED, a decision that was justified by the 
argument that the physicians handling patients within the Turku cohort were reluctant to 
discontinue medication and as 75% of those with 3 year remission at last follow up had been in 
remission for at least 10 years, it was considered unlikely that these patients would relapse off 
medication. However, the model predicts wrongly in about 1 out of 3 children, and worse in the 
external validation cohort (39% vs. 32%). 
 
The 3 externally validated models have not been evaluated prospectively in a randomised 
clinical trial to assess their effect in clinical practice, possibly owing to their poor performance 
and the fact that they only reported probabilities, which did not necessarily recommend any 
particular course of action that may be assessed in a trial. Only the model from the Nova Scotia 
cohort presented scores and the scores may be easy to use for physicians, as well as patients. 
The other 2 models did not present scores for their models, and with the variables included, 
(mostly of syndromic diagnosis) may not be quite as easy to assess for physicians and patients. 
Finally, 2 of the 3 models (Nova Scotia intake and Nova Scotia reconstituted) had the most 
consistent predictor variable, intellectual disability, in their model.  
 
5.6 REMISSION ON OR OFF MEDICATION 
 
PROPORTION WITH REMISSION ON OR OFF ANTIEPILEPTIC MEDICATION 
Four study factors were important in explaining the variation in the proportion of patients that 
was reported to have achieved remission on or off medication among the cohorts and studies: 
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the definition of remission, the length of follow up, the study design, and the age of patients 
within the cohort.  
 
In studies that described their outcome as terminal remission (number of seizure-free months or 
years immediately before the last follow up) the proportion of the cohort in remission varied 
according to the length of seizure-free period that defined terminal remission: the proportion in 
remission rises with length of follow up and falls with the length of terminal remission. When it 
was 3 month terminal remission with 1 year minimum follow up, the proportion in remission is 
as low as 50%.(93) It rises to between 73% and 76%, with 1 to 3 years terminal remission when 
the minimum follow up ranged from 5 years to 20 years,(66, 68-70) and drops to 64% when 5 
years seizure-free period defined terminal remission, even though the minimum follow up was 
20 years.(32) For 2 largely prospective studies that defined terminal remission as 1 year seizure-
free period,(66, 70) the proportion of patients in remission remained at 76% in spite of doubling 
(5 and 10 years) of minimum length of follow up between the 2 studies. (Box 18) These findings 
show that it does take time for people with newly diagnosed epilepsy to enter terminal 
remission; however, after a time period, possibly 5 years, patients who will ultimately enter 
remission would already have achieved the outcome.  
 
However, the result from Hui et al(97) a study of an adult cohort, had a lower proportion of 
patients in remission relative to all the other comparable studies conducted in childhood onset 
epilepsy. The proportion in remission for prospective studies was also higher than in comparable 
cohorts with mixed and retrospective case ascertainment. This is in keeping with the evidence 
that retrospective studies introduces bias to estimates of proportion of patients in remission(20) 
and that childhood onset epilepsy may have a better prognosis than adult-onset epilepsy. (48, 
303-305) 
 
  
 
 
 
 
 
 
 
 
 
 
Eight studies defined remission by the seizure-free period during follow up, which may or may 
not be terminal. Three (101, 104)of the 8 studies did not present the proportion of patients in 
remission. Of the 5 that presented the proportion with outcome, as expected, the percentage of 
patients in remission decreased as the number of seizure-free years that defined remission 
increased. In these studies, the proportion of patients in remission was higher for the same 
number of years when compared with those that entered terminal remission for the same 
50% - 3 month TR with 1 year minimum follow up | Banu et al (Retrospective) 
69% - 6 month TR with 2 years minimum follow up | Arts et al 1999 (Prospective) 
60% - 1 year TR with 1 year minimum follow up | Hui et al 2007 (Mixed) 
73% - 1 year TR (length of follow up not stated) | Lossius 1999 (Retrospective) 
76% - 1 year TR with 5 years minimum follow up | Arts et al 2004 (Prospective) 
76% - 1 year TR with > 10 years minimum follow up | Sillanpaa et al 2009 (Prospective) 
76% - 3 year TR with > 20 years minimum follow up | Sillanpaa 1990 (Mixed) 
64% - 5 year TR with > 20 years minimum follow up | Sillanpaa et al 1998 (Mixed) 
 
     Box 18 |Remission as seizure-free period immediately before last assessment i.e. Terminal Remission (TR) 
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number of years and with comparable length of follow up. This is also an expected pattern as 
relapses may occur at any time to truncate terminal remission, whereas what is needed to 
satisfy the definition “seizure-free period during follow up” is 1 stretch of the designated 
seizure-free year(s) at any point during follow up.  
 
 
 
 
 
 
 
 
One study (24)had a different measure for refractoriness (not achieving remission) which was 
defined as having multiple recurrences of up to 10 seizures within about 8 years. In their cohort, 
patients were initially identified at the point of first seizure, and the diagnosis of epilepsy 
prospectively was confirmed with the second seizure. Of the patients with epilepsy 71% did not 
have 10 recurrences after a mean follow up of about 8 years. Therefore the predictors 
considered in this study included pre-diagnosis variables such as having the second seizure 
(which confirms the diagnosis of epilepsy) within 1 year of the first. 
 
PREDICTORS AND NON PREDICTORS 
There were 5 consistent predictors of achieving remission on or off antiepileptic medication: 
having mixed seizure types at onset, symptomatic aetiology, intellectual disability, number of 
seizures before index and the number of seizures in the first 6 months of follow up. 
 
The finding from an all age cohort was that patients with mixed seizure types at onset are 30% 
(95%CI -4% to 63%) less likely than patients with a single seizure type to achieve remission on or 
off medication, although the 95% confidence interval crosses zero for this estimate and so may 
not be reliable.(64) However, in childhood onset epilepsy, the odds of achieving remission are 
about 1 in 4 [0.23 (95%CI 0.10 to 0.48)] for patients with multiple seizure types at onset 
compared to those with a single seizure type at onset.(93) However, this estimate may also not 
be reliable as it was from the study (93) that defined remission as 3 month terminal remission, 
rather than much longer (e.g. 6 months to up to 5 years) as in the other studies that defined 
remission as terminal remission. 
 
None of the 4 studies (21, 24, 77, 104) that retained remote symptomatic aetiology in their 
model defined remission as terminal remission. Three defined remission as “seizure-free period 
during follow up” and 1 defined remission as not having up to 10 recurrences in an average of 8 
years. However, the estimates from the 4 studies were similar. Of the 3 studies that defined 
remission more conventionally, (as “seizure-free period during follow up”), 2 were in childhood-
onset epilepsy cohorts and of the 2, Berg et al(21) was the study with the less likelihood for bias 
as it is a population based prospective study. Berg et al(21) estimate that it was 37% (95%CI 16% 
80% - 1 year R with 1 year minimum follow up | Abduljabbar et al 1998 (Mixed) 
78% - 1 year R (during the last 10 of min. 20 years) follow up | Sillanpaa 1993 (Mixed) 
74% - 2 year R with 2 years minimum follow up | Berg et al 2001b (Prospective) 
68% - 2 year R by 5 years of follow up | CGSEPI 1992 (Mixed) 
51% - 3 year R by 5 years of follow up | CGSEPI 1992 (Mixed) 
 
 
 
 
Box 19 | Remission (R) as seizure-free period during follow up  
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to 53%) less likely for children with remote symptomatic aetiology to achieve remission 
compared to children with idiopathic/cryptogenic aetiology. The other study(77) was from a 
mixed population based cohort, and the estimate was higher and with wider 95% confidence 
interval at 56% (95%CI 8% to 75%). The adult-onset epilepsy study(104) also estimated that it 
was 56% less likely for people with remote symptomatic aetiology to achieve remission 
compared to those with idiopathic and cryptogenic aetiology, but without reporting the 95% 
confidence interval. These estimates, particularly the similarity between the estimate from the 
childhood-onset epilepsy study with mixed case ascertainment and a retrospective adult-onset 
study suggest that the bias of the childhood-onset study may be towards a poorer prognosis for 
achieving remission.  
 
Intellectual disability was retained in 2 models: The odds of achieving remission are 4 in 10 [0.40 
(95%CI 0.18 to 0.90) in children with intellectual disability compared to those with normal 
cognitive development.(93) However, for adults-onset epilepsy, the odds are 1 in 10 [0.10 
(95%CI 0.05 to 0.25)].(97) These results suggest that intellectual disability may be a more 
important predictor of not achieving remission in adult-onset epilepsy compared to patients 
who are diagnosed in childhood. 
 
Two studies from different cohorts retained the natural logarithm of the number of seizures 
before index in their models. For Arts et al(65)the risk of achieving remission reduced by 34% 
(95%CI 5% to 54%) for every unit increase in the natural logarithm of the number of seizures a 
child has before the index seizure at presentation, and for MacDonald et al(101) by 19% (95%CI 
1% to 34%) for every unit increase in the natural logarithm of the number (plus 1) of seizures a 
child has before the index seizure at presentation. This finding further suggests that “seizures 
beget seizures”(49) could be true in that increasing number of seizures a child experiences 
before intake/medication reduces the probability of achieving remission on or off medication.  
 
The same studies also retained the natural logarithm of the number of seizures from the index 
seizure to 6 months after intake/medication in their models, showing that early response to 
antiepileptic medication is a predictor of eventual remission: For Arts et al(65)the risk of 
achieving remission reduced by 50% (95%CI 28% to 65%) for every unit increase in the natural 
log of the number (plus 1) of seizures a child has from the index seizure to 6 months after 
intake/medication, and for MacDonald et al(101) by 41% (95%CI 30% to 50%) for every unit 
increase in the natural log of the number (plus 1) of seizures a child has from the index seizure 
to 6 months after intake/medication. 
 
The other variables not consistently predictive of remission on or off medication include age at 
onset, gender abnormal EEG at intake and the range of seizure types considered as  were factors 
like family history of epilepsy, history of neonatal seizures and the specific aetiological factors 
considered.  
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EXTERNALLY VALIDATED MODELS 
Two models were derived in Arts et al 1999 by logistic regression(65) (one with only intake 
variables, and the other including both intake and 6 month variables) were temporally validated. 
(107)  
  
The model with only intake variables was calibrated, with a plot of 4 risk groups of unequal size. 
The calibration plot suggests that the model was well calibrated with the percentage of children 
correctly predicted not to achieve remission increasing with the predicted chance of not 
achieving remission, although calibration was not assessed using a formal statistical test. The 
model however had poor discriminative ability (AUC <0.70) on both internal and external 
validation. For the model, the chosen best probability cut-off was 38%: i.e. probability value 
greater than 38% indicates not achieving 6 month terminal remission.(107) 
 
The model performed slightly worse on external validation with sensitivity reducing from 62% to 
60% in external validation, and specificity from 69% to 61%. This shows that the model’s ability 
to detect poor outcome (no 6 month terminal remission at 2 years) was similar to its ability to 
detect positive outcome (6 month terminal remission at 2 years) in the external validation 
population.(107) However, the NPV increases as expected from 20% to 25%, but the PPV 
reduces marginally from 47% to 45% in spite of the fact that the pre-test probability (i.e. 
proportion of cohort with outcome, not achieving 6 month terminal remission) was higher in the 
validation sample at 34% compared to 31% in the derivation cohort. Therefore, in the validation 
cohort, the knowledge that a child is within that cohort allows for a prediction of a child not 
entering remission to be correct 34% of the time (pre-test probability). However, if the 
prediction is based on the model and not prevalence, the positive prediction improves by 11%, 
compared to a loss of 9% in negative prediction. The model also predicts wrongly in more than 1 
out of 3 children in internal and external validation. The negative predictive loss may be due to 
the fact that the cut-off model was particularly set to enhance sensitivity at the expense of 
specificity, thereby allowing for better prediction of not achieving 6 month terminal remission at 
2 years. 
 
The model with intake and 6 month variables was also calibrated, with a plot of 4 risk groups of 
unequal size. The calibration plot suggests that the model was well calibrated with the 
percentage of children correctly predicted not to achieve remission increasing with the 
predicted chance of not achieving remission, although calibration was not assessed using a 
formal statistical test. The model however had a fairly good discriminative ability (AUC >0.70) on 
both internal and external validation. The best probability cut-off for the model was 34%: i.e. 
probability value greater than 34% indicates not achieving 6 month terminal remission.(107) 
 
The model performed worse on external validation with sensitivity reducing from 73% to 67% in 
external validation, and specificity from 73% to 60%. This shows that the model’s ability to 
detect poor outcome (no 6 month terminal remission at 2 years) was better than its ability to 
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detect positive outcome (6 month terminal remission at 2 years) in the external validation 
population.(107) However, the NPV increases as expected from 14% to 22%, but the PPV 
reduces from 55% to 47% in spite of the fact that the pre-test probability (i.e. proportion of 
cohort with outcome, not achieving 6 month terminal remission) was higher in the validation 
sample at 34% compared to 31% in the derivation cohort. Therefore, in the validation cohort, 
the knowledge that a child is within that cohort allows for a prediction of a child not entering 
remission to be correct 34% of the time (pre-test probability). However, if the prediction is 
based on the model and not prevalence, the positive prediction improves by 13%, compared to 
a loss of 12% in negative prediction. In spite of its positive predictive gain over pre-test 
probability, the model also predicts wrongly in more than 1 out of 3 children in internal and 
external validation. The negative predictive loss, as in the first model may be due to the fact that 
the cut-off model was particularly set to enhance sensitivity at the expense of specificity, 
thereby allowing for better prediction of not achieving 6 month terminal remission at 2 years. 
 
Each of the models contained 2 of the 5 factors found to be consistent predictors of remission: 
model with intake only variables (natural logarithm of the number of seizures before intake, and 
remote symptomatic aetiology) and model with intake and 6 month variables (natural logarithm 
of the number of seizures in the first 6 months after intake, and remote symptomatic aetiology). 
They both presented scores for the assessment of risk, although the scores were complex, the 
predictors many and the models may not be easily used by physicians and patients. The models 
however have not been assessed in a randomised study to confirm their usefulness in a clinical 
setting. 
 
5.7 INTRACTABILITY 
 
PROPORTION WITH MEDICALLY INTRACTABLE SEIZURES 
Two factors explained the differences in the proportion of patients with medically intractable 
seizures in individual studies: how intractability was defined and the study design/setting. 
Medically intractable seizures is usually defined as having “at least 1” or “more than 1” seizure 
per month for about 1 year (ranged between at least 6 months and at least 2 years) after more 
than 2 antiepileptic drug trials singly or in combination, at their maximum tolerable dose.(78) 
 
However, studies that defined intractability as having “1 or more” seizures per month (72, 75, 
76) had more patients who met the criteria for intractability (13% to 14%) compared to the 
studies(73, 74) that defined intractability as only “more than 1” seizure per month (9% to 10%). 
The were 2 outliers, both from retrospective hospital based cohorts: the one that defined 
intractability as having recurrent seizures in the 6 months immediately before last follow up had 
7% while the other, even though it defined intractability as having “at least 1” or more seizures 
per month, one third (32.5%) of the cohort met the criteria for intractability. (78) 
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PREDICTORS AND NON PREDICTORS 
Five variables were consistently retained in models as independent predictors of having 
medically intractable seizures: age at onset (continuous variable), onset of seizures in infancy 
(age < I year), remote symptomatic aetiology, idiopathic aetiology and intellectual disability. 
 
Three studies had models that retained age at the onset of epilepsy (as a continuous variable) as 
an independent predictor of medical intractability. One of the studies(78) was a remarkably 
biased retrospective hospital based study with about a third of the cohort having intractable 
seizures. The second study (75) has an estimate that was not significant as the confidence 
interval that crosses unity, hence unreliable. The third study(79) is also likely to be biased in 
terms of study participation as there was also an over-representation of patients with 
intractable seizures (being about 4 times as many as patients who are in remission). 
 
However, when onset of seizures at less than 1 year was considered, 3 studies retained it in 
their model. Ramos-Lizana et al(74)estimated that people with onset of seizures at infancy were 
2.6 (95%CI 1.0 to 6.9) times more likely to have medically intractable seizures compared to 
children whose seizures begin after the age of 1. The estimate is remarkably similar at 2.6 
(95%CI 1.1 to 4.30) in Casetta et al(75). The third estimate is however different from the other 2, 
possibly because the study by Chawla et al(94) may be particularly prone to bias. In the quality 
appraisal for potential for bias, it was unlikely to be biased in only 1 area of potential bias 
(multivariate analysis) out of 5 (others being study participation, study attrition, prognostic 
factor measurement and outcome measurement). For the study,(94) the estimate was that 
people with onset of seizures at infancy were 3 (95%CI 2.0 to 3.6) times more likely to have 
medically intractable seizures than children whose seizures begin after the age of 1. 
 
Of the 4 models that identified remote symptomatic aetiology as an independent predictor of 
medically intractable seizures, 3 were particularly prone to bias. Two (78, 79) of the 3 were 
estimates from cohorts within which patients with intractable seizures were significantly over-
represented. The third study was Chawla et al(94) which was unlikely to be biased in only 1 out 
of 5 areas of potential bias assessed in the studies included in this review. The 3 estimates from 
bias prone studies were similar with relative risk between 1.34 and 2.06 and largely overlapping 
confidence intervals. However, Casetta et al(75) estimates that it is about 5.48 (95%CI 2.10-
07% - “6 months recurrent” | Retrospective, Hospital | Oskoui et al 2005 
09% - “At least 1 Seizure” | Mixed, Hospital | Ramos-Lizana et al  
10% - “At least 1 Seizure” | Prospective, Population | Berg et al 2001a  
13% - “More than 1 Seizure” | Retrospective, Hospital | Oskoui et al 2005  
14% - “More than 1 Seizure” | Prospective, Population | Casetta et al 1999  
14% - “More than 1 Seizure” | Mixed, Population | Kwong et al 2003 
33% - “At least 1 Seizure” | Retrospective, Hospital | Berg et al 1996  
 
Box 20 | Influence of definition and study design/setting on the proportion of patients with intractable seizures 
119 
 
9.64), indicating that children with remote symptomatic aetiology are 5.5 times more likely to 
have medically intractable seizures than those with idiopathic/cryptogenic aetiology. 
 
Three studies identified idiopathic aetiology as an independent predictor of intractable seizures 
in that children with idiopathic aetiology are less likely than those with symptomatic aetiology 
and cryptogenic aetiology to develop intractable seizures. However, 1 of the studies had an 
atypical definition of intractability (recurrent seizures in the 6 months before last follow up or 
requiring surgery or ketogenic diet to control seizures); the study estimates that it is 87% (95%CI 
48% to 97%) less likely for a patient with idiopathic epilepsy to develop intractable seizures 
compared to children with symptomatic/cryptogenic aetiology. Estimates from the other 2 
studies estimate are similar: 80% (95%CI 20% to 100%) less likely and 77% (95%CI 37% to 91%) 
less likely to develop intractable seizures with idiopathic aetiology than children with 
symptomatic/cryptogenic aetiology. 
 
Intellectual disability was also shown to consistently predict medically intractable seizures. The 
odds of having intractable seizures are 7 times [7.2 (95%CI 1.0-50.8)] in 1 study,(72) albeit with 
EPV less than 10,  and much higher in the other study which is less likely to be biased(76) at 18 
times [18.2 (95%CI 5.2-63.6)] greater for children who have intellectual disability and/or 
cerebral palsy relative to those with normal cognitive development and without cerebral palsy. 
However, the confidence interval is remarkably wide for both estimates, which is probably due 
to few children in both studies having intellectual disability.   
 
However, other potential predictors such as mixed seizure types, specific seizure types, seizure 
frequency, abnormal EEG, occurrence of status epilepticus, and family history of epilepsy or 
history of neonatal seizures, and were not found to be a predictor of intractability.  
 
5.8 REMISSION AFTER RELAPSE 
There was only 1 study(25) in this category. This fact precludes much further discussion. 
However, the study showed that the odds of not achieving remission after a relapse are about 8 
times as high in children with remote symptomatic aetiology compared to those without 
symptomatic aetiology.  
5.9 IMPLICATIONS FOR CLINICAL PRACTICE 
The results of this review suggest that in deciding whether to initiate antiepileptic drug therapy 
in patients with newly diagnosed epilepsy, particular consideration should be given to whether 
the newly diagnosed patient is a child or an adult, if the epilepsy has asymptomatic aetiology 
and also possibly the occurrence of more than 1 seizure before the index seizure. 
 
In making the decision, or in advising patients already in remission on whether to discontinue 
antiepileptic drug therapy, it may be important for physicians to be more reluctant or more 
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careful in patients with intellectual disability and those who had more than 1 seizure during the 
period between 6 and 12 months while on medication.  
 
Patients with mixed seizure types at onset, remote symptomatic aetiology, intellectual disability, 
high number of seizures before diagnosis and poor early response to medication indicated by 
more than 1 seizure in the first 6 months of antiepileptic medication may require a more 
aggressive treatment strategy to prevent their seizures from becoming refractory to 
antiepileptic medication.  
 
The children with onset of seizures in infancy (age < I year), with remote symptomatic aetiology, 
and intellectual disability, unlike children with idiopathic aetiology may require a more 
aggressive treatment strategy to prevent their seizures from becoming medically intractable and 
to also be managed with a view to early consideration of epilepsy surgery within 2 years of 
diagnosis. The parents and relatives of the children with these risk factors, especially when they 
occur together in the same child may need to be informed early on in the course of the illness 
regarding the possibility of intractability and the management strategies that may be necessary 
in addition to pharmacological intervention in case of intractability. 
 
In all, there are at present no satisfactory prediction models for any of the outcome categories.  
It may suffice however to inform and advise patients and their relatives based on the proportion 
of patients that achieve each outcome. These predictors may be all that is presently available for 
the purpose of devising management strategy early in the course of the disease and for advising 
patients. 
 
5.10 DIRECTIONS FOR FUTURE RESEARCH 
This segment presents the suggested directions and recommendations for future studies related 
to this systematic review. These issues are discussed under the sub-headings based on the key 
areas of this review: the literature search, reporting characteristics and quality appraisal of 
studies, the classification of studies included in this review and the results of the review of 
prognostic factor studies in newly diagnosed epilepsy. 
 
THE LITERATURE SEARCH  
Four recommendations are made based on findings from the literature search: 1) There is need 
for more evidence on the number and exact databases that would be necessary to search in 
order to identify observational studies. Previous research on this issue has focused on 
identifying randomised trials. 2) Future systematic reviews of studies containing multivariate 
analysis may benefit from concentrating their search period to say the last 20 years. 3) Future 
systematic reviews of observational studies in epilepsy may benefit from hand-searching recent 
editions of Epilepsia especially where the resources are available, and the search does not 
include EMBASE as the 4 publications unique to EMBASE were actually published in 2009 and 
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2010 in MEDLINE-indexed journals. 4) The clinical uptake of the results of future studies of 
prognosis in newly diagnosed patients with epilepsy may benefit from authors and journal 
editors choosing to publish some of those studies in non-specialist and primary care journals. 
 
QUALITY AND REPORTING CHARACTERISTICS 
Four recommendations are made based on findings from quality appraisal and reporting 
characteristics of included studies: 1) To enhance the robustness of multivariate analyses, it may 
be necessary to engage in international collaboration studies in order to boost the number of 
patients included in analyses. This may have the added advantage of rare syndromes being 
better represented in multivariate analyses to better ascertain their prognostic significance, and 
for including studies based in Africa and Australasia as none of the studies in the review 
included patients from the 2 continents. 2) It would be beneficial in assessing the quality of 
future observational studies and for future systematic reviews if authors and journals adhered 
to the STROBE checklist as minimum standard for reporting observational studies. 3) It may also 
be possible therefore for a future systematic review to compare the reporting characteristics of 
publications in STROBE-endorsing journals with journals that leave the reporting of 
observational studies to the discretion of authors. 4) The review, especially of studies predicting 
medical intractability, shows that studies with a higher potential for bias according to the quality 
items used in this review have risk estimates that differ in most cases remarkably from studies 
with a lower potential for bias. There is need for further research into ways of adapting the 
Hayden et al criteria to reviews of prognosis studies in other subject areas. 
 
THE CLASSIFICATION OF STUDIES  
The classification scheme developed in this thesis has a potential advantage for future studies 
because study categories were presented with the prognostic sub-groups (i.e. potential seizure 
outcome categories) used to define and delineate comparison groups. It would be a task of 
future studies of seizure outcome of newly diagnosed epilepsy to determine the proportion of 
patients in each sub-group. To ease and facilitate subsequent systematic reviews and meta-
analyses, authors of future studies of seizure outcome in patients with newly diagnosed epilepsy 
may locate their study within this classification scheme or its extension and label them as such. 
This will also allow results of the studies to be interpreted more easily and readily within the 
context of previous studies in the same category. 
 
PROGNOSTIC FACTOR STUDIES IN NEWLY DIAGNOSED EPILEPSY 
Further studies of immediate remission in newly diagnosed epilepsy will benefit from ensuring 
prospective case ascertainment at the point of a second seizure as this is the most important 
factor determining the proportion with outcome in this category of studies of seizure outcome 
in newly diagnosed patients with epilepsy. 
 
The deliberate inclusion of the consistent predictors of outcome across seizure outcome 
categories, especially remote symptomatic aetiology and intellectual disability and of 1 year 
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variables, especially of the occurrence of seizures within the first year after diagnosis or while on 
medication may also be important in studies predicting remission off medication, and remission 
on or off medication.  
 
The fact that intractability is a rare outcome, occurring in less than 15% of cohorts makes it 
particularly important for future studies to ensure that sample size is adequate to build the 
model with at least 10 events per independent variable entered into the model. 
 
There should also be studies investigating predictors of seizure outcome in patients with adult-
onset epilepsy as most the studies eligible for this review were in childhood-onset epilepsy. 
 
The distinguishing characteristic of the only study that investigated remission after relapse is 
that it is a cohort with long follow up, ranging from 11 to 42 years.(25) It would require such 
long follow up to determine patients who will relapse, and then following relapse achieve 
terminal remission or not achieve terminal remission. Therefore, it is hoped that presently 
existing cohorts will continue to be followed so that we can better understand the 
characteristics that influence achieving remission after relapse(s) and of other seizure outcome 
categories. 
5.11 STRENGTHS AND WEAKNESSES OF THE REVIEW 
This review of prognosis studies in unselected populations of patients with newly diagnosed 
epilepsy has accomplished its aim of classifying studies, exploring heterogeneity, and identifying 
consistent predictors of seizure outcome in patients with newly diagnosed epilepsy. The main 
strengths of this thesis are its thorough examination of studies included for their potential for 
bias and exploration of sources of heterogeneity. The review was focussed specifically on 
studies with multivariate regression analysis because they are best suited to control for possible 
confounding bias(23). The thesis has also explored other potential sources of bias, using 
objectively identified and clearly defined criteria.  
 
The studies included in the review were also classified such that like was compared to like within 
the study categories. The study also fills an important gap in the literature as there has been no 
previous review of the methods and results of prognosis studies that identified independent 
predictors of seizure outcome in newly diagnosed epilepsy. The quality appraisal items for 
systematic reviews of prognosis studies developed by Hayden et al(39) and adapted for use in 
this review have not been tested for validity and reliability. This review provides an instance 
where the quality items have been adapted for use in a specific subject area.  
 
However, the work has several limitations and future discussion on the methods of identifying 
and handling consistent independent predictors in systematic reviews and meta-analysis is 
needed. There is a potential drawback to predictors identified by multivariate analysis, 
especially when it is in studies not aimed at investigating the predictive value of a particular 
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prognostic variable, and when a stepwise algorithm is used in selecting variables to include in 
the model.(45) It has been demonstrated through multiple bootstrap and split-sample analyses 
that the models so derived have low reproducibility within the same study sample.(306) 
However, the strategy this review employed to mitigate potentially spuriously identified 
predictors was to stipulate from the outset that only predictors identified in more than 1 study 
conducted by different groups on different cohorts will be considered to be consistent 
predictors of a particular outcome. 
 
The discussions particularly relating to exploring factors that may explain the variations in the 
proportion of patients with seizure outcome in each category of studies is limited by the fact 
that only studies with multivariate analysis were included in the review. There are more studies 
in the literature that may have determined these proportions and might have thus provided 
more material for the discussions. However, the sample of studies in each category provides a 
heterogeneous sample of studies. Therefore there were enough studies on which to base the 
exploration and discussions in order to understand the characteristics that explain biases in the 
studies in each category. 
 
The Zhang-Yu equation(266) was used where possible to convert the odds ratios from logistic 
regression analyses in order to approximate relative risk. The equation allowed for comparison 
of odds ratio with the risk estimates (hazard ratios) from Cox regression analyses, which was 
assumed to be a good approximation of relative risk. However, the conversion of odds ratio to 
relative risk is in itself only an approximation. (307, 308) The formula has been shown to 
account for only 85% of the required adjustment of odds ratio towards the relative risk. The 95% 
confidence intervals calculated using the formula are also much narrower, with the results from 
the formula being only about two thirds (67%) of the appropriately determined 95% confidence 
interval of the relative risk.(308) However, the Zhang-Yu equation provides a useful approach to 
interpreting risk estimates from logistic regression in a way that enhances comparison with the 
relative risk which is more intuitive to understand. There is a need to use alternatives to the 
odds ratio because of the limitations(308)  of  the Zhang-Yu equation.(266) Results of simulation 
studies have shown that there are viable alternative models to the logistic regression 
model.(309, 310) These models (Poisson regression and log-binomial regression) better 
approximate the relative risk and could be used on longitudinal data with binary outcomes.(309) 
 
There is a possibility of selection bias in this systematic review. The prognosis studies that did 
conduct multivariate analysis to identify independent predictors may be of higher quality. There 
may be publication bias as studies with significant results (i.e. that identified independent 
predictors) may be more likely to get published. The search strategy yielded reviews published 
in English-language, peer-reviewed, MEDLINE- and EMBASE-indexed journals with adequate 
keywords and Medical Subject Heading (MeSH) or Emtree terms. There was no search of the 
grey literature. The methods used to identify publications may have missed some eligible, likely 
lower quality publications. However, given time and budget constraints, it was not feasible to 
search the grey literature or to translate non–English-language publications. Indeed, given that 
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the search is likely exhaustive within its limited framework, these factors are unlikely to have 
had much impact on the results and recommendations of this review. 
 
For the same purpose of time and budget constraints, the data extraction, quality appraisal and 
calculations were conducted by 1 reviewer. This is a potential source of error and bias in the 
systematic review. However, the reviewer (MPhil candidate) extracted the data directly from 
the relevant publications 3 times while checking against the previous extraction at each stage to 
ensure accuracy. The quality appraisal was also conducted transparently and the information 
upon which quality appraisal was based was explicitly reported in the review such that 
researchers and practitioners can independently assess the quality of the studies included in the 
review. There was also limitation due to incomplete reporting by authors as only published data 
was used and the MPhil candidate did not contact authors to obtain additional information due 
to time constraints. However, the candidate searched referenced papers and also publications 
from the same group or cohorts for additional information where such information may be 
important for the quality appraisal. 
 
Indeed, this work has several limitations. Future research should continue to discuss, debate 
and explore bias in prognosis studies and how to identify independent predictors of outcomes 
from studies conducted by multivariate analysis. This will further develop, expand and establish 
this burgeoning area of interest.  
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6  CHAPTER SIX: CONCLUSION 
 
This thesis has shown that although a wide range of variables have been considered across the 
different seizure outcome categories, only a few have been consistently confirmed as being 
statistically significant independent predictors in multivariate analysis. The study demonstrates 
the feasibility of systematic review with thorough quality appraisal as a means of identifying the 
consistent predictors of an outcome in studies that do not specifically investigate one particular 
prognostic variable. Table 24 summarises the independent predictors and presents the least 
biased estimate for childhood-onset and adult-onset epilepsy from each study category:   
 
1.) Having more than 1 seizure before intake and remote symptomatic aetiology were 
positive predictors of recurrence of seizure after intake (i.e. no immediate/early 
remission) in childhood-onset and adult-onset epilepsy. 
 
2.) Having more than 1 seizure in the period between 6 and 12 months on medication and 
intellectual disability were negative predictors of achieving remission off medication in 
childhood-onset epilepsy. None of the studies in this category considered adult-onset 
epilepsy. 
 
3.) Having more than 1 seizure before intake, having seizures in the first 6 months after the 
index seizure, mixed seizure types at onset of epilepsy, intellectual disability and remote 
symptomatic aetiology were negative predictors of achieving remission on or off 
medication in both childhood-onset and adult-onset epilepsy. 
 
4.) Having onset of seizures in infancy, intellectual disability, and remote symptomatic 
aetiology were positive predictors of medical intractability, while idiopathic aetiology 
was a negative predictor of intractability in childhood-onset epilepsy. None of the 
studies in this category considered adult-onset epilepsy. 
 
The neurobiology of epilepsy is heterogeneous. Therefore the aetiological classification, number 
of seizures, mixed seizure types, and comorbidity with intellectual disability that feature among 
independent predictors of seizure outcome may not fully capture the details of the biology, and 
possibly the prognosis of epilepsy. Important as the independent predictors are, they may not 
be important in the consideration of treatment and interventions in individual patients. For 
example, some types of seizure manifestation (e.g. focal seizures without impaired 
consciousness, absence seizures or seizures occurring only during sleep), and the benefits of 
treatment may not outweigh the potential adverse effects of medication. When seizures occur 
infrequently, even when the seizures are of a more severe form, the benefits of treatment over 
adverse effects also have to be weighed on a case by case basis.(8) Therefore these predictors 
can only serve as flexible guides to treatment and overall management strategy.  
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Table 24 | Consistent early predictors of seizure outcome in newly diagnosed epilepsy 
 IMMEDIATE REMISSION  
 
REMISSION OFF MEDICATION REMISSION ON OR OFF 
MEDICATION (REMISSION) 
MEDICAL INTRACTABILITY 
ONSET OF SEIZURES IN 
INFANCY (AGE < 1YEAR) 
   RR 5.48 (95%CI 2.10-9.64) C 
 
MORE THAN 1 SEIZURE BEFORE 
INTAKE 
 
RR NOT STATED CA 
RR 0.63 (95%CI 0.36-1.11) A 
 RR 0.66 (95%CI 0.46-0.95)* C 
RR 0.81 (95%CI 0.66-0.99)* CA 
 
NUMBER OF SEIZURES FROM 
INTAKE TO 6 MONTHS 
  RR 0.50 (95%CI 0.35-0.72)‡ C 
RR 0.59 (95%CI 0.50-0.70)‡ CA 
 
 
NUMBER OF SEIZURES, 6 TO 12 
MONTHS ON MEDICATION 
 RR 0.24 (95%CI 0.10-0.60) C   
MIXED SEIZURE TYPES AT 
ONSET 
  RR 0.70 (95%CI 0.37-1.04) CA 
OR 0.23 (95% CI 0.10-0.48) A 
 
 
INTELLECTUAL DISABILITY  RR 0.77 (95%CI 0.61-0.94) C OR 0.40 (95%CI 0.18-0.90) C 
OR 0.10 (95%CI 0.05-0.25) A 
OR 18.2 (95%CI 5.2-63.6) C 
REMOTE SYMPTOMATIC 
AETIOLOGY 
 
RR 0.59 (95%CI 0.41-0.86) C 
RR 0.44 (95% CI 0.26-0.77) A 
 RR 0.63 (95% CI 0.47-0.84) C 
RR 0.44 (95% CI NOT STATED) A 
RR 5.48 (95%CI 2.10-9.64) C 
IDIOPATHIC AETIOLOGY 
 
   RR 0.20 (95%CI 0.0-0.80) C 
RR-Relative Risk, OR-Odds Ratio, C-Estimate from childhood-onset epilepsy, A-Estimate from adult-onset epilepsy, CA-Estimate from cohort with both 
childhood-onset and adult-onset epilepsy 
*Relative risk of the natural logarithm of every additional seizure before intake 
‡Relative risk of the natural logarithm of every additional seizure in the first 6 months of follow up. 
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The findings of this systematic review, especially of lack of association of several factors with seizure 
outcome, is in keeping with a dated systematic review by Berg and Shinnar in 1991(44) which identified 
factors associated with recurrence after first seizure, although mostly in studies with univariate analysis. 
They found, as in this thesis, that age at onset, gender, abnormal EEG, family history of epilepsy, history 
of neonatal seizures, status epilepticus or febrile seizures, antiepileptic medication were not consistently 
predictive of seizure outcome (recurrence after a first seizure). However, they also found that aetiology 
(remote symptomatic increasing the risk for recurrence and idiopathic with lower risk), was a consistent 
predictor of recurrence as was seizure type (focal seizures tend to recur after a first). 
 
For Berg and Shinnar(44) as well, the method of case ascertainment was an important source of 
discrepancy in the proportion of patients with outcome as retrospective and mixed case ascertainment 
tend to result in biased estimates. In this thesis, the exploration of potential reasons for discrepancies in 
the proportion of patients with seizure outcome in each category was an illuminating exercise which 
yielded much information in assessing potential of individual studies for bias, and the differences in 
outcome between studies of childhood-onset epilepsy and those of adult-onset epilepsy. The adoption 
of this strategy in further systematic reviews of outcome in epilepsy is recommended.  
 
Part of the sources of discrepancies in proportion of patients within cohorts with particular outcomes 
was the specific details of how seizure outcome measure was defined in each study. For example, 
studies that defined remission as terminal remission had fewer patients in remission relative to 
comparable studies that defined remission as seizure-free period during follow up. Therefore it is 
important to qualify estimates specifically by how they were defined in the study, the design of the 
study, the setting of the study, and the patient population in the study when quoting proportion of 
patients with any seizure outcome in epilepsy. It is also recommended that a future task for ILAE 
(International League Against Epilepsy) in updating the guidelines for epidemiological research in 
epilepsy(1, 2) will be to define to the specific details, the outcome measures (e.g. remission and 
intractability) that studies within the categories identified in this thesis will have to adhere.  
 
The current models for predicting seizure outcome in newly diagnosed patients with epilepsy are 
neither accurate, nor have been rigorously developed and externally validated. The predictors identified 
in this thesis may therefore be the only reliable data currently available to allow the easy identification 
of those patients at the greatest risk of experiencing poor seizure outcome when newly diagnosed with 
epilepsy. Further research in this area would be of considerable importance not only in terms of 
increasing the understanding risk factors for poor outcome in epilepsy, but also in advancing health care 
delivery to improve patient care and reduce the burden of seizures on quality of life.  
 
As challenging as they are to conduct, population based studies with prospective case identification at 
the point of second seizure remain the ideal study design for seizure outcome in epilepsy. More of these 
studies will need to be conducted, especially among the 3 populations that were not well represented in 
the cohorts on which the studies that made up this thesis were based: populations of people with adult-
onset epilepsy, people in Australasia and people in developing countries, especially of Africa, as about 
80% of epilepsy patients live in developing countries(3).   
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7  APPENDICES 
7.1 Appendix I: PROTOCOL  
 
EARLY PREDICTORS OF SEIZURE OUTCOME IN NEWLY DIAGNOSED EPILEPSY –  
SYSTEMATIC REVIEW OF PROGNOSIS STUDIES 
 
INTRODUCTION 
Prognosis studies investigate the relationship between occurrences of outcomes and predictors in 
defined populations of people with disease.(1, 2) The importance of prognostic research in epilepsy as in 
other chronic illnesses/diseases is overwhelming. They help to improve the understanding of the disease 
process, to guide treatment decision making (if and when to commence antiepileptic medication, if and 
when to have epilepsy surgery and other non-pharmacological interventions), and to predict the 
outcome of epilepsy more accurately for the purpose of patient information and counselling. (3)  
 
However, in spite of the methodological demands, prognostic studies are usually not protocol driven, 
small sized, widely heterogeneous in characteristics of patients, choice and number of predictor 
variables, outcome and follow up measures, and often prognostic analyses are improvised as icing on 
the cake of studies designed for quite another purpose. For these reasons, the results of prognostic 
research are largely fraught with limitations, with attendant uncertainty about the reliability of 
conclusions of their synthesis/meta-analyses. (1) 
 
This has led to the creation of a new Cochrane Prognosis Methods Group in 2008 aimed at providing 
support and a forum for discussion to facilitate and improve the quality of systematic reviews of 
prognosis research.(4) Systematic review of prognosis studies with particular focus on methodology is 
therefore a burgeoning field of interest, and there have been efforts at ensuring the quality of such 
reviews. Hayden et al have developed a set of criteria for quality assessment through a meta-review of 
systematic reviews of prognosis studies. (5)  
 
There have only been systematic reviews in the literature of epidemiological studies that focus on 
incidence and prevalence of epilepsy generally(6) and with regional focus - Asia(7), Latin America(8), 
Middle East and North Africa(9), Europe(10) and sub-Saharan Africa(11). However, these studies, when 
they do, only make passing reference to the methodology and/or results of prognosis studies. Ross et al 
also systematically reviewed the literature, but on management issues in epilepsy from 1980 to 
1999.(12) The studies on prognosis were therefore only partly considered and only in passing, without 
methodological rigour.  
 
Parenthetically, also no systematic review has considered other outcomes in prognosis studies, 
important as they are: psychopathology outcomes (depression, anxiety, et cetera), neurodevelopmental 
outcomes (especially IQ in children), mortality, and quality of life measures. This will be the focus of 
future systematic review(s) following completion of the present one that is being proposed. 
 
However, an epidemiological synthesis of the natural history of epilepsy by Kwan and Sander(13) 
suggest that there are three prognostic groups: group 1 (20–30%) comprises patients with excellent 
prognosis, as there is long term remission after a period of seizure activity, with or  without antiepileptic 
drug treatment and the primary aim of antiepileptic drug treatment in this group of patients is to 
suppress seizures until ‘spontaneous’ remission occurs, and patients can be successfully withdrawn after 
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a period of seizure freedom; for group 2 (20–30%) seizure remission occurs only with treatment and 
patients only remain seizure-free with continuing antiepileptic drug treatment; and in group 3 (30–40%) 
there is continuing seizures despite antiepileptic drug treatment with some patients having frequent 
debilitating seizures qualifying them as having ‘refractory’ epilepsy.  
 
Significance 
Seizure outcome in epilepsy is varied. Epilepsy itself is a multi-aetiological and diverse disorder. The first 
seizure brings with it the opening of a fresh chapter in the life of the patient, with tough decisions to be 
made for the patient and for clinicians especially of when or whether to start medication as they carry 
risks of acute idiosyncratic reactions, dose-related and chronic toxic effects, and teratogenicity.  
 
However, for most patients diagnosed with epilepsy, the benefits of treatment will far outweigh the 
risks associated with treatment, but for those who have had a single seizure and for those who have 
seizures with minor symptoms, this risk to benefit ratio is more finely balanced.(14) There is also the 
group of patients (Kwan & Sander’s Group 3)(13) that may be candidates for epilepsy surgery as they 
will develop debilitating drug-resistant epilepsy; as seizures themselves are not benign events, there is 
the consequent considerable clinical and psychosocial distress or even mortality. 
 
There is thus the need for studies that attempt to identify independent predictors of these seizure 
outcomes and also therefore useful to review the methodology and possibly synthesise the results of 
studies that have identified the factors which best predict clinically relevant seizure outcomes in 
patients that have been newly diagnosed with epilepsy. 
 
There is a greater tendency for publication bias in observational studies compared to randomised clinical 
trials (15) and prognosis studies particularly so, as it is probable that studies showing a strong, 
statistically significant prognostic ability are more likely to be published and this can lead to invalid 
results and incorrect inferences.(16) The proposed review will therefore thoroughly assess for quality 
based on indices that reflect how prone the studies are to bias. 
 
Objectives 
This thesis aims to answer the following questions: 
 
1.) What is the quality of prognosis studies that have attempted to identify independent predictors of 
seizure outcome among unselected population patients with newly diagnosed epilepsy?  
2.) What is the effect of study quality, especially potential risk for bias, on the results of the prognosis 
studies? 
3.) Which factors have been consistently identified as independent predictors of seizure outcome and 
which factors have been consistently identified as non-predictors? 
4.) Do satisfactory seizure outcome prediction models already exist? 
 
The review also proposes to assess the state of evidence of the prognosis of seizure outcomes in 
epilepsy with the view towards a possible synthesis of the results. A systematic review of methodology 
may also help in identifying areas of potential limitation and specific actions that may improve future 
investigations of prognosis in epilepsy. 
 
METHODS 
The guidelines for the design, performance and reporting for meta-analyses of observational studies 
published by the MOOSE group (17) will be followed in this systematic review. 
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Eligibility Criteria 
The review will seek for inclusion, published cohort, nested case control and case control studies of 
unselected population of people with epilepsy that assess the independent effect of 3 (an arbitrary 
decision, following the example of Counsell and Dennis(18), based on the fact that 2 variables will be too 
few to give significant information about their independent effect) or more predictor variables on a 
range of measures of seizure outcome in patients with epilepsy collected within the first year of onset, 
diagnosis, or presentation, with patients followed up for at least 1 year. Only studies published in English 
will be included in the review. 
 
There is no consensus on sample size estimations for multivariable models. However the standard rule 
of thumb is 10 or more events per variable entered into the model to allow a robust estimation of the 
coefficients (19), although a recent study showed that this number could be lower (20). Since about 30-
40%(13) of patients with epilepsy do not achieve seizure remission despite continued AED treatment, a 
study of association of 3 predictor variables with this outcome will require at least 100 patients to 
achieve an EPV of 10 or more. Therefore we will also be seeking studies that include at least 100 
patients. Studies with fewer than 100 patients will only be included if they have an EPV greater than 10 
or have been validated on other data sets.   
 
Seizure outcome has been assessed using different concepts of measure. However, the review will not 
be limited to outcomes assessed in these forms only: Terminal Remission (length of seizure-free period 
immediately before last follow up evaluation); Longest Remission (longest seizure-free period during 
follow up); Time to Remission (time from diagnosis to the commencement of remission); Time to 
Recurrence (time from diagnosis to recurrence of seizures); Seizure Frequency (number of seizures per 
specified period of time); Refractoriness (lack of response to antiepileptic medication); and Intractability 
(lack of response to seizures with debilitating frequency of seizures). 
 
Search Strategy 
There is probably no widely acknowledged optimal strategy for searching the literature for prognostic 
studies.(3) Wilczynski et al (21)have developed search strategies that optimise the yield for prognostic 
studies in MEDLINE(21) with good sensitivity (the proportion of high quality articles that are retrieved 
for a particular topic) and specificity (the proportion of low quality articles not retrieved), although 
understandably low precision (proportion of retrieved articles that are of high quality) as searches were 
not limited by clinical content terms. The most sensitive search strategy is recommended for those 
interested in all articles reporting studies on prognosis and who are willing to sort out less relevant 
articles. The search strategy developed using Ovid's search engine syntax for combination of terms with 
the best sensitivity was:    
 
Incidence (MeSH) OR explode mortality OR follow-up studies (MeSH) OR prognos* (text word)  
OR predict* (text word) OR course (text word) 
 
These results will serve as a guide in deciding the search strategy for the review. These results were 
from searches not limited by specific clinical/disease terms and the authors suggest rather guardedly 
that it may be possible to increase  the performance measures by combining search strategies with 
content specific terms using the Boolean 'AND'. Therefore MEDLINE was searched (from inception to 
March 2010) using “epilepsy” or “seizure” or “seizure disorders” with the explode feature where 
applicable, in combination with the search terms for prognostic studies developed by Wilczynski et al 
(21).  
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Furlan et al(22) identified terms in EMBASE related to study design and analysis that could reverse 
identify non-randomized studies in 4 systematic reviews across 4 different clinical areas. They found that 
text word “multivariate” was 1 of 2 terms which limit topic only searches in all 4 clinical areas. The text 
word “regression” (Cox regression and logistic regression) was among others common to 2 of the 4 
clinical areas. These terms identified by Furlan et al(22) focusing on terms related to study design and 
statistical analysis will be used for the EMBASE search. The terms “multivariate” and “regression” are 
common to the inclusion criteria for studies to be included in the review. The terms were thus selected, 
and they will be used in addition to “multivariable” to limit an “epilepsy” topic search [explode epilepsy 
(Emtree) OR epilepsy (text word)]. The search will also be from inception to March 2010, and will not be 
limited to EMBASE-specific records alone. 
 
The results of the MEDLINE and EMBASE search will be screened after they have been exported to the 
EndNote citation manager. There will be a three-step selection process to identify eligible studies. In the 
first step, the title and abstracts will be screened to identify all studies that are neither about prognosis 
nor epilepsy and do not meet any of the inclusion criteria, duplication or redundant studies, papers that 
are review, editorial, commentary or letter, studies with non-seizure outcomes, studies with population 
restricted to a particular epilepsy subtype or patient population (e.g. surgical cohort, drug withdrawal 
cohort et cetera), studies with epilepsy or seizures as an outcome of or in relation to another 
pathological process and exclusively first seizure studies. These publications will be excluded, and will 
then be left with only the potentially eligible papers. In the second step, after reading the full text 
versions of the remaining studies, those without multivariate analysis of predictor variables for seizure 
outcomes in unselected cohort of people with epilepsy will again be excluded. Then in the third step, 
there will be a manual search the reference lists of all eligible publications. 
 
Data Extraction 
The data will first be extracted from each paper directly into a form, then from the paper also directly 
onto an Excel spread sheet database; results of the 2 rounds of data extraction will be compared for 
accuracy, and where there are discrepancies, the paper will be consulted for clarification. The extracted 
data will include authors and title of study, year of publication, study design, study size, age range and 
sex of the participants, predictor variables assessed, investigated seizure outcome measures, and the 
independent predictors with their risk estimates and corresponding 95% confidence intervals. All data 
will be extracted from the published studies and their authors will not be contacted for further 
information. 
 
REVIEW OF METHODS OF STUDIES 
In a meta-review of systematic reviews of prognosis studies, Hayden et al (5) developed extensive 
guidelines for assessing quality in prognosis studies on the basis of a framework of potential biases. 
Hayden and colleagues set out by identifying quality items in systematic reviews of prognosis studies, 
and subsequently pooling the items identified into 6 areas of potential bias (Study Participation, Study 
Attrition, Prognostic Factor Measurement, Confounding Measurement, Outcome Measurement and 
Analysis) all of which are relevant to the purpose and question of the present systematic review and will 
therefore be adapted in the analysis of methodology of the studies being reviewed. (Appendix IV) 
 
Studies with Externally Validated Models 
For studies with externally validated prognostic models, further analysis will be done with particular 
reference to the models. Laupacis et al(23) suggested additional criteria specific to prognostic models in 
their 1997 paper which was an addition to previous criteria suggested by Wasson et al (24) in 1985, 
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many of which were again identified in the more recent work Hayden et al(5). The factors peculiar to 
prognostic models from Laupacis et al that are not present in Hayden et al are:  
 
Internal validation: Although not explicitly stated and only implied by Laupacis et al, internal validation 
is important in assessing the performance of the model, although it does not provide information about 
the model’s performance in another population. This is usually done by splitting the dataset randomly 
into 2 parts (often 2:1). The model is developed using the first portion and its predictive accuracy is 
assessed on the second portion.  If the available data are limited, the model can be developed on the 
whole dataset and techniques of data re-use, such as cross validation and bootstrapping, applied to 
assess performance. (25)  
 
External validation: It is important to prospectively validate the model in a group of patients different 
from the group in which it was derived, and preferably with different clinicians. This examines the 
generalisability of the model. (25) 
 
Sensibility: The evaluation of sensibility relies on judgment rather than statistical methods: Is the model 
clinically sensible? Clinicians should think that the items in the model are clinically sensible and that no 
important items are missing. It is difficult to determine which factors are important in the prognosis of 
seizure outcomes in epilepsy, but this will be determined retrospectively following the systematic 
review, and then it will subsequently be documented whether these variables were entered into the 
analysis.(18) Is the model easy to use? This includes factors like time needed to apply the model, and 
how simple it is to use. Models that require extensive calculations may be less likely to be used than 
models with simpler scoring schemes. However, this may change as part of a cultural shift involving the 
increasing surrender of clinical information to the computer and statistical analysis, and this may further 
facilitate the use of prognostic scores. (26) Probability of outcome vs. Course of action: Laupacis et 
al(23) are of the opinion that prognostic models that recommend a course of action are more likely to 
be used compared with those that simply describe the probability of an outcome. Both indices of 
sensibility will be assessed.  
 
Effects of use on clinical practice: This refers to the prospective evaluation of the effect on clinical 
practice of using the prognostic model in a patient population other than the one in which it was 
developed and validated to show if physicians and patients are willing to use the model and how its use 
affect patient behaviour and clinical outcomes. This is best done in randomised controlled trials.(27) 
 
REPORT AND SYNTHESIS OF RESULTS / META-ANALYSIS 
For each study, data will be collected on all of the variables shown to be independently predictive of 
seizure outcome. The variables included in the prognosis studies will be analysed and reported. 
Predictive variables consistently found to be independent predictors of an outcome in a range of studies 
will also be reported. 
 
The results of quality assessment will incorporated into the review’s synthesis of the evidence. 
Information on each of the areas of bias in prognosis studies as identified by Hayden et al(5) will be 
included in the review synthesis. For example, the evidence of effect would be presented on the basis of 
studies with low risk for bias associated with study participation, study attrition, prognostic factor 
measurement, outcome measurement, confounding measurement and account, and analysis. The 
review synthesis will also include an assessment of evidence of effect based on studies with an overall 
low risk for any important bias. Therefore studies of acceptable quality for inclusion in the synthesis 
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would at least partly satisfy each of the areas of potential bias i.e. studies from the analysis that are at 
high risk for any important bias would be omitted from synthesis of results.  
 
REFERENCES 
1.  Hemingway H, Riley R, Altman D. Ten steps towards improving prognosis research. BMJ2009; 
339:b4184  
2.  Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG, Moons KGM, et al. Prognosis and 
prognostic research: what, why, and how? BMJ2009; 338:b375. 
3.  Altman D, Lyman G. Methodological challenges in the evaluation of prognostic factors in breast 
cancer. Breast Cancer Research and Treatment1998;52(1):289-303. 
4.  Riley RD, Ridley G, Williams K, Altman DG, Hayden J, de Vet HC, et al. Prognosis research: toward 
evidence-based results and a Cochrane methods group. Journal of Clinical Epidemiology2007 
Aug;60(8):863-5; author reply 5-6. 
5.  Hayden JA, Cote P, Bombardier C, Hayden JA, Cote P, Bombardier C. Evaluation of the quality of 
prognosis studies in systematic reviews. Annals of Internal Medicine2006 Mar 21;144(6):427-37. 
6.  Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA, Kotsopoulos IAW, et al. 
Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. 
Epilepsia2002 Nov;43(11):1402-9. 
7.  Mac TL, Tran DS, Quet F, Odermatt P, Preux PM, Tan CT, et al. Epidemiology, aetiology, and 
clinical management of epilepsy in Asia: a systematic review. Lancet Neurology2007 
Jun;6(6):533-43. 
8.  Burneo JG, Tellez-Zenteno J, Wiebe S, Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the 
burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. 
Epilepsy Res2005 Aug-Sep;66(1-3):63-74. 
9.  Benamer HT, Grosset DG, Benamer HTS, Grosset DG. A systematic review of the epidemiology of 
epilepsy in Arab countries. Epilepsia2009 Oct; 50(10):2301-4. 
10.  Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe - a systematic 
review. Eur J Neurol2005 Apr;12(4):245-53. 
11.  Preux PM, Druet-Cabanac M, Preux P-M, Druet-Cabanac M. Epidemiology and aetiology of 
epilepsy in sub-Saharan Africa. Lancet Neurology2005 Jan;4(1):21-31. 
12.  Ross SD, Estok R, Chopra S, French J. Management of Newly Diagnosed Patients with Epilepsy: A 
Systematic Review of the Literature.  Rockville, MD: Agency for Healthcare Research and Quality 
(AHRQ) September 2001; 
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hserta&part=A56819. 
13.  Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. Journal of 
Neurology, Neurosurgery & Psychiatry2004 Oct; 75(10):1376-81. 
135 
 
14.  Kim LG, Johnson TL, Marson AG, Chadwick DW, group MMS, Kim LG, et al. Prediction of risk of 
seizure recurrence after a single seizure and early epilepsy: further results from the MESS 
trial.[Erratum appears in Lancet Neurol. 2006 May;5(5):383]. Lancet Neurology2006 
Apr;5(4):317-22. 
15.  Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. 
Lancet1991 Apr 13;337(8746):867-72. 
16.  Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of 
cancer risk in Barrett's esophagus? Gastroenterology2000 Aug;119(2):333-8. 
17.  Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of 
observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) group. JAMA2000 Apr 19;283(15):2008-12. 
18.  Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. 
Cerebrovascular Diseases2001;12(3):159-70. 
19.  Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, 
evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med1996 Feb 
28;15(4):361-87. 
20.  Vittinghoff E, McCulloch CE, Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per 
variable in logistic and Cox regression. Am J Epidemiol2007 Mar 15;165(6):710-8. 
21.  Wilczynski NL, Haynes RB, Hedges T, Wilczynski NL, Haynes RB. Developing optimal search 
strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC 
Medicine2004 Jun 9;2:23. 
22.  Furlan AD, Irvin E, Bombardier C, Furlan AD, Irvin E, Bombardier C. Limited search strategies 
were effective in finding relevant nonrandomized studies. Journal of Clinical Epidemiology2006 
Dec; 59(12):1303-11. 
23.  Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of 
methodological standards. JAMA1997 Feb 12;277(6):488-94. 
24.  Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and 
methodological standards. New England Journal of Medicine1985 Sep 26;313(13):793-9. 
25.  Altman DG, Vergouwe Y, Royston P, Moons KG, Altman DG, Vergouwe Y, et al. Prognosis and 
prognostic research: validating a prognostic model. BMJ2009;338:b605. 
26.  Hemingway H. Prognosis research: Why is Dr. Lydgate still waiting? Journal of Clinical 
Epidemiology2006; 59(12):1229-38. 
27.  Moons KG, Altman DG, Vergouwe Y, Royston P, Moons KGM, Altman DG, et al. Prognosis and 
prognostic research: application and impact of prognostic models in clinical practice. BMJ2009; 
338:b606. 
136 
 
7.2 Appendix II: LIST OF CITATIONS  
This is the list of citations from screening endnote library (MEDLINE & EMBASE) and references of eligible publications 
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7.3 Appendix III: DATA EXTRACTION AND QUALITY APPRAISAL FORM  
This contains the three versions of the data extraction and quality appraisal form, from the first two pilots (Versions 1 and 2) to the final version (Version 3) 
 
Data Extraction and Quality Appraisal Form Version 1 
Data Extraction 
 
First Author, Year, Title & Journal: _________________________________________________________________________________  
 
Study Design  Prospective    Retrospective    Mixed    Unclear 
 
Type of Study  Randomised Controlled Trial    Cohort Study    Nested Case Control Study    Case Control Study   
 
Study Population Characteristics 
Gender  Male    Female    Both 
 
Age 
Bracket ________________  
Remark   Children    Adolescents    Adults 
 
Setting  Hospital    Population    Both 
 
Follow up 
Population 
Initial________,   Final_________,   %__________   Not Stated/ Unclear 
 
Length of Reported Follow up 
Minimal_________, Average_________, Median_________, Maximum__________  Not Stated/ Unclear 
 
Outcome Measure  
Seizure 
 Remission – terminal remission, longest remission 
 Seizure status at specified points within follow-up timeline 
 Time to event – remission, recurrence of seizures, intractability 
 Time to recurrence of seizures 
 Intractability 
 Refractoriness 
 
Epilepsy Subtypes Included/Excluded 
 All Included/ Unselected 
 Undetermined/ Not stated / Not sure 
Method of Multivariate Analysis 
 Logistic Regression Model 
 Cox Proportional Hazards Model 
 
Treatment Details of Cohort _____________________________________________________________________________________________ 
 
Independent Predictors 
(with Regression Coefficient, Odds Ratio or Hazard Ratio and 95% CI) 
142 
 
Quality Appraisal for All Studies 
 
Study participation 
The source population or population of interest is adequately described for key characteristics   Yes     Partly     No     Unsure  
The sampling frame and recruitment are adequately described                                                   Yes     Partly     No     Unsure   
Inclusion and exclusion criteria are adequately described                                                           Yes     Partly     No     Unsure   
There is adequate participation in the study by eligible individuals                                               Yes     Partly     No     Unsure  
The baseline study sample (or cohort) is adequately described for key characteristics                  Yes     Partly     No     Unsure  
 
Study attrition 
Response rate (proportion of study sample completing the study and providing outcome data) is adequate (>90%)  Yes     Partly     No     Unsure  
Information on participants who dropped out of the study are described                                                               Yes     Partly     No     Unsure  
Reasons for loss to follow-up are provided                                                                                                          Yes     Partly     No     Unsure  
Participants lost to follow-up are adequately described for key characteristics                                                        Yes     Partly     No     Unsure  
There are no important differences between those who completed the study and those who did not                      Yes     Partly     No     Unsure  
 
Prognostic factor measurement 
The prognostic factors measured are clearly defined or described where necessary                                   Yes     Partly     No     Unsure 
Continuous variables are reported or appropriate (i.e. not data-dependent) cut-points are used                 Yes     Partly     No     Unsure 
The prognostic factor measure and method are adequately valid and reliable to limit misclassification bias   Yes     Partly     No     Unsure  
The method and setting of measurement are the same or similar for all study participants                          Yes     Partly     No     Unsure 
Adequate proportion of the study sample has complete data for prognostic factors                                   Yes     Partly     No     Unsure 
Appropriate methods are used if imputation is used for missing prognostic factor data                               Yes     Partly     No     Unsure 
 
Outcome measurement 
A clear definition of the outcome of interest is provided, including duration of follow-up and level and extent of the outcome construct  Yes     Partly     No     Unsure 
The outcome measure and method used are adequately valid and reliable to limit misclassification bias                                                   Yes     Partly     No     Unsure 
The method and setting of measurement are the same or similar for all study participants                                                                      Yes     Partly     No     Unsure 
 
Confounding measurement and account 
Important confounders are measured                                                                                                                                                          Yes     Partly     No     Unsure 
Clear definitions of the important confounders measured are provided                                                                                                         Yes     Partly     No     Unsure 
Measurement of important confounders is adequately valid and reliable                                                                                                         Yes     Partly     No     Unsure 
The method and setting of confounding measurement are the same for all study participants.                                                                          Yes     Partly     No     Unsure 
Appropriate methods are used if imputation is used for missing confounder data                                                                                            Yes     Partly     No     Unsure 
Important potential confounders are accounted for in the study design (e.g. matching, stratification, or initial assembly of comparable groups)   Yes     Partly     No     Unsure 
Important potential confounders are accounted/adjusted for in the analysis                                                                                                    Yes     Partly     No     Unsure 
 
Analysis 
There is sufficient presentation of data to assess the adequacy of the analysis                                                                        Yes     Partly     No     Unsure 
The strategy for model building (i.e. inclusion of variables) is appropriate and is based on a conceptual framework or model    Yes     Partly     No     Unsure 
The selected model is adequate for the design of the study                                                                                                  Yes     Partly     No     Unsure 
There is no selective reporting of results                                                                                                                            Yes     Partly     No     Unsure 
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Data Extraction and Quality Appraisal Form Version 2 
Data Extraction 
 
First Author, Year, Title & Journal: ___________________________________________________________________________________  
Study Design 
 Prospective    Retrospective    Mixed    Unclear 
 
Type of Study 
 Randomised Controlled Trial    Non-Randomised Controlled Trial    Cohort Study    Nested Case Control Study   Case Control Study   
 
Study Setting 
 Hospital    Population 
 
Study Recruitment Period  
From___________________ To________________________        (n=  ) 
 
Age 
Bracket ________________, Mean ___________ ± _________SD 
 
Follow up 
Initial Population ________,   Final_________,   %__________   Not Stated/ Unclear 
 
Length of Reported Follow up 
Minimal_________, Mean_________, Median_________, Maximum__________  Not Stated/ Unclear 
 
Outcome         More Information 
Seizure Outcome Measure 
 Remission  
 Time to Event 
 Intractability/ Refractoriness 
 Status at specified points within follow-up timeline 
 Others ______________________________________ 
 
Proportion of Patients with Outcome ______________________%___________  Not Stated/ Unclear 
 
Independent Predictors of Seizure Outcome  
(with Regression Coefficient, Odds Ratio or Hazard Ratio and 95% CI) 
  
1. 
2. 
3. 
4. 
5. 
6.  
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Epilepsy Subtypes Included/Excluded      More Information 
 All Included - Unselected 
 Not stated - Not sure 
 Selected 
 
Method of Multivariate Analysis      More Information 
 Logistic Regression Model 
 Cox Proportional Hazards Model 
Number of Predictor Variables entered into Model__________________________  Not Stated/ Unclear 
 
 
ILAE Reference Standards       More Information 
Definition of Epilepsy              Yes     Partly     No    Unsure  
Classification of Seizures         Yes     Partly     No    Unsure  
Classification by Aetiology      Yes      Partly     No    Unsure 
Classification by Syndromes    Yes      Partly     No    Unsure  
 
AED Treatment & Withdrawal Details in Cohort    More Information 
 According to a published or newly developed protocol 
 At the discretion of treating physician 
 Every participant on the same regimen 
 Randomised 
 Not Stated/ Unclear 
 
 
Quality Appraisal for All Studies 
 
Study participation 
The source population or population of interest is adequately described for key characteristics   Yes    Partly    Unsure    No     
There is adequate participation in the study by eligible individuals                                               Yes    Partly    Unsure    No     
Inclusion and exclusion criteria are adequately described                                                           Yes    Partly    Unsure    No     
The baseline study sample (or cohort) is adequately described for key characteristics                  Yes    Partly    Unsure    No     
 
Study attrition 
Response rate (proportion of study sample completing the study and providing outcome data) is adequate (>80%)                  Yes    Partly    Unsure    No     
Information on participants who dropped out of the study are described                                                                               Yes    Partly    Unsure    No     
Reasons for loss to follow-up are provided and participants lost to follow-up are adequately described for key characteristics  Yes    Partly    Unsure    No     
There are no important differences between those who completed the study and those who did not                                      Yes    Partly    Unsure    No     
 
Prognostic factor measurement 
The prognostic factors measured are clearly defined or described where necessary                                    Yes    Partly    Unsure    No     
The prognostic factor measure and method are adequately valid and reliable to limit misclassification bias   Yes    Partly    Unsure    No     
The method and setting of measurement are the same or similar for all study participants                          Yes    Partly    Unsure    No     
Adequate proportion of the study sample has complete data for prognostic factors                                    Yes    Partly    Unsure    No     
 
Outcome measurement 
A clear definition of the outcome of interest is provided, including duration of follow-up and level and extent of the outcome construct  Yes    Partly    Unsure    No     
The outcome measure and method used are adequately valid and reliable to limit misclassification bias                                                   Yes    Partly    Unsure    No     
The method and setting of measurement are the same or similar for all study participants                                                                     Yes    Partly    Unsure    No     
The outcome measurement was blinded to prognostic factor measure or vice versa                                                               Yes    Partly    Unsure    No     
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Analysis 
There is sufficient presentation of data to assess the adequacy of the analysis                                                                        Yes    Partly    Unsure    No     
The strategy for model building (i.e. inclusion of variables) is appropriate and is based on a conceptual framework or model    Yes    Partly    Unsure    No     
The selected model is adequate for the design of the study                                                                                                  Yes    Partly    Unsure    No     
There is no selective reporting of results                                                                                                                            Yes    Partly    Unsure    No     
 
 
Quality Appraisal for Models 
 
Statistical validity 
The mathematical technique used to derive the model is adequately justified                                                                                               Yes    Partly    Unsure    No     
There is no over-fitting the data with too few outcome events per predictor variable (i.e. EPV at least 10)                                                    Yes    Partly    Unsure    No     
There is an account of how predictor variables were selected (i.e. univariate association, stepwise analysis, and assessment for colinearity)    Yes    Partly    Unsure    No     
There is the use of appropriate imputation methods for missing data                                                                                                          Yes    Partly    Unsure    No     
 
Internal validation & Reproducibility of predictive variables 
The method of ensuring/verifying interobserver reliability of predictor variables is described           Yes    Partly    Unsure    No     
The final model was validated on the data that was used to generate it to assess its performance    Yes    Partly    Unsure    No     
The method used for internal validation of the model is adequately described                                Yes    Partly    Unsure    No     
The model produced accurate predictions on the patients that were used to generate it                Yes    Partly    Unsure    No     
 
External validation & Effects of use on clinical practice 
The final model was/has been prospectively validated on new cohort(s) of patients, producing accurate results                 Yes    Partly    Unsure    No     
The prospective validation study was conducted by different clinicians from those who were used to develop the model   Yes    Partly    Unsure    No     
The model produced accurate predictions on the patients other than those used to generate it                                       Yes    Partly    Unsure    No     
RCTs have shown that physicians and patients are willing to use the model based on its effect on clinical outcomes          Yes    Partly    Unsure    No     
 
Sensibility 
The model is clinically sensible as no obviously clinically important items are missing                                           Yes    Partly    Unsure    No     
The variables included in the model are easily assessable clinically                                                                      Yes    Partly    Unsure    No     
The model is easy and simple to use arithmetically as it does not require much time and extensive calculations    Yes    Partly    Unsure    No     
The model prescribes a course of action to be taken following certain probability of outcome                            Yes    Partly    Unsure    No     
 
ROC Curve  Yes    No 
 
Predictive Performance – Development Data 
Sensitivity - 
Specificity - 
Positive Predictive Value - 
Negative Predictive Value - 
Correct Prediction – 
 
Predictive Performance – External Validation 
Sensitivity - 
Specificity - 
Positive Predictive Value - 
Negative Predictive Value - 
Correct Prediction – 
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Data Extraction and Quality Appraisal Form Version 3 (Final) 
Data Extraction 
 
First Author, Year, Title & Journal: ___________________________________________________________________________________  
Study Design 
 Prospective    Retrospective    Mixed    Unclear 
 
Type of Study 
 Randomised Controlled Trial    Non-Randomised Controlled Trial    Cohort Study    Nested Cohort Study    Case Control Study   
 
Study Setting 
 Hospital    Community 
 
Study Recruitment Period  
From___________________ To________________________        (n=  ) 
 
Age 
Bracket ________________, Mean ___________ ± _________SD 
 
Follow up 
Initial Population ________,   Final_________,   %__________   Not Stated/ Unclear 
 
Length of Reported Follow up 
Minimal_________, Mean_________, Median_________, Maximum__________  Not Stated/ Unclear 
 
Outcome         More Information 
Seizure Outcome Measure 
 Remission  
 Time to Event 
 Intractability/ Refractoriness 
 Status at specified points within follow-up timeline 
 Others ______________________________________ 
 
Proportion of Patients with Outcome ______________________%___________  Not Stated/ Unclear 
 
Independent Predictors of Seizure Outcome  
(with Regression Coefficient, Odds Ratio or Hazard Ratio and 95% CI) 
  
1. 
2. 
3. 
4. 
5. 
6.
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Epilepsy Subtypes Included/Excluded      More Information 
 All Included - Unselected 
 Not stated - Not sure 
 Selected 
          
Method of Multivariate Analysis      More Information 
 Logistic Regression Model 
 Cox Proportional Hazards Model 
 
ILAE Reference Standards       More Information 
Definition of Epilepsy              Yes     Partly     No    Unsure  
Classification of Seizures         Yes     Partly     No    Unsure  
Classification by Aetiology      Yes      Partly     No    Unsure 
Classification by Syndromes    Yes      Partly     No    Unsure  
 
AED Treatment & Withdrawal Details in Cohort    More Information 
 According to a published protocol 
 At the discretion of treating physician 
 Every participant on the same regimen 
 Randomised 
 Not Stated/ Unclear 
 
Reporting Characteristics of Studies  
Justification of sample size        Yes   No   
Report of test for colinearity    Yes   No 
Report of test for interactions  Yes   No 
Model assumptions tested        Yes   No 
Mention of missing data            Yes   No 
Criteria for Variable in Model   Yes   No 
Report on loss to follow up      Yes   No 
Statistical Package Stated          Yes   No 
Type of stepwise analysis          Yes   No 
  
How continuous variables were treated   None Considered  Kept continuous Categorised _____________________________ 
Quality Appraisal for All Studies 
 
Study participation 
The study sample represents the population of interest on key characteristics, sufficient to limit potential bias to the results 
 
The source population is adequately described for key characteristics   Yes    Partly    Unsure    No     
Inclusion criteria and baseline cohort described         Yes    Partly    Unsure    No     
There is adequate participation in the study by eligible individuals         Yes    Partly    Unsure    No     
 
Study attrition 
Loss to follow-up is not associated with key characteristics (i.e., the study data adequately represent the sample) 
 
Response rate (proportion of study sample completing the study and providing outcome data) is adequate   Yes    Partly    Unsure    No     
Reasons for loss to follow-up are provided and those lost to follow-up are adequately described                 Yes    Partly    Unsure    No     
There are no important differences between those who completed the study and those who did not           Yes    Partly    Unsure    No     
 
Prognostic factor measurement 
The prognostic factor of interest is adequately measured in study participants  
 
The prognostic factors measured are clearly defined                Yes   Partly    Unsure    No     
The measure methods adequately limit misclassification bias    Yes    Partly    Unsure    No     
Adequate proportion of the study sample has complete data   Yes    Partly    Unsure    No     
The continuous variables were handled appropriately              Yes    Partly    Unsure    No     
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Outcome measurement 
The outcome of interest is adequately measured in study participants 
 
A clear definition of the outcome is provided                          Yes    Partly    Unsure    No     
The measure method adequately limit misclassification bias      Yes    Partly    Unsure    No     
The outcome was blinded to prognostic factor or vice  versa    Yes    Partly    Unsure    No     
 
Analysis 
The statistical analysis is appropriate for the design of the study, limiting potential for presentation of invalid results 
 
There is sufficient presentation of data to assess the adequacy of the analysis      Yes    Partly    Unsure    No     
The strategy for model building (i.e. inclusion of variables) is described               Yes    Partly    Unsure    No     
There is no over-fitting the data                                                                       Yes    Partly    Unsure    No     
 
Quality Appraisal for Externally Validated Models 
 
Validation  
The final model was validated on the data that was used to generate it to assess its performance                               Yes    No     
The final model was/has been prospectively validated on new cohort(s) of patients, producing accurate results           Yes    No     
RCTs have shown that physicians and patients are willing to use the model based on its effect on clinical outcomes    Yes    No     
 
Sensibility 
The model is clinically sensible (no important items are missing )        Yes   No     
The variables included in the model are easily assessable clinically       Yes   No     
The model is easy and simple to use arithmetically                             Yes   No     
The model prescribes a course of action to be taken                         Yes   No     
 
ROC Curve Characteristics Presented  Yes    No 
 
Predictive Performance – Development Data 
Sensitivity - 
Specificity - 
Positive Predictive Value - 
Negative Predictive Value - 
Correct Prediction – 
 
Predictive Performance – External Validation 
Sensitivity - 
Specificity - 
Positive Predictive Value - 
Negative Predictive Value - 
Correct Prediction -
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7.4 Appendix IV: ITEMS FOR THE ASSESSSMENT OF BIAS IN 
PROGNOSIS STUDIES* 
 
* Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of 
Internal Medicine2006 Mar 21;144(6):427-37. 
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7.5 Appendix V: ITEMS TO BE CONSIDERED IN REPORTING 
OBSERVATIONAL STUDIES* 
 
* von Elm E, Altman DG, Egger M, Pocock SJ, GÃtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. Annals of 
Internal Medicine2007 October 16, 2007; 147(8):573-7. 
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